GENOMIC INSTABILITY
December 8, 2023(NRF2) (ACTIVATOR | ACTIVATORS | ACTIVATION)
December 8, 2023
- Immunoregulatory functions of mTOR inhibition
- Dissecting the role of mTOR: lessons from mTOR inhibitors
- Updates of mTOR inhibitors
- mTOR inhibitors: an overview
- The pharmacology of mTOR inhibition
- Current development of mTOR inhibitors as anticancer agents
- Functional consequences of mTOR inhibition
- mTOR inhibitors in the treatment of cancer
- Will mTOR inhibitors make it as cancer drugs?
- mTOR pathway and mTOR inhibitors as agents for cancer therapy
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
- mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
- The biology behind mTOR inhibition in sarcoma
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
- Predicted mechanisms of resistance to mTOR inhibitors
- mToR inhibitors-induced proteinuria: mechanisms, significance, and management
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
- The applicability of mTOR inhibition in solid tumors
- Enhanced radiation damage of tumor vasculature by mTOR inhibitors
- The potential role of mTOR inhibitors in non-small cell lung cancer
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
- The role of mTOR inhibitors in the management of posttransplant malignancy
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
- Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma
- mTOR inhibitor‐associated dermatologic and mucosal problems
- DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
- mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor
- The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
- PI3K/AKT/mTOR inhibitors in ovarian cancer
- mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
- mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
- Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases
- PI3K and mTOR inhibitors—a new generation of targeted anticancer agents
- Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
- The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents
- Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
- Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
- Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)
- Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
- Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
- mTOR inhibitors in polycystic kidney disease
- mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
- Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals
- Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa
- Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
- Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
- Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies
- mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
- In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
- The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
- The pleiotropic effects of mTor inhibitors.
- AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
- Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
- Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
- A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
- mTOR inhibition and its effect on cancer in transplantation
- Chemoprevention and treatment of experimental Cowden’s disease by mTOR inhibition with rapamycin
- mTOR inhibitors for hepatocellular cancer: a forward-moving target
- In vivo antitumor effect of the mTOR inhibitor CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer
- Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer
- Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia
- Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders
- The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
- A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver …
- The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
- Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin’s lymphoma
- mTOR inhibition induces endothelial progenitor cell death
- The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
- The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors
- Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents
- Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?
- Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
- Replacing calcineurin inhibitors with mTOR inhibitors in children
- Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved …
- In vitro release of the mTOR inhibitor rapamycin from poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
- Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients
- Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy
- Augmentation of autophagy by mTOR-inhibition in myocardial infarction: when size matters
- Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma
- [18F] fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor …
- A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN-Mutant Glioma
- NCCN Task Force Report: mTOR inhibition in solid tumors
- The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells
- A novel mTOR inhibitor is efficacious in a murine model of colitis
- Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
- Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
- mTOR inhibitors: do they help preserve renal function?
- Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
- Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus
- Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs
- mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels
- Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
- Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors
- The synthesis and anti-proliferative effects of β-elemene derivatives with mTOR inhibition activity
- The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
- A novel dual PI3Kα/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells
- Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
- Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition
- Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
- The role of mTOR inhibitors for treatment of sarcomas
- AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells
- Synergistic antiproliferative effect of mTOR inhibitors in combination with 5‐fluorouracil in scirrhous gastric cancer
- The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms.
- The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat
- Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement
- mTOR inhibition: the learning curve in kidney transplantation
- IRS-1: auditing the effectiveness of mTOR inhibitors
- Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process
- Mammalian target of rapamycin (mTOR) inhibitors
- The impact of mTOR inhibitors on the development of malignancy
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
- Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors
- Comprehensive lung injury pathology induced by mTOR inhibitors
- The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
- BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor …
- mTOR inhibitors in oncology
- Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
- Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast …
- … inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor …
- NVP‐BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors
- Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor
- Management of mTOR inhibitor side effects.
- Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive …
- Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
- Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma
- Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
- Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas
- Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Rα signaling
- mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
- The role of mTOR inhibition in augmenting radiation induced autophagy
- Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells
- Use of mTOR inhibitors in human organ transplantation
- Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
- Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway
- Can mTOR inhibitors reduce the risk of late kidney allograft failure?
- Enhancing mammalian target of rapamycin (mTOR)–targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-independent Akt activation
- FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
- A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid …
- Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
- Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial
- Targeting endocrine resistance: is there a role for mTOR inhibition?
- mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo
- Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer
- Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
- Do mTOR inhibitors still have a future in ADPKD?
- 18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model
- Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal …
- Clinical development of mTOR inhibitors: a focus on lymphoma
- The dual PI3K/mTOR inhibitor PI‐103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib‐treated melanoma cells
- Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal …
- Hypoxia‐inducible factor‐2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor
- … of (thienopyrimidin-2-yl) aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of …
- Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma
- 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model
- mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo
- Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme
- Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 …
- Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity
- Recent advances in the discovery of small molecule mTOR inhibitors
- Everolimus and mTOR inhibitors in liver transplantation: opening the “box”
- Sunitinib, sorafenib and mTOR inhibitors in renal cancer
- Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
- mTOR inhibitors in hematologic malignancies.
- … pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with …
- Role of dual PI3/Akt and mTOR inhibition in Waldenstrom’s Macroglobulinemia
- A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with …
- Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET
- Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
- … a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition …
- mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours
- Rapamycin and mTOR kinase inhibitors
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
- Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy
- Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers
- mTOR pathway and mTOR inhibitors in cancer therapy
- Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease
- The rationale for mTOR inhibition in epithelial ovarian cancer
- Involvement of autophagy via mammalian target of rapamycin (mTOR) inhibition in tributyltin-induced neuronal cell death
- Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
- Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and …
- Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells
- The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin
- … )phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of …
- Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors
- mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP
- mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats
- Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
- Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
- A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
- Treatment options in metastatic renal cell carcinoma: focus on mTOR inhibitors
- Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with …
- Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
- mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).
- Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition
- mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
- Time to rethink immunosuppression by mTOR inhibitors?
- Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily X 5 every other week in patients (pts) with …
- Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme
- mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells
- A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas
- Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option
- Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
- Nephrotoxicity of calcineurin and mTOR inhibitors
- A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS)
- Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway
- The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat
- mTOR inhibitors and their secondary effects in cardiac trasplant recipients: a descriptive study
- Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non–small cell lung cancer with the mTOR inhibitor everolimus
- PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress
- A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).
- Synergistic activity of combinations of JAK2 kinase inhibitor with PI3K/mTOR, MEK or PIM kinase inhibitor against human myeloproliferative neoplasm cells expressing …
- mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma
- A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study …
- PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
- Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
- Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
- Rapamycine and mTOR inhibitors: from bench to bedside
- Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors
- Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent
- A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s …
- mTOR inhibition is a rational target for the treatment of endometrial cancer
- Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors
- A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.
- Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with …
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- Changes in Magnesium and Potassium Homeostasis after Conversion from a Calcineurin Inhibitor Regimen to an mTOR Inhibitor–Based Regimen
- Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature
- The potential role of mTOR inhibitors in the treatment of endocrine tumors
- Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients
- Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).
- Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
- Expression and activation of mTOR in neuroendocrine tumors. Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signalling in …
- Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
- Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea …
- Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment
- A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and …
- Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase …
- Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins
- Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is …
- Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
- N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma
- Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
- Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
- mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro-and microvascular endothelial cells
- Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
- Construction of the 3D structure of the mTOR kinase-domain and discovery of novel mTOR inhibitors
- Potential of mTOR inhibitors as therapeutic agents in hematological malignancies
- Drug evaluation: AP-23573–an mTOR inhibitor for the treatment of cancer.
- Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition
- Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group
- PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to …
- Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease
- D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced …
- mTOR inhibition and adult T-cell leukemia
- The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- … Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor …
- mTOR inhibition leads to increased sensitivity to methotrexate
- A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies
- … effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor …
- Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients …
- A phase Ib study combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine in untreated elderly AML
- Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia
- PP2AT61ɛ is an inhibitor of MAP4K3 in nutrient signaling to mTOR
- Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
- Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography …
- Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
- A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
- A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
- Dual inhibition of IGFR and mTOR pathways.
- Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A …
- Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease
- Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation
- Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model
- Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.
- Effect of mTOR inhibition on sensitivity of triple-negative breast cancer cells to epidermal growth factor inhibition
- Structure of the human mTOR complex I and its implications for rapamycin inhibition
- mTOR inhibitors: pleiotropic antiproliferative drugs
- Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses
- Role of FK778 Alone or in Combination with Tacrolimus or mTOR Inhibitors as an Immunomodulator of Immunofunctions: In Vitro Evaluation of T Cell Proliferation and …
- PI3K-AKT-mTOR pathway inhibitors
- Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis
- Sirolimus, the first mTOR inhibitor
- Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function
- Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
- mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
- A Phase I Dose Escalation Study of the mTOR Inhibitor Sirolimus and MEC Chemotherapy Targeting Signal Transduction in Leukemic Stem Cells for Acute …
- Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE)
- mTOR pathway inhibitors in cancer therapy: moving past rapamycin
- Inhibition of mTOR in kidney cancer
- Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer
- … mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR
- Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
- Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.
- mTOR inhibition affects primary liver cancer
- Compensatory activation of Akt in response to mTOR and Raf inhibitors–a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
- A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
- The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
- Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases
- 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo [3.2. 1] octan-8-yl) triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human …
- A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom’s macroglobulinemia.
- Abstract S3-6: Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with trastuzumab-DM1 antibody drug conjugate …
- Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
- Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma
- mTor inhibition in lymphoma: A rational and Promising Strategy
- VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway
- mTOR inhibition as a potential treatment for progesterone refractory endometrial hyperplasia
- A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.
- Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
- … EFFECTS ON DOSE-DEPENDENT PK FOLLOWING DIFFERENT DOSING SCHEDULES IN TWO PHASE I TRIALS OF AP23573 (AP), AN mTOR INHIBITOR
- Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor
- The potential of mTOR inhibitors for the treatment of human cancers
- Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
- A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma …
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice
- RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-κB–Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN
- Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.
- Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
- Activation of the mTOR signalling pathway is required for pancreatic growth in protease‐inhibitor‐fed mice
- A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results
- Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
- High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after …
- Regulation of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: rationale for combined treatment with ERK inhibitors and …
- Combination of a MEK inhibitor, AZD6244, and dual PI3K/mTOR inhibitor, NVP-BEZ235: an effective therapeutic strategy for acute myeloid leukemia
- Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
- A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence
- The mTOR inhibitor CCI-779 (temsirolimus) downregulates p21 and induces cell cycle arrest and autophagy in mantle cell lymphoma (MCL)
- MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature
- eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy
- Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)
- The mTOR Inhibitor RAD001 (Everolimus) Improves Survival in Preclinical Models of Primary Human ALL.
- Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38
- Genomic and pathway connectivity analyses identify novel strategies to overcome mTOR inhibitor resistance in DLBCL
- Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients …
- Temozolomide combined with the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin inhibits melanoma cell growth, survival and invasion
- … LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND PROTEINURIA IN RENAL ALLOGRAFT RECIPIENTS TREATED WITH mTOR INHIBITORS …
- mTOR inhibitors for treatment of sclerodermatous chronic graft-versus-host disease following allogeneic stem cell transplantation
- Conversion from calcineurin inhibitors to mTOR inhibitors
- Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164–Driven Angiogenesis, in Part by Blocking S6Kinase
- Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma
- Activity of mTOR-inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
- Effects of mTOR inhibitor rapamycin on Smad 3 protein and collagen type I expression in rat myocardial fibroblasts infected with coxsackie virus B 3
- Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?
- … activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
- mTOR inhibitors in ADPKD
- … analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human …
- A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer.
- The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.
- Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways
- Dual inhibition of PI3Kα and mTOR as an alternative treatment for Kaposi’s sarcoma
- mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals
- Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: a phase I study
- Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia
- Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.
- Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis
- Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic …
- … [2, 3-b] pyridin-3-yl) methylene-4-hydroxybenzofuran-3 (2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
- Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
- Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
- … replacement in 6-aryl-1H-pyrazolo [3, 4-d] pyrimidines and 2-arylthieno [3, 2-d] pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
- Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis …
- Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
- Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload
- Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: A Neurofibromatosis Consortium study.
- Construction of the Three-dimensional Structure of the MTor Kinase-domain and Discovery of Novel MTOR Inhibitors
- Phase 1b study defining the optimal dosing combinations of the mTOR inhibitor AP23573 and Paclitaxel (PTX)
- The FRB Domain of mTOR: NMR Solution Structure and Inhibitor Design,
- Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
- NVP-BEZ235, A novel dual PI3K/mTOR inhibitor, elicits multifaceted antitumor activities in human gliomas
- A dual PI3K α/mTOR inhibitor cooperates with blockade of EGFR in PTEN-mutant glioma
- Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p53-mutated breast cancer.
- Dual proteasome and mTOR inhibition promotes apoptosis in non-Hodgkin lymphoma cell lines
- Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5)
- Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells
- S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt
- Discovery of 2-arylthieno [3, 2-d] pyrimidines containing 8-oxa-3-azabi-cyclo [3.2. 1] octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K
- The mTOR inhibitor rapamycin demonstrates activity against AML in combination with imatinib mesylate and with 5-azacytidine.
- Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
- Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without …
- Response of a neuronal model of tuberous sclerosis to mTOR inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function
- Drug Essentials mTOR* Inhibitors
- Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice
- Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer
- Current status of mTOR inhibitors as novel therapeutic agents
- Safety and efficacy of the mTOR inhibitor everolimus as early interventional replacement for calcineurin inhibitors in graft-versus-host disease (GvHD) …
- Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.
- Anti-tumor activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in sarcoma and endometrial cancer models and exploration of molecular correlates of …
- Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors
- Differential impact of mTOR inhibition on CD4+ CD25+ Foxp3+ regulatory T cells as compared to conventional CD4+ T cells
- The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition
- WJD008, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant
- Survival signaling by Notch1: mammalian target of rapamycin (mTOR)–dependent inhibition of p53
- The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?
- Abstract B145: Highly selective pyrazolopyrimidine mTOR inhibitors with profound in vivo antitumor activity
- Integrative approaches to investigate the molecular basis of the in vivo activity of NVP-BEZ235, a dual pan-PI3K / mTOR inhibitor
- The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth In Vivo and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide.
- The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition
- Synergistic Growth Inhibition with a PI3 Kinase/mTOR Inhibitor Plus Lapatinib.
- Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells
- A chemical genetic screen for mTOR pathway inhibitors based on 4E-BP-dependent nuclear accumulation of eIF4E
- Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis
- Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide
- 44: mTOR inhibitors (mTOR-I) and proteinuria after lung transplantation
- Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia
- … -6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the …
- GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma
- mTOR Inhibitor Rapamycin Interacts Synergistically with Farnesyltransferase Inhibitor FTI-277 To Induce Growth Inhibition in Human Leukemia Cells.
- An exploratory biomarker trial of an mTOR inhibitor in subjects with newly diagnosed advanced stage squamous cell carcinoma of the head and neck
- Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells
- Sera from Diabetics does not Alter the Effect of mTOR Inhibition on Smooth Muscle Cell Proliferation
- Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells
- Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase
- Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells.
- Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress
- Combined use of HDAC and mTOR inhibitors has synergistic effect on inhibiting B-cell tumor cell lines
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines
- Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence
- Combination therapy targeting hypoxia inducible factor-α (HIF-1 α) and tissue factor (TF) by the mTOR inhibitor rapamycin and the histone deacetylase inhibitor …
- Modulation of antifolate sensitivity in cancer chemotherapy using mTOR inhibitors
- Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
- RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer
- Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells.
- Another step in defining the role of mTOR inhibitors in kidney transplantation
- PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
- Abstract P6-15-07: A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic …
- In vitro evaluation of dual pan-PI3-kinase/mTOR inhibitor in HER2 overexpressing breast cancer cells
- PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical …
- LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
- Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer …
- Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin
- Comparison of radiosensitizing effects of the mTOR inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
- Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models
- Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.
- Targeted inhibition of mTORC1 and mTORC2 by the active-site mTOR inhibitors, PP-242 and OSI-027, has cytotoxic effects in T-cell acute lymphoblastic leukemia
- REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase
- AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection
- A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).
- PTEN expression in archival tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor
- Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and …
- Abstract C65: Enhanced antitumor effect by the combination of a PI3K inhibitor ZSTK474 with an mTOR inhibitor rapamycin
- Combined Bcl-2/mTOR inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small-cell lung tumor xenograft model
- FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.
- Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway
- Effective targeting of the PI3-K pathway in CLL with NVP-BEZ235, a novel orally available dual PI3K/mTOR inhibitor
- EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation
- Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.
- Clinical activity of Azacitidine in combination with the oral mTOR inhibitor everolimus (RAD001) in relapsed and refractory AML: interim analysis of a phase Ib …
- Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells
- Temsirolimus, an mTOR inhibitor, in combination with low-dose clofarabine in older patients with advanced acute myeloid leukemia: results of a phase 2 …
- Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy …
- Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
- Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells
- Anti-Angiongenic Effects of mTOR-Inhibitors Is Regulated by AKT Activity in Multiple Myeloma Cells.
- Inhibition of mTOR suppresses experimental liver tumours
- Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel
- Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells
- Methylnaltrexone potentiates the antiangiogenic effects of the mTOR inhibitor, temsirolimus
- Combined Bcl2/mTOR Inhibition Leads to Enhanced Radiosensitization via Induction of Autophagy and Apoptosis in Non-small Lung Tumor Xenograft Model
- P1-084: Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F …
- The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line
- Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.
- The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation
- The role of mTOR inhibition in the control of autosomal dominant polycystic kidney disease
- Pediatric Preclinical Testing Program (PPTP) evaluation of the mTOR inhibitor rapamycin
- Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type …
- mTOR Inhibitors Are Safe and Effective Radiosensitizers in Glioblastoma Multiforme Pre-Clinical Models
- Brain-selective mTOR inhibitors as potential therapeutics for glioblastoma multiforme
- Enhancing mTOR-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
- Oncogenic Pim Kinase Activity Provides Resistance to Mtor Inhibition in Vitro and In Vivo.
- Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer
- Combining mTor inhibitors with rapa-resistant T cells: a two-pronged approach to tumor elimination
- Abstract B143: Distinct antitumor mechanisms of VEGFR inhibitor tivozanib (AV‐951) and mTOR inhibitor rapamycin support rational combination for solid tumors to …
- mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching
- Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways
- Molecular Inhibition of mTOR with Temsirolimus (TORISEL™, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.
- Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes
- The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and …
- Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR
- Molecular analysis of hormone refractory prostate cancer biopsies supports the rationale of using mTOR inhibitors
- The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia.
- mTOR signal pathway and its inhibitors in antitumor therapy: A review
- Overcoming cisplatin resistance with mTOR inhibition in small cell lung cancer: A phase I-II trial design
- Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs
- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
- The discovery and optimisation of pyrido [2, 3-d] pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinase
- … , mTOR, and Pharmacodynamic Strategies for a Targeted Cancer Therapy: Commentary re: JM Peralba et al., Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in …
- Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes
- Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative …
- Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension
- Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model
- Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor …
- Abstract C60: In vitro efficacy of the dual PI3‐kinase/mTOR inhibitor NVP‐BEZ235 in hepatocellular carcinoma
- Human Eukaryotic Release Factor 3a Depletion Causes Cell Cycle Arrest at G1 Phase through Inhibition of the mTOR Pathway
- Current perspectives in metastatic renal cell carcinoma treatment: the role of mammalian target of rapamycin (mTOR) inhibition
- Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.
- The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.
- Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα
- Abstract P5-06-05: Catalytic mTOR Inhibition with pp242 but Not Allosteric Inhibition with Rapamycin RAD001 Enhances the Radiosensitivity of Inflammatory Breast …
- TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells
- Melatonin represses oxidative stress‐induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras
- Transcription inhibitors stimulate translation of 5′ TOP mRNAs through activation of S6 kinase and the mTOR/FRAP signalling pathway
- New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic …
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- Chemical genomic screening reveals that PI3K/mTOR inhibition enhances activity of the anti-leukemia stem cell compound parthenolide.
- The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in …
- Inhibition of amino acid-mTOR signaling by a leucine derivative induces G1 arrest in Jurkat cells
- NVP-BEZ235 a dual PI3K/mTOR inhibitor destabilises Mycn in vitro and is growth inhibitory in the TH-MYCN murine neuroblastoma model
- Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro
- Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
- The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with …
- Combined mTOR and AKT inhibition in renal cell carcinoma (RCC).
- Antiproliferative effects of mTOR inhibition with rapamycin (RAP) either given as a single agent or in combination with carboplatin and paclitaxel in Human Head and …
- mTOR inhibitors for the treatment of lymphoma
- Of Mice and (Hu) man: Therapeutic mTOR Inhibition
- Direct inhibition of mTOR may be detrimental when combining mTOR inhibitors or dual PI3 kinase/mTOR inhibitors with paclitaxel
- Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support
- Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway
- Tuberous sclerosis complex tumor suppressor–mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent
- ATP depletion increases phosphorylation of elongation factor eEF2 in adult cardiomyocytes independently of inhibition of mTOR signalling
- … Inhibition of Growth of Tuberous Sclerosis Complex 2–Null Cells by Atorvastatin Is Associated with Impaired Rheb and Rho GTPase Function and Reduced mTOR …
- MTOR INHIBITORS (MTOR-I) AND LUNG TRANSPLANTATION: CAN ITS USE BE JUSTIFIED?: 364
- Evaluation of metabolic imaging for assessment of tumor response to mTOR inhibitors
- A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor …
- 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
- 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
- Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis
- FDG-PET in mTOR inhibitor therapy (mTOR Rx): A study of the relationship between Akt/mTOR and glycolytic pathways
- MTOR INHIBITORS IN LIVER TRANSPLANTATION-THE BUDAPEST PRACTICE: 1237
- Inhibition von mTOR reduziert Tumorwachstum und Angiogenese des Magenkarzinoms in einem experimentellen Modell
- Biochemical determinants for mTOR inhibitor sensitivity in lung cancer cell lines
- A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer: Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J …
- A Novel mTOR Inhibitor Is Efficacious in a Murine Model of Colitis: 1044
- New mTOR* Inhibitor for Renal Cell Cancer
- BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
- PRONOSTIC FACTOR FOR MTOR INHIBITORS (MTOR-I) PROTEINURIA AFTER LUNG TRANSPLANTATION: 365
- Novel indole α-methylene-γ-lactones as potent inhibitors for AKT-mTOR signaling pathway kinases
- Antitumoral effect of farnesiltransferase and mtor inhibitors in hepatocellular carcinoma: in vitro studies
- Inhibition of human melanoma proliferation by combination treatment with ODC inhibitor and mTOR inhibitor
- SEQUENCING TKIs AND mTOR INHIBITORS IN RENAL CELL CARCINOMA
- The Dual PI3K and mTOR Kinase Inhibitor NVP-BEZ235 Induces Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells and Potentiates the Cytotoxicity of …
- Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway
- Serum glucose measurements as a pharmacodynamic biomarker for mTOR inhibition
- Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway
- mTOR inhibitors in the treatment of advanced renal cell carcinoma
- Abstract C66: Development of mechanistic assays to differentiate PI3K and mTOR inhibitors
- Novel mTOR inhibitors with distinct anticancer profiles and favorable DMPK properties
- Synergistic effects of mTOR inhibitor on the growth of gastric cancer in combination with 5-Fluorouracil
- Tumorstammzell-gerichtete Therapie mit mTOR-inhibitor RAD001 und Hedgehog-signaling-inhibitor Cyclopamin sensitiviert chemotherapieresistente …
- mTOR Inhibitors in Kidney Cancer: Template for Personalized Therapy
- Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2
- Abstract 1308A: Novel antiinvasive and antiangiogenic mechanisms of mTOR inhibition in glioblastoma
- PI3-Kinase Inhibition Decreases the Proliferation of ALL Cells, Potentiates mTOR Inhibition, and Abrogates Growth Factor-Mediated Reversal of mTOR Inhibition.
- Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E …
- Administration of RAD001 in patients with metastasized renal cell carcinoma: Review of the clinical development of an oral mTOR inhibitor
- Abstract# 817: mTOR inhibitor temsirolimus (Torisel) overcomes adriamycin resistance in head and neck cancer
- mTOR inhibitor sensitizes chemo-cytotoxicity for hepatocellular carcinoma
- Abstract C55: Involvement of oxidative stress in the antitumor effect of mTOR inhibitors in mantle cell lymphoma
- Combination of HSP90 and mTOR inhibition promotes pancreatic cancer growth inhibition
- The Role of mTOR Inhibition in Augmenting Radiation Induced Autophagy
- The mTOR pathway and its inhibitors
- AKT Activity Regulates Sensitivity of Multiple Myeloma Cells to mTor Inhibitors.
- EFFECTS OF MTOR-INHIBITION ON HYPOXIC ADAPTATION BY HIF–PREFERENTIAL INFLUENCE ON ERYTHROPIETIN REGULATION: 540
- The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway
- XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR
- … HEPATOCELLULAR CARCINOMA WITH A DUAL TYROSINE KINASE RECEPTOR INHIBITOR (AEE788) AND AN MTOR INHIBITOR (RAD001, EVEROLIMUS): 121
- P52: In vivo anti-tumor effect of mTOR inhibitor RAD001 on xenograft tumor of human pancreatic cancer
- Abstract B147: Lack of an additive effect of radiation treatment on PI3K or mTOR inhibition in prostate cancer cell lines
- Differential regulation of cytokine expression determines the differential drug sensitivity between carcinomas and lymphomas towards mTOR inhibitor
- Interaction between the p53 genotype of lung cancer and response to mTOR inhibitor combined with irradiation therapy
- mTOR Inhibition and Diet Induced Obesity in a Mouse Model of Postmenopausal Breast Cancer.
- HORMONAL STATUS INFLUENCES ADAPTIVE AND MALADAPTIVE SIGNALING AFTER MTOR INHIBITION IN FEMALE CARDIOMYOCYTES: 1125
- … : The PI3K pathway inhibition in prostate cancer cells is enhanced by dual targeting with the mTOR inhibitor RAD001 and a mTOR/PI3K inhibitor leading to decreased …
- Cooperative induction of apoptosis through p53 signaling and mTOR inhibition in neuroblastoma
- Abstract #5239: Erlotinib enhances RAD001#8217;s anticancer activity in vivo involving abrogation of mTOR inhibition-induced eIF4E phosphorylation
- The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.
- Effect of mTOR inhibition by rapamycin on promotion of skin tumors in BK5. Aktwt transgenic mice
- Nuclear PTEN-mediated autophagy is independent of mTOR inhibition in U251MG cells
- Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
- The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
- A potential for combining the mTOR inhibitor RAD001 (everolimus) with the EGFR receptor tyrosine kinase inhibitor erlotinib.
- Mammalian target of rapamycin (mTOR) inhibitors with therapeutic potential for colitis
- MRI molecular imaging monitors downstream anti-angiogenic effects of mTOR inhibition
- Tumor FDG uptake as biomarker for defining the optimal biological dose of the mTOR inhibitor everolimus
- Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor …
- The anti-tumor activity of the mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma (NPC)
- mTOR Inhibitors Induce Apoptosis and Inhibit Growth of Primary Adult Human ALL in Xenograft and Tissue Culture Models.
- Response of extensive sclerodermatous chronic graft-versus-host disease to an mTOR inhibitor-based treatment
- MTOR (Mammalian Target of Rapamycin) Inhibition with RAD001 Induces Cell Cycle Arrest in Diffuse Large B Cell Lymphoma (DLBCL) Cells and Sensitizes DLBCL …
- Improvement of anti-hormone therapy of human breast cancer xenografts by combination with the mTor inhibitor RAD001
- Combination of the mTOR Inhibitor Rapamycin and Revlimid™(CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).
- EARLY VERSUS LATE CONVERSION TO MTOR-INHIBITORS IN LIVER TRANSPLANT RECIPIENTS WITH IMPAIRED RENAL FUNCTION AT THE TIME OF …
- TYROSINE KINASE AND MTOR INHIBITION IN RENAL CELL CARCINOMA SPHEROIDS: 79
- … Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.
- Abstract #2749: In vitro and in vivo efficacy of the dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in renal cell carcinoma (RCC)
- Tumor T1 is a non-invasive imaging marker of proliferation and response to the mTOR inhibitor everolimus
- Effects of a novel PI3 kinase/mTOR inhibitor on proliferation and pAKT signaling in canine lymphoma
- Limited Growth-suppressive effect of RAD001, an mTOR inhibitor, in hepatocellular carcinoma cells may be related to the compensatory activation of Akt
- Abstract# LB-215: Antiproliferative effects of a novel mTOR inhibitor (Temsirolimus) provide the prolonged survival in a pleural dissemination model using non-small …
- Contrast Enhanced Sonography shows Superior Microvascular Renal Allograft Perfusion in Patients Receiving mTOR-inhibitor Therapy
- Long Term Follow-up of Patients Treated with mTOR Inhibitors for Severe Chronic Gvhd Following Allogeneic Stem Cell Transplantation.
- Antiproliferative effect of a novel mTOR inhibitor (temsirolimus) in esophageal cancer cells
- Synergistic Antilymphoma Effect of Protein Kinase C Beta (PKCβ) and mTOR Inhibition in Mantle Cell Lymphoma.
- Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
- … /AKT/mTOR mediates resistance to MEK inhibition in preclinical model of Acute Myeloid Leukemia (AML): synergistic effect of combined MEK and mTOR inhibition.
- Targeting the Hypoxic Microenvironment by mTOR Inhibitors Sensitizes ALL Cells to Chemotherapy
- THERAPEUTIC MONITORING OF MTOR-INHIBITOR INDUCED IMMUNOSUPPRESSION BY PHOSPHO-FLOW CYTOMETRY: 2145
- Tolerability of the mTOR inhibitor rapamycin in cirrhotic patients with advanced hepatocellular carcinoma
- mTOR inhibition influences cell viability of medullary thyroid carcinoma primary cultures
- Expression of mTOR and IGF2 and in vitro effects of mTOR inhibitor drugs on cell proliferation and cortisol production in human adrenocortical cancer cells
- RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential …
- The mTOR inhibitor rapamycin inhibits proadhesive activity of arterial intimal smooth muscle cells
- Combinations of Cytotoxic Drugs, Ionizing Radiation, and Mammalian Target of Rapamycin (mTOR) Inhibitors
- Abstract# 2321: The mTOR inhibitor, temsirolimus, inhibits tumor growth, vascularization, and macrophage infiltration in a transgenic model of mammary carcinoma in …
- Rapamycin, mTOR inhibitor, a potent inhibitor for the cell growth and proliferation by p21-dependent mitotic arrest in human gastric cancers
- The contribution of antiangiogenic agents and mTOR inhibitors to the treatment of endocrine tumours of the gastro-intestinal tract
- Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based …
- DE NOVO USE OF MTOR INHIBITOR EVEROLIMUS IN COMBINATION WITH MYCOPHANOLATE SODIUM IN PATIENTS UNDERGONE ORTHOTOPIC LIVER …
- MTOR Inhibitors Activate the AKT Kinase in Multiple Myeloma Cells by Upregulating the IGF-1/IRS-1/PI-3 Kinase Cascade.
- … growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of rapamycin (mTOR) inhibitor (CCI‐779) to overcome resistance to mTOR inhibition
- Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus
- The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin sensitize melanoma cells to cisplatin and temozolomide
- The dual PI3K/mTOR inhibitor BEZ235 impairs gastric cancer growth in vitro and in vivo
- mTOR and FTY 720 inhibitors
- Abstract# 3204: Effects of the novel PDK-1 inhibitor OSU-03012 and the dual PI3 kinase/mTOR inhibitor PI103 on neuroblastoma
- Inhibition of PI3K, but not mTOR inhibition sensitizes glioblastoma cells for death receptor-or chemotherapy-induced apoptosis
- Molecular combined therapy in hepatocellular carcinoma with an EGFR/Her2/VEGF RTK inhibitor (AEE788) and an mTOR inhibitor (RAD001, everolimus) results in …
- Cytostatic action of the dual PI3K/mTOR inhibitor NVP-BEZ235 in non-functioning pituitary adenomas
- Abstract# 1838: C/EBP# 946; and MnSOD as targets of mTOR inhibitors in mantle cell lymphoma.
- … Role of AKT and ERK in Regulating D-Cyclin Translation Inhibition and G1 Arrest in Multiple Myeloma Cells Treated with mTOR Inhibitors: Rationale for Combination …
- Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (rapamycin)
- Abstract P6-15-19: PI3K-MTOR Inhibitor BEZ235 Shows Antitumor Activity Against a Panel of Basal-Like Cells and Potentiates the Antitumor Activity of Taxanes and …
- mTOR Inhibition and Alloantigen-Specific Regulatory T Cells Synergize to Promote Long-Term Graft Survival in Immunocompetent Recipients
- Activation of the AKT pathway in tumor cells following mTOR-raptor inhibition is dependent on the mTOR-rictor complex and does not define the antiproliferative …
- Combined mTOR inhibition and post-transplant infusion of alloantigen-specific Treg promotes long-term graft survival in otherwise unmanipulated hosts (141.42)
- 040 mTOR inhibition reverses alveolar epithelial neoplasia induced by oncogenic K-ras
- Targeting Tissue Factor-Factor VIIa Signaling Pathway to Enhance Activity of mTOR Inhibitors in the Treatment of Breast Cancer
- Cyclosporine, but Not mTOR Inhibitors, Hampers the Reconstitution of Bone Marrow-Derived Tregs in Long-Term Complete Donor chimeras.
- Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation.
- Abstract# 2707: Design and synthesis of dual PI3K/mTor inhibitors
- Abstract# 5590: mTOR inhibitor CCI-779 enhances the efficacy of radiotherapy in a cisplatin-resistant HNSCC cell line
- Abstract B20: In vitro and in vivo antitumor activities of the dual PI3K/mTor inhibitor NVP‐BEZ235. Implications for patient stratification strategies
- The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast …
- BEZ235, a dual PI3K/mTOR inhibitor, enhances the activity of the multikinase inhibitor sorafenib in acute myeloid leukemia (AML)
- Treatment of Retinal Degeneration by mTOR Inhibition in the T17M Mouse Model of Rhodopsin Retinitis Pigmentosa
- Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
- PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
- Treatment of Retinal Degeneration by mTOR Inhibition in Mouse Model of Rhodopsin Retinitis Pigmentosa
- mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene expression levels
- Phosphomimetic mutation of hnRNP A1 inhibits AKT-dependent IRES function and results in mTOR inhibitor sensitivity
- Pin1 as a Biomarker of ER+ Breast Cancers to Predict the Response to Tamoxifen and mTOR Inhibitors
- P2-110: Combined Caspase-3/mTOR inhibition Enhance Radiosensitization of Non-Small Cell Lung Cancer via Upregulation of Autophagy
- Rapamycine et inhibition de mTOR: des voies de signalisation aux applications cliniques
- Phase I and pharmacokinetic study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
- Pin1 as a Biomarker of ER+ Breast Cancers to Predict the Response to Tamoxifen and mTOR Inhibitors PRINCIPAL INVESTIGATOR
- EFFECT OF MTOR INHIBITOR ON DYSLIPIDEMIA IN HEART TRANSPLANT RECIPIENTS RECEIVING STATINS. IS THERE ANY DIFFERENCE BETWEEN …
- … -0941 synergizes with mTOR inhibitors by blocking negative feedback and causes distinct effects on signaling and apoptosis compared to a dual PI3K/mTOR inhibitor
- mTOR inhibitors rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH3 cell line and human pituitary adenomas
- Tumor stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5-Fluorouracil in …
- Abstract C249: Down‐regulation of the HIF pathway enhances anti‐tumor effects of the mTOR inhibitor ridaforolimus in the Her2/Neu mouse model of breast cancer
- mTOR INHIBITORS (MTI) ARE SYNERGISTIC WITH METHOTREXATE: AN EFFECTIVE COMBINATION TO BOTH PREVENT POST-HSCT RE-LAPSE OF ALL …
- Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone
- Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of …
- Abstract# 2017: Novel imidazolopyrimidines as dual PI3-kinase/mTor inhibitors
- Abstract C59: Discovery and characterization of selective PI3Kα and PI3Kα/mTOR‐dual inhibitors for targeting PI3Kα‐activated tumors
- Metformin augments rituximab and chemotherapeutic agents-induced apoptosis via mTOR inhibition in rituximab-resistant B lymphoma cell lines
- DE NOVO USE OF mTOR INHIBITOR EVEROLIMUS IN COMBINATION WITH MYCOPHANOLATE SODIUM OR MYCOPHENOLATE MOPHETIL AND EARLY …
- Abstract B142: PKI‐402, a dual PI3K/mTOR inhibitor
- A phase I study of the mTOR inhibitor sirolimus (rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers
- The mTOR inhibitor rapamycin inhibits p27 protein degradation by downregulating the expression of its ubiquitin ligase Skp2 in breast cancer
- Inhibition of the mTOR pathway enhances sensitivity of breast cancer triple negative cell lines to EGFR family inhibition.
- FLT3-ITD–, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment
- mTOR inhibition impairs proliferation of hepatocytes with DNA damage during chronic liver injury thereby delaying liver tumor development
- Preclinical investigation of MEK and mTOR inhibitors on human-derived Neurofibromatosis Type 1 malignant peripheral nerve sheath tumours
- Abstract #2901: FDG-PET uptake is a surrogate marker for defining the optimal biological dose of mTOR inhibitors in vivo
- 971 COMBINED TREATMENT WITH CISPLATIN AND DUAL PI3K-MTOR INHIBITOR NVP-BEZ235 CAN RESTORE CASPASE DEPENDENT APOPTOSIS IN …
- 58: mTOR inhibitors (MTI) are synergistic with methotrexate: An effective combination to both prevent post-HSCT relapse of all and prevent GVHD
- Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus with Mitoxantrone …
- IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL …
- The mTOR inhibitor everolimus cooperates with the Toll-like receptor 9 (TLR9) agonist IMO in renal cell carcinoma by interfering with both tumor cells and …
- Abstract PD02-09: Effects of an mTOR Inhibitor RAD001 on Human Breast Cancer Stem Cells In Vitro
- The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and-resistant breast cancer xenografts
- Effect of EGFR and IGF1R on feedback activation of AKT arising from inhibition of mTOR in malignant pleural mesothelioma (MPM).
- 499: Acute Rejection and Survival Following Late Replacement of CNIs with an mTOR Inhibitor Plus MMF after Heart Transplantation
- COMBINED TREATMENT WITH CISPLATIN AND DUAL PI3K-MTOR INHIBITOR NVP-BEZ235 CAN RESTORE CASPASE DEPENDENT APOPTOSIS IN …
- Abstract# 1887: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer
- Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor
- Abstract LB-301: The impact of Abcb1 and Abcg2 on the brain penetration of PI3K-mTOR inhibitors
- Androgen receptor antagonist bicalutamide sensitizes androgen-independent prostate cancer cells to mTOR inhibitor rapamycin by regulating phosphorylation of …
- Genomic profiling of ovarian tumor cell lines provides a predictive signature of sensitivity to PF-4691502, a dual PI3kinase and mTOR inhibitor
- Study of mammalian target of rapamycin (mTOR) signaling and the effects of its specific inhibitors in hepatocellular carcinoma
- Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3‐kinase (PI3K) and the mammalian target of rapamycin (mTOR)
- Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel …
- PNEUMONITIS FROM INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR) IN PATIENTS WITH METASTATIC CANCER
- Abstract #2817: Ex vivo and in vivo effects of NVP-BEZ235, a dual pan-PI3K / mTOR inhibitor, on insulin signaling and metabolic regulation.
- Abstract# 2328: Preclinical testing of a vascular disrupting agent in combination to an mTOR inhibitor in renal cell carcinoma models.
- Abstract P2-19-01: Modulating Response to Phosphoinositol-3-Kinase/mTOR Inhibition in ER Positive Breast Cancer Cell Lines after Acquired Resistance to Estrogen …
- 298: Usefulness of mTOR Inhibitors for Treatment of Heart Transplant Patients with Non-Cutaneous Non-Lymphomatous Tumours: Data from the Spanish Post-Heart …
- Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and …
- Abstract #2301: Combined Bcl2 /mTOR inhibition leads to enhanced radiosensitization via autophagy and apoptosis in non-small lung numor nenograft model
- Neuroendocrine Tumors: RAD00l Inhibitor of mTOR Used with Octreotide Shows Activity
- 381: Immunosuppression after Post-Heart-Transplant Neoplasia with MMF and mTOR Inhibitors and Withdrawal of Calcineurin Inhibitors. Is It Safe Enough for …
- Topics in mTOR pathway and its inhibitors
- 39: Differential impact of mTOR inhibition on FoxP3+ regulatory T cells as compared to conventional T cells after allogeneic bone marrow transplantation
- … : A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 with standard …
- Abstract LB-159: An orthotopic model of head and neck squamous carcinoma reveals that mTOR inhibition with rapamycin halts lymph node metastasis
- Abstract# 1071: Tumor stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5 …
- Abstract# 2816: Biologic effects of NVP-BEZ235, an orally available dual PI3K/mTOR inhibitor, in human breast, lung, colon, pancreas, and liver cancer cell lines in …
- Insights into the regulation of mTOR signaling and the consequences of pharmacological inhibition
- … signaling pathway constitutively activated in esophageal squamous cell carcinona cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
- Abstract# 2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and …
- Influence of the genotype in the response of lung cancer cells to inhibitors of ampk and pik3/akt/mtor.
- A selective PIM kinase inhibitor is highly active in multiple myeloma: the biology of single agent and PI3K/AKT/mTOR combination activity
- PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.
- Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a Phase I clinical trial
- Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II …
- Acetaldehyde promotes rapamycin-dependent activation of p70S6K and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human …
- 5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer
- Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies
- Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation
- Der mTOR-Inhibitor Sirolimus inhibiert die VEGF-C getriggerte physiologische Lymphangiogenese: Eine experimentelle Erklärung für frühe postoperative Probleme
- Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site …
- Kombination von antiangiogener Therapie mit dem mTOR Inhibitor RAD001 und Strahlentherapie als neues Therapiekonzept in der Tumortherapie
- Inhibition of mammalian target of rapamycin (mTOR) induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation
- Inhibition of mTOR Induces Cumulus Expansion and Meiotic Maturation in Mouse Oocytes Without Gonadotropin Stimulation.
- Abstract P6-14-10: Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors
- Verminderte Anfallsfrequenz unter mTOR-Inhibitor
- Das neue Wirkprinzip der mTOR-Inhibition
- … Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This …
- Inhibition of AKT/mTOR Signaling Pathway Induces Cell Cycle Arrest and Apoptosis in Acute Myelogenous Leukemia.
- Die Tyrosinkinasen-Inhibitoren Imatinib (Glivec) und NVP-AEE788 und der mTOR-Inhibitor Sirolimus hemmen das Wachstum von Gallengangskarzinomen in vitro …
- Antitumor effects of sorafenib, bevacizumab and cetuximab as single agents or in combination with an MEK, mTOR or bcl-2 inhibitor, in a SNU-398 human …
- Chronische Allograftdysfunktion nach Nierentransplantation-Rolle der mTOR-Inhibition und prädiktiver Wert der Proteinurie
- Abstract C8: Short‐chain fatty acids induce autophagy through inhibition of mTOR pathway
- Activation of mTOR by inhibitors of translation is dependent on PKC-delta.
- Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in …
- Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG
- Dual inhibition of Akt/mTOR pathway by nab-rapamycin and perifosine induces anti-tumor activity in multiple myeloma
- Inhibition of AKT/mTOR Signaling Induces Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma.
- Inhibitors of the Proteasome and mTOR
- Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells
- mTOR kinase inhibitors exhibit properties that distinguish them from Rapamycin
- Small-molecule inhibitors of mTOR and DNA-PK
- Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR …
- Research article Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- Novel PI3K/mTOR dual inhibitor, NVP-BGT226, displays potent inhibitory activity against human head and neck cancer cell growth in vitro and in vivo
- Intravenöse mTOR-Inhibition auch in der Hämatologie erfolgreich
- Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC‐0980, currently in phase I clinical trials
- … ) inhibition of mTOR in tamoxifen sensitive and resistant human breast cancer cells produces estrogen dependent growth inhibition but paradoxical induction of …
- Pharmacological studies of a novel inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway
- Inhibition of mTOR signaling by psoralidin in breast cancer
- AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling
- Inhibition of mTOR for the treatment and prevention of lung cancer
- Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis.
- MTOR as therapeutic target for T-cell leukemia: Synergism with conventional cytotoxic drugs and signaling inhibitors.
- A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
- mTOR inhibitors: interest and development for oncology purpose
- Enhanced anti-tumor effect of combination therapy with anti-CD40 antibody and the mTOR kinase inhibitor AZD8055
- The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design
- Abstract B267: AR‐mTOR‐1: A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy
- Intra-Pathway Inhibition of Upstream (PI3K) and Downstream (mTOR) Kinases Synergistically Induces Apoptosis in AML.
- Chemosensitization by dual pharmacological inhibition of MEK and mTOR signaling pathways in human non-small cell lung cancer (NSCLC)
- Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole
- Methoxychalcone induces cell‐cycle arrest and apoptosis in human hormone‐resistant prostate cancer cells through PI 3‐kinase‐independent inhibition of mTOR …
- Abstract# 3710: Novel potent and selective mTOR/PI3K inhibitors that inhibit tumor growth in animal models through efficient and sustained shut down of the PI3K/Akt …
- … bei Lebertransplantierten nach Umsetzen einer Calcineurin-Inhibitor-basierten auf eine mTOR-Inhibitor-basierte immunsuppressive Therapie
- Anti-proliferative aminopeptidase inhibitors inhibit mTOR and alter expression of Noxa and Mlc-1 in leukemic cells via amino acid deprivation
- Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase
- Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells
- Simultaneous inhibition of Hsp90 and mTOR synergistically reduces tumor growth and angiogenesis of hepatocellular cancer in an experimental model
- Inhibition of protein translation via mTOR signaling as a target in radiotherapy
- Abstract# LB-52: NVP-BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2 positive cells
- Inhibition of the mammalian target of rapamycin (MTOR) for the chemoprevention of tobacco-carcinogen induced lung tumorigenesis
- Dual Inhibition of mTOR and Pim Kinase Pathways Using Small Molecule Inhibitors Synergistically Kills Myeloid Leukemic Cells In Vitro and In Vivo.
- A Novel mTOR Kinase Inhibitor Causes Growth Inhibition, Cell Cycle Arrest, Apoptosis and Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct …
- Abstract# 1683: mTOR pathway inhibition via folate receptor specific delivery of the folate-everolimus conjugate EC0565
- Disruption of DEPTOR/mTORC1/mTORC2 signaling cascade using a novel selective mtor kinase inhibitor azd8055 results in growth arrest and apoptosis in multiple …
- AMPK-Mediated Inhibition of mTOR Kinase
- Abstract B138: SB2312, a novel and potent dual inhibitor of mTOR and PI3K with high target inhibition and antitumor efficacy
- Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function
- PI-103, a Novel Dual Inhibitor of PI3-Kinase and mTOR, Enhances the Activity of Imatinib Mesylate in BCR-ABL-Positive Acute Leukaemia Cells
- Inhibition of mTOR activity potentiates 2-DG-induced cell death in hypoxic cells via down-regulation of HIF-1α
- Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.
- Inhibition of Human T-Cell Proliferation by mTOR antagonists requires Non-Coding RNA growth-arrest-specific transcript 5 (GAS5)
- FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma
- Glucocorticoid Induction of Autophagy in Lymphocytes, Mediated by Dig2 and Inhibition of mTOR Signaling
- Abstract B15: Targeted inhibition of mTOR signaling attenuates the growth and progression of colorectal cancer
- Inhibition of PI3K/mTOR Pathways In Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation
- Interactions between inhibitors of mTOR and EGFR/ERK signaling in SiHa cervical carcinoma
- mTOR Inhibition vermindert die proinflammatorische und profibrogene Genexpression bei experimenteller NASH
- Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
- DUAL INHIBITION OF CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE AND mTOR AS A NEW THERAPEUTIC OPTION FOR T-CELL ACUTE …
- Abstract A41: Combined inhibition of mTOR and MAPK signaling attenuates the growth and progression of colorectal cancer
- Fatty acid synthase (Fas) inhibitors modulate energy balance via Mtor complex 1 (Mtorc1) signaling in the central nervous system (Cns)
- Abstract B141: Effects of AZD8055, a novel mTOR kinase inhibitor, in human cancer cells developing resistance to rapamycin
- Inhibition of mTOR Reverses the Ability of c-MYC To Block the Differentiation of Murine Granulocytes.
- Inhibitors of mToR Mediate Anti-Myeloma Activity by Apoptosis through the Extrinsic Pathway.
- Inhibition of mTOR and targeting insulin-like growth factor I synergistically enhance taxol-induced cytotoxicity in estrogen receptor positive breast cancer cells.
- First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on …
- Targeted inhibition of mtor by azd8055 blocks protein translation and has anti-leukemic activity in acute myeloid leukemia
- Reduziertes Wachstum kolorektaler Karzinomzelllinien-Xenografts nach kombinierter EGF-Rezeptor-und PI3K/AKT/mTOR-Inhibition
- AR-mTOR-26–A Potent, Selective mTORC 1/2 Kinase Inhibitor for the Treatment of Malignancy
- mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching
- The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies
- Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of rapamycin (mTOR)
- INCREASED FREQUENCY OF ANGIOEDEMA UNDER COMBINED TREATMENT WITH MTOR–AND ACE-INHIBITOR IN KIDNEY TRANSPLANTED PATIENTS: 1618
- p53-independent radiosensitization of lung cancer cells by inhibition of mTOR pathway
- Targeting mTORC1/2 by a mTOR kinase inhibitor (PP242) induces apoptosis in AML cells under conditions mimicking bone marrow microenvironment
- … -70: In vitro anti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel …
- Pre-clinical treatment of adrenal cortical carcinoma with a combination of small molecule inhibitors to IGF-1R and mTOR
- A novel PI3K/mTOR dual inhibitor provides correlations of pharmacokinetic pharmacodynamic and tumor growth inhibition in a prostate PC3 xenograft model for …
- Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells
- A small molecule inhibitor against kinase domain of mammalian target of rapamycin (mTOR) causes autophagic cell death in glioblastoma
- Investigation of the inhibition of the cell growth and down-regulation of mTOR in the cholangiocarcinoma QBC939 cells transfected with plasmid PTEN in vitro
- RAD001, An Inhibitor of mTOR, Enhances Monocytic Differentiation Induced by ATRA through Phosphorylation of C/EBPα In AML Cell Lines
- Inhibition of the mTOR/ p70 S6K pathway by FTI and the involvement of Rheb (Ras homologue enriched in brain)
- The inhibition of insulin stimulated proliferation of vascular smooth muscle cell by rosiglitazone is mediated by the Akt-mTOR-p70S6K pathway
- In vivo activity of combined PI3k/mTOR and MEK-inhibition in a K-RASG12D; PTEN deletion mouse model of ovarian cancer
- Transcription inhibitors stimulate translation of 5â ² TOP mRNAs through activation of S6 kinase and the mTOR/FRAP signalling pathway
- J013 Inhibition of mTOR survival pathway by an embryonic developmental Wnt pathway suppresses preconditioning induced cardioprotection
- Sweet gum extract inhibits proliferation of prostate cancer through dual inhibition of PI3K/Akt and mTOR pathways.
- Targeted therapy for osteosarcoma using 17AAG and rapamycin: Characterization of induced apoptosis and inhibition of mTOR and AKT/MAP kinase pathways
- Dual inhibition of PI3K/mTOR by PI-103 inhibits pancreatic cancer cell growth mediated via autophagy and cell cycle arrest
- INHIBITION OF MTOR SURVIVAL PATHWAY BY AN EMBRYONIC DEVELOPMENTAL WNT PATHWAY SUPPRESSES PRECONDITIONING INDUCED …
- Combined Inhibition of MEK and mTOR Prevents Proliferation of Glioblastoma Cell Lines by Abolishing Phosphorylation of Cyclin-Dependent Kinase 4
- Inhibition of the PI3K and mTOR survival pathways enhances apoptosis in human mesothelioma tumor fragment spheroids
- Inhibition of mTOR and the MEK/ERK pathway enhance paclitaxel-induced cytotoxicity in estrogen receptor-positive breast cancer cells.
- Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)
- Eine mTOR Inhibition mittels Rapamycin vermindert die proinflammatorische und profibrogene Genexpression bei experimenteller NASH
- PF-04691502, a potent and selective mTOR/PI3K dual inhibitor, demonstrates in vitro and in vivo antitumor activity in non-small cell lung carcinoma cells
- Polyamine catabolism drug N1, N11-Diethylnorspermine caused cell death in glioblastoma cells via inhibition of mTOR-regulated protein initiation
- PI3K/Akt/mTOR activity is a major determinant for the sensitivity of NPM-ALK (+) anaplastic large cell lymphoma cells to ALK inhibition
- Reversion of the resistance to tamoxifen and cross-resistance to fulvestrant in a novel breast cancer cell line by inhibition of the PI3K/Akt/mTor signaling pathway
- Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.
- Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains
- Farnesyltransferase inhibitor (FTI) disruption of Rheb/FKBP38 association leads to FKBP38-mediated inactivation of mTOR
- AMPK activation vs. inhibition induces apoptosis in acute lymphoblastic leukemia cells by differentially altering PI3K/Akt/mTOR or RAS/cRAF/MEK/Erk signaling
- Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3‐kinase and the mammalian target of rapamycin (mTOR)
- Inhibition of PI3 kinase by NVP-BEZ235 suppresses the PI3K/Akt/mTOR pathway and is growth inhibitory in human orthotopic primary pancreatic cancer xenografts
- Abstract# 5241: Effect of targeted inhibition of mTOR complexes on proliferation, apoptosis and cell cycle progression in colorectal carcinoma
- … # 2757: Combination therapy with inhibitors of mTOR and MEK1/2 (AZD6244) kinases, shows enhanced apoptosis and tumor growth inhibition in preclinical models
- Cyclosporin A and Cannabinoids induce autophagy-associated cell death in malignant glioma cells through inhibition of mTOR/S6K1 pathway
- Targeted Therapy: mTOR-Inhibition (Temsirolimus/CCI-779) in der Behandlung des metastasierten Mammakarzimons–Daten einer Phase II-Studie bei intensiv …
- Research article The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not …
- 2619: Inhibition Of mTOR or Apopotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells
- Wirkung des Tyrosinkinase-Inhibitors Sunitinib und des mTOR-Inhibitors Rapamycin auf die Proliferation und Apoptose von Ewing-Sarkom-Zellen in vitro
- Induction of granzyme B expression in human regulatory T cells requires TCR and CD28 triggering but not IL-2 and is suppressed by inhibitors of the PI3K-mTOR …
- 548: Inhibition of the MTOR Pathway by Rapamycin Reverses Renal Cystogenesis in Polycystic Kidney Disease Models
- Palomid 529, An Inhibitor of the Akt/mTOR Pathway Reduces Photoreceptor Cell Death Following Experimental Retinal Detachment
- Abstract P2-19-02: mTOR Pathway Inhibitor Nanoparticles Beneficially Modulate Autophagy in Triple Negative Breast Cancer Cells
- Palomid 529, a PI3K/Akt/mTOR dual TORC1/2 inhibitor, is a radiosensitizer with effect in both subcutaneous and orthotopic U251 glioblastoma tumor xenograft models
- Preclinical PKPD modeling and human dose projection of PF-04691502, a PI3K/mTOR dual inhibitor
- Abstract# 3202: Dual inhibition of phosphoinositide-3-kinase (PI3K) and mTOR shows enhanced efficacy in human neuroblastomas (NBs)
- PF-04691502, a potent and selective PI3K/mTOR dual inhibitor with antitumor activity
- … ) induces caspase-independent autophagic cell death in human non-small cell lung cancer cell lines through the inhibition of akt/mtor signaling pathways and …
- … pathway in hepatocellular carcinoma: evidence of its blockade and antineoplastic effect with a novel dual tyrosine kinase inhibitor (aee788) and a mtor inhibitor …
- … -negativen Mammakarzinomzellinien MDA-MB-231 und SKBr3 durch Behandlung mit GHRH-Rezeptor-Antagonist JMR-132 in Kombination mit mTOR-Inhibitor …
- Abstract# 2302: NVP-BEZ235 a dual inhibitor of phosphatidylinositol 3-Kinase (PI3 Kinase) and mammalian target of rapamycin (mTOR) potently enhances the effects …
- … -Studienprogramm zur Behandlung des HER2/neu-positiven (BOLERO 1/3) und ER-positiven (BOLERO 2) metastasierten Mammakarzinoms mit dem mTOR-Inhibitor …
- … Chemotactic Lipid S1P Regulates Hematopoietic Progenitor Cell Egress and Mobilization Via Its Major Receptor S1P1 and by SDF-1 Inhibition In a p38/Akt/mTOR …
- … tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor (TAE226) leads to apoptosis in esophageal cancer by inhibiting AKT-mTOR …
- MKC-1 significantly increases survival of mice bearing renal cell carcinoma CAKI-1 xenograft tumors through inhibition of the Akt/mTOR pathway
- Abstract# 2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with …
- … # 3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR …
- Abstract# LB-261: Combined inhibition of histone deacetylase and mTOR: A novel therapeutic approach for pancreatic cancer
- Abstract# 4405: Cytotoxic effects of simultaneous inhibition of AMPK/mTOR and IGF-1R signaling pathways on acute lymphoblastic leukemia
- Transduction of cells with adenovirus lacking early regions 1 and 3 overcomes hypoxia-induced inhibition of the mTOR pathway, and promotes the accumulation of …
- … ciblées dans le carcinome rénal: Description de la voie signalétique mTOR (mammalian target of rapamycin) et de l’importance de son inhibition dans le traitement du …
- … au tamoxifène et au fulvestrant dans le cancer du sein hormono-dépendant: stratégies de réversion par inhibition des voies PI3K/Akt/mTOR et MAPK: identification de …
- Inhibition of Amino Acid-mTOR Signaling by a Leucine Derivative Induces G1 Arrest in Jurkat Cells
- Präsidentenposter: Duale Inhibition der PI (3) K-Akt-mTOR und der Ras-Raf-MEK-Erk1/2 Signalkaskade in neuroendokrinen Tumorzelllinien pankreatischen-, midgut …
- P. 238 Inhibition de la voie de signalisation PI3K/mTOR dans les cellules endocrines tumorales STC-1: étude in vitro et in vivo
- mTOR inhibitors in cancer therapy
- mTOR signaling pathway and mTOR inhibitors in cancer therapy
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
- mTOR inhibitors in renal cell carcinoma
- mTOR inhibitors in tuberous sclerosis complex
- mTOR inhibitors in advanced renal cell carcinoma
- mTOR drives its own activation via SCFβTrCP-dependent degradation of the mTOR inhibitor DEPTOR
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- Current development of the second generation of mTOR inhibitors as anticancer agents
- Clinical presentation and management of mTOR inhibitor-associated stomatitis
- Development of ATP-competitive mTOR inhibitors
- PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
- mTOR inhibitor–associated proteinuria in kidney transplant recipients
- Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model
- The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
- Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
- The evolving role of mTOR inhibition in transplantation tolerance
- Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
- Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition
- Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer
- miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1
- Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
- Updating progress in sarcoma therapy with mTOR inhibitors
- mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK …
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- mTOR pathway and mTOR inhibitors in head and neck cancer
- Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells
- The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses
- Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis
- “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?
- Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition
- mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma
- mTOR inhibitors in breast cancer: a systematic review
- Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis
- Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma
- Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer
- Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials
- Utility of mTOR inhibition in hematologic malignancies
- Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
- Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
- Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro
- DEPTOR, an mTOR inhibitor, is a physiological substrate of SCFβTrCP E3 ubiquitin ligase and regulates survival and autophagy
- mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis
- Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats
- Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor–based immunosuppression? A systematic review and meta-analysis
- mTOR signaling, function, novel inhibitors, and therapeutic targets
- Tuberous sclerosis complex–associated angiomyolipomas: focus on mTOR Inhibition
- Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with …
- The promise of mTOR inhibitors in the treatment of colorectal cancer
- mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma
- Advancing age is associated with gene expression changes resembling mTOR inhibition: evidence from two human populations
- The mTOR inhibitor rapamycin suppresses DNA double-strand break repair
- The role of mTOR inhibitors for the treatment of B-cell lymphomas
- PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors
- Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
- A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
- Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor
- Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy
- MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
- Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma
- Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
- Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination
- Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
- Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy
- Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model
- Expanding human T regulatory cells with the mTOR-inhibitor rapamycin
- Combined therapeutic application of mTOR inhibitor and vitamin D3 for inflammatory bone destruction of rheumatoid arthritis
- The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines
- Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
- Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury
- The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells
- The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
- mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy
- Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
- Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family …
- Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model
- The efficacy of a novel, dual PI3K/mTOR inhibitor NVP‐BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
- mTOR inhibition and erythropoiesis: microcytosis or anaemia?
- mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions
- mTOR inhibitor for the treatment of hepatocellular carcinoma
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and …
- Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics
- Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast …
- Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT …
- Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations
- The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment
- The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice
- Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects
- mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
- Discovery and assembly-line biosynthesis of the lymphostin pyrroloquinoline alkaloid family of mTOR inhibitors in Salinispora bacteria
- Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma
- Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo
- Levels of p27 sensitize to dual PI3K/mTOR inhibition
- Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors
- Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
- Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
- Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells
- Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells
- Inflammation-Driven Reprogramming of CD4+Foxp3+ Regulatory T Cells into Pathogenic Th1/Th17 T Effectors Is Abrogated by mTOR Inhibition in vivo
- Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo
- The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models
- Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
- Costimulatory blockade with mTor inhibition abrogates effector T‐cell responses allowing regulatory T‐cell survival in renal transplantation
- Pushing the envelope in the mTOR pathway: the second generation of inhibitors
- ATP-competitive inhibitors of mTOR: an update
- Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC
- Perspectives on mTOR inhibitors for castration-refractory prostate cancer
- Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review
- Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing
- Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001
- Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy
- A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome
- Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
- Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II …
- Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients …
- A decade of experience using mTor inhibitors in liver transplantation
- Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
- Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001
- A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
- Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
- Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
- Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition
- The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy
- Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor
- mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation
- The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced …
- Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
- Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells
- Evidence for the involvement of mTOR inhibition and basal autophagy in familial Mediterranean fever phenotype
- Successful outcome of ganciclovir‐resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors
- Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin
- The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy
- The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
- Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors
- A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
- Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line …
- Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor
- Vascular disruption in combination with mTOR inhibition in renal cell carcinoma
- Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma
- mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma
- The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of …
- Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under …
- Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition
- Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR‐inhibitors in peripheral human blood
- … -cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive …
- Aging and cancer: can mTOR inhibitors kill two birds with one drug?
- The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines
- mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
- Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
- Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
- Brief report: a phase II “window-of-opportunity” frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC …
- Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
- mTOR inhibitors: A novel class of anti-cancer agents
- Quantitative visualization of autophagy induction by mTOR inhibitors
- Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model
- Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction
- Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
- Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug
- Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
- Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
- Resistance to the mTOR-inhibitor RAD001 elevates integrin α2-and β1-triggered motility, migration and invasion of prostate cancer cells
- Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
- Relief with rapamycin: mTOR inhibition protects against radiation-induced mucositis
- JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
- Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
- Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy
- Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease–antiprotease system by the mTOR inhibitor rapamycin
- … )phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of …
- Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1, 3, 5-triazine sulfonamide scaffold
- Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer
- MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition
- mTOR inhibition, a potential novel approach for bronchial carcinoids
- Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled …
- New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs)
- Inhibitors of PI3K/Akt and/or mTOR inhibit the growth of cells of myeloproliferative neoplasms and synergize with JAK2 inhibitor and interferon
- Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
- mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation
- Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
- mTOR inhibitors: facing new challenges ahead
- Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial
- AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation
- Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines
- Effects of mTOR inhibitors on components of the Salvador-Warts-Hippo pathway
- Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors
- Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
- The role of mTOR inhibitors in renal diseases
- How to use mTOR inhibitors? The search goes on
- The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer–a phase I trial
- SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
- The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response
- Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia
- mTOR inhibition in kidney transplant recipients
- The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro
- Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?
- The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma
- Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors
- Does the use of mTOR inhibitors increase long-term mortality in kidney recipients?
- Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1
- mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
- Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors
- Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells
- Inhibition of MTOR disrupts autophagic flux in podocytes
- Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer …
- Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors
- Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
- Rash to mTOR inhibitor everolimus: Systematic review and meta-analysis.
- Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER−) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors
- TNFα-mediated apoptosis in human osteoarthritic chondrocytes sensitized by PI3K-NF-κB inhibitor, not mTOR inhibitor
- α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
- … -dimensional quantitative structure–activity relationship (3D-QSAR) analysis and molecular docking of ATP-competitive triazine analogs of human mTOR inhibitors
- PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter
- Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy
- mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
- Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance
- Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma
- EGFR-and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells
- Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease
- The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.
- Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability
- Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality?
- The role of mTOR inhibition in renal transplant immune suppression
- mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro
- PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
- The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
- An evaluation tool for FKBP12-dependent and-independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR
- Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs
- … of mTOR activation by an AKT-independent mechanism provides support for the combined treatment of PTEN-deficient prostate tumors with mTOR and AKT inhibitors
- The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer.
- Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models
- Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
- Molecular imaging of therapy response with 18F-FLT and 18F-FDG following cyclophosphamide and mTOR inhibition
- Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic …
- mTOR kinase inhibitors as a treatment strategy in hematological malignancies
- A mechanism for synergy with combined mTOR and PI3 kinase inhibitors
- Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non–small-cell lung cancer
- Antihormonal therapy in breast cancer and mTOR inhibitors
- mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment
- Inhibition of mTOR by rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory
- Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors
- Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo
- PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).
- A review of research on mTOR inhibitors
- Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
- The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
- Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).
- Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and …
- A new clue to explain resistance to mTOR inhibitors
- Combined mTOR inhibition and OX40 agonism enhances CD8+ T cell memory and protective immunity produced by recombinant adenovirus vaccines
- Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition
- PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
- Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
- mTOR pathway and mTOR inhibitors in cancer therapy
- Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature
- mTOR pathway inhibition in renal cell carcinoma
- Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor
- mTOR inhibitors in sarcoma
- Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor
- Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) …
- Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor–mediated PI3K feedback loop activation via ERK1/2 and …
- Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma
- Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy
- mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
- … cohort study of the safety, pharmacokinetics and pharmacodynamics of SAR245409 (S09), an orally administered PI3K/mTOR inhibitor, in patients with …
- GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway
- Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition
- mTOR inhibitor as a potential drug of age-related disease
- The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
- Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors
- mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis
- EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
- Everolimus, an mTOR inhibitor, in combination with docetaxel for second-or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
- A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R …
- The mTOR inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B ALL
- Impairment of object recognition memory by rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation
- mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah …
- Effects of an mTOR inhibitor RAD001 on human breast cancer stem cells in vitro and in vivo.
- Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high …
- Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
- Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?
- In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
- Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma
- Phase I study of mTOR inhibitor everolimus plus CHOP in patients with advanced, aggressive T-cell lymphomas
- Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway
- Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
- The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing
- Mtor inhibition and the tumor vasculature
- Use of mTOR-inhibitors in solid tumors
- The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts
- Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies
- Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors
- Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
- mTOR Inhibition: a promise for a young heart
- mTOR inhibitor therapy for patients with carcinoid
- Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant …
- The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells
- Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype
- Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition
- Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
- The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal …
- Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
- Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management
- PI3K–AKT–mTOR inhibitors for the systemic treatment of endometrial cancer
- Abstract P4-08-01: PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT
- Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors
- Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis
- 3D-QSAR and docking studies of 4-morpholinopyrrolopyrimidine derivatives as potent mTOR inhibitors
- The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice
- PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2− Negative Metastatic Breast Cancer …
- Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone.
- Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
- Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
- Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy
- Genetic determinants of mTOR inhibitor response in breast and endometrial cancer
- Incidence and clinical features of mTOR inhibitor-induced interstitial lung disease
- Combined mTOR inhibition and autophagy inhibition: phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors
- Absence of mTOR inhibitor effect on hepatic cyst growth: a case report of a kidney transplant recipient with autosomal dominant polycystic kidney disease
- Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity
- Research progress of PI3K/Akt/mTOR signaling pathway and mTOR inhibitors in urologic malignancies
- The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis
- Discovery of triazine-benzimidazoles as selective inhibitors of mTOR
- Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for …
- Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience
- mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
- … of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the …
- Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival
- Inhibition of mTOR in carcinoid tumors
- Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
- Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells
- Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro
- In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
- Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells
- mTOR inhibitors in ovarian cancer
- The dual PI3K/mTOR inhibitor, PI-103, demonstrates therapeutic efficacy in undifferentiated pleomorphic sarcoma
- Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus
- Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin …
- Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA …
- Evaluating the Therapeutic Potential of mTOR Inhibitors Using Mouse Genetics
- mTOR inhibitors: a myth, a cure for cancer or something in between?
- Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.
- A phase 1b study to evaluate the safety and pharmacology of the dual PI3K-mtor inhibitor GDC-0980 in combination with a fluoropyrimidine, oxaliplatin, and …
- Identification and Optimization of Dual PI3K/mTOR Inhibitors
- Effect of sequential docetaxel followed by mTOR inhibitor temsirolimus on suppression of PI3K overactivation resistance mechanism.
- Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice
- Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling
- Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
- Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62 …
- mTOR inhibition in management of advanced breast cancer
- Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
- Inhibition of autophagy as a strategy to augment radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235
- Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake
- mTOR targets its own inhibitor
- The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells
- Suppression Of Lung Fibrosis By Dual MTOR Inhibitors
- Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen …
- Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway
- Preclinical assessment of the absorption and disposition of the PI3K/mTOR inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human
- PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells
- A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with …
- Inhibition of mTOR signaling by oleanolic acid contributes to its anti‐tumor activity in osteosarcoma cells
- The Role of mTOR Inhibitors and P13K Pathway Blockade in RCC
- Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR
- Azacitidine in combination with the mTOR inhibitor everolimus in relapsed and refractory AML
- Oral toxicity with mTOR inhibitors in cancer therapy
- Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.
- mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
- The effect of mTOR inhibitors on the rabbit ovarian secretory activity
- Abstract P5-19-02: Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
- Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.
- Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)
- Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine
- Combining allografting with mTOR inhibitors for metastatic renal cell cancer
- Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells
- What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI?
- Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats
- Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling
- LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain …
- … cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1
- β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/mTOR signalling pathways
- Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells
- 402 Reconstitution of CMV-Specific Immunity after Heart Transplantation Is Modulated by mTOR Inhibition, but Not by Antiviral Strategy
- Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling
- Abstract LB-7: HPV-associated HNSCC: widespread mTOR pathway activity and preclinical evaluation of mTOR inhibitors rapamycin and RAD-001
- Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis
- Biological Toxicity can be a Surrogate Marker of Efficacy in Patients (PTS) Treated with MTOR Inhibitors (MTORI) for MRCC
- Abstract C69: Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix …
- A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR
- Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy
- Dehydrocostuslactone Suppresses Angiogenesis In Vitro and In Vivo through Inhibition of Akt/GSK-3β and mTOR Signaling Pathways
- Efficacy of sunitinib rechallenge in kidney cancer: are mTOR inhibitors involved or is it only a matter of time?
- Unique Role of mTOR Inhibitor, Everolimus in Inducible Regulatory T Cells
- Subependymal giant cell astrocytoma: role of mTOR pathway and its inhibitors
- Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake
- PDK1-driven Myc signaling regulates cellular response to mTOR inhibitors
- Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)
- PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of …
- Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor
- Somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor
- Radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235
- Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma
- Sorafenib (Sor) and mTOR inhibitors (mTORinh) combination for hepatocarcinoma recurrence after liver transplantation.
- Radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235
- mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations
- Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent nonresectable chondrosarcomas.
- ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma
- Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and …
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
- Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on chemotherapy and antiangiogenic response in pancreatic cancer.
- … with HR+/HER2–locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment–BELLE-3
- Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia
- The dual PI3K/mTOR inhibitor NVP-BEZ235 has a potent antiproliferative action in human nonfunctioning pituitary adenomas
- A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex
- mTOR inhibitors in cancer treatment
- Fisetin, a dietary flavonoid and novel mTOR inhibitor for treatment and prevention of prostate cancer
- AKT/mTOR as novel targets of polyphenol piceatannol possibly contributing to inhibition of proliferation of cultured prostate cancer cells
- Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development
- Combination strategy of gemcitabine with the dual PI3K/mTOR inhibitor NVP-BEZ235 in pancreatic cancer cells.
- Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40
- A phase I trial of the mTOR inhibitor temsirolimus (TEM) in combination with capecitabine (CAP) in patients with advanced malignancies.
- Overview and mechanism of action of mTOR inhibitors
- Inhibition of autophagy in combination with ponatinib or dual PI3K/mTOR inhibition to improve treatment response for both Bcr-Abl dependent and …
- Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered …
- Dual inhibition of PI3K/Akt/mTOR pathway and role of autophagy in non-small cell lung cancer cells
- Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1, 4‐phenylenebis (methylene) selenocyanate in human prostate cancer cells
- Dual PI3K/mTOR inhibitor NVP BEZ-235 suppresses translation of hypoxia-inducible factor (HIF)-1α and increases cell death under hypoxia
- sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR
- The effect of dual PI3K/mTOR inhibitor NVP-BGT226 on cell cycle and survivin and STAT3 gene expression in human pancreatic cancer cell lines.
- Effect of the combination of mTOR inhibitor ridaforolimus and HDAC inhibitor vorinostat on in vitro synergism in synovial sarcoma, osteosarcoma, and a range of other …
- mTOR inhibitors in breast cancer
- Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors.
- MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells
- mTOR inhibitors in Hodgkin’s and non-Hodgkin’s lymphomas
- Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells
- … -3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or …
- Pml represses tumour progression through inhibition of mTOR
- Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway
- Utilizing mTOR inhibition to study the role of mTOR signal transduction in angiogenesis
- Anti-tumor clinical research of mTOR inhibitor
- mTOR inhibitors in renal cell carcinoma
- Effects of an mTOR inhibitor on immune subpopulations
- Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels
- DEPTOR is a regulator of response to mTOR kinase inhibitors in multiple myeloma
- New developments in the therapy for NETs: new drugs including mTOR inhibitors
- MTOR Inhibitors and Beyond: Targeting a Critical Pathway
- Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non‐small‐cell lung cancer cells
- Abstract A52: Comparison of the efficacy of different mTOR inhibitors for the treatment of prostate cancer
- Dual inhibition of PI3K/AKT and mTOR signaling in human non-small cell lung cancer cells by a dietary flavonoid fisetin
- Identification and Optimization of Dual PI3K/mTOR Inhibitors
- The mTOR inhibitor, RAD001, displays higher cytotoxicity in leukemias with hyperactivated PI3K/AKT/mTOR pathway
- PI3K and/or MTOR Inhibitors: Current Status, Future Directions
- A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways
- Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
- Investigation of the effects of different mTOR inhibitors on protein synthesis
- mTor inhibition in RCC: proof of concept, clinical use, and future directions
- Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification
- Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
- Late Conversion Is a Risk Factor for mTOR Inhibitor Induced Proteinuria: 1616
- Research Article A Decade of Experience Using mTor Inhibitors in Liver Transplantation
- mTOR Drives Its Own Activation via SCFᵝᵀʳCᴾ-Dependent Degradation of the mTOR Inhibitor DEPTOR
- GSK3 plays a crucial role in determining cell response to mTOR inhibitors
- Inhibition of PI3K/mTOR leads to adaptive resistance in extracellular matrix attached cancer cells
- Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
- Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR
- Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells
- Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors
- Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer
- Enhancing anti cancer activity of PI103, a dual PI3K/mTOR inhibitor, by designing a self assembled Nanoformulation
- Early switch from calcineurin inhibitors to mTOR inhibitors leads to improved renal graft function
- UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma
- mTOR inhibition in hormone-resistant breast cancer
- mTOR inhibitors hamper cell viability in selected human medullary thyroid carcinoma primary cultures
- Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemia
- Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL
- MTOR INHIBITORS REDUCES THE IN VITRO MINERALIZATION OF VASCULAR SMOOTH MUSCLE CELLS: PP. 33.125
- Effects of mTOR inhibitors in the control of non functioning pituitary adenomas cell growth
- PIK3CA Mutations Predict Response to PI3K/AKT/mTOR Inhibitors
- GFR meets mTOR: value of different methods to measure and estimate GFR & (side) effects of mTOR inhibition in renal transplantation
- mTOR Inhibition in Liver Transplantation: How to Dose for Effective/Safe CNI Reduction?: 1562
- Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling
- Genotype-dependent efficacy of a Dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
- The Effect of Mtor-Inhibition on Inflammation in Kidney Ischemia-Reperfusion Injury in Mice: 1124
- Use of PTEN status to determine the functional outcome of combined MEK and mTOR inhibition.
- Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
- Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen …
- Treatment of Patients with Metastatic Kidney Cancer During Haemodialysis with mTOR Inhibitors
- Combined Effect of Mtor Inhibitors and FTI for the Growth Inhibition of T Cell Lymphoma-Involvement of Different Molecular Mechanisms According to the Lymphoma …
- Design, Synthesis, Characterization and Pharmacological Evaluation of mTOR Inhibitors for Anticancer Activity.
- Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with …
- Efficacy of the ATP-competitive mTOR inhibitor AZD8055 in PTEN-wild type cancer cells
- Radiosensitizing Effects of mTOR Inhibitor (Temsirolimus) Under Normoxic/Hypoxic Conditions
- Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors
- Severe Cardiotoxicity in a Patient with Renal Cell Carcinoma Treated with MTOR Inhibitor: A case Report
- Abstract PR4: Incomplete inhibition of phosphorylation of 4EBP1 is a mechanism for KRAS driven resistance to the ATP-competitive mTOR inhibitor PP242 in …
- mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
- The novel mTOR inhibitor RAD001 (Eeverolimus) induces antiproliferative effects in goat fetal fibroblasts
- mTOR Inhibition Results in Oocyte Loss in Human Ovarian Cortex.
- Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression
- Understanding the mechanism of mTOR inhibition in Human Herpes Virus-8 associated malignancies
- mTOR inhibitor Torin1 induces antiproliferative effects in MtT/E cell line and human pituitary tumors
- Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
- mTOR inhibition radiosensitizes bladder cancer tumor cells in vitro and in vivo: A novel strategy for treatment
- PUK13 COST-EFFECTIVENESS ANALYSIS OF THE EARLY CONVERSION OF TACROLIMUS TO MTOR INHIBITORS IN PATIENTS WITH RENAL …
- Early detection of cardiac dysfunction induced by the mTOR inhibitor temsirolimus.
- Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma.
- Multimodal Imaging of a Dual PI3K/mTOR Inhibitor Demonstrates Strong Effects on Vascular Function
- Identifying and Targeting Molecular Deregulations in Uterine Leiomyosarcoma: A Role for mTOR Inhibition-Based Combination Therapies
- Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH …
- Addition of the mTOR Inhibitor Rapamycin Deepens Response to HDAC Inhibition or Hypomethylating Therapy in Myelodysplastic Syndromes
- Late Conversion from CNI to mTOR Inhibitors Rather Preserves than Improves Renal Function in Kidney Allograft Recipients: 2263
- … Impairs Vascular Endothelial Recovery After Stent Placement In the Setting of Locally Eluted mTOR inhibitors via S6K Dependent Inhibition of Cell Proliferation
- Prostate Cancer Stem Cells Display Lowered Activity of the mTOR Pathway and Resistance against mTOR Inhibition Caused by Elevated Hypoxic Signaling
- Development of novel, potent and selective small molecular weight PI3K/mTOR inhibitors for the treatment of cancer
- MEK and PI3K/mTOR Inhibition in RAS Mutant Colorectal Cancer
- Loss of TSC2 function predicts optimal therapeutic response to combinations of MEK and mTOR inhibitors
- Preclinical efficacy of the novel dual PI3K/mTOR inhibitor, BEZ235 compared with RAD001 in HER2+ breast tumors
- mTOR inhibitor increases radiation sensitivity in a radiation-resistance cancer cells through induction of cellular senescence
- Abstract P352: The Anticancer mTOR-Inhibitor Temsirolimus Produces Left Ventricular Dysfunction in Murine Hearts
- The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors
- … Of Mesenchymal Stromal Cell From Individual IPF Patients To MTOR Inhibitor Rapamycin And Its Correlation To Dysregulation In The PI3K/PTEN/Akt/mTOR Pathway
- Radiosensitization by the mTOR inhibitor RAD001 involves the induction of autophagy in two cancer cell lines
- Cell death induction end-points to identify new cancer indications with high likelihood of response to dual PI3K/mTOR inhibitors
- Protein microarray analysis of aberrant signaling pathways in acute myeloid leukemia to predict the patients responsiveness to PI3K/akt/mtor inhibitors
- mTOR Inhibition has Similar Effects to Treatment with Substance P in the Cornea of Pseudomonas aeruginosa-Infected BALB/c Mice
- … of inhibitors specific for torc2 as strategy to overcome feedback erk activation in multiple myeloma cells when treated with second generation mtor inhibitors
- Abstract P058: Necessity of mTOR Inhibition and Autophagy Induction for Maintaining Cardiac Homeostasis During Caloric Restriction
- Abstract C67: Investigating PI3K/mTOR inhibition in a mouse model of colorectal cancer mutant for both Apc and Pten.
- mTOR inhibition promotes autophagy that reduces chemosensitivity and is partially restored by chloroquine
- Lymphoma Resulting From β-Catenin Stabilization are Sensitive to mTOR Inhibition: A Unit on Cancer and the Immune System.
- mTOR inhibition hampers cell viability in selected human medullary thyroid carcinoma primary cultures
- Combination of a PI3K/mTOR inhibitor and a MEK inhibitor at suboptimal dose significantly inhibits growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
- miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1
- Enhanced therapeutic efficacy of transarterial chemoembolisation treatment in hepatocelluar carcinoma (HCC) by mTOR inhibitor RAD001: implication for a novel …
- A novel flow cytometry based assay for therapeutic monitoring of mTOR-inhibitor induced immunosuppression after heart transplantation
- SORAFENIB PLUS MTOR-INHIBITOR COMBINATION THERAPY FOR TREATMENT OF RECURRENT HEPATOCELLULAR CARCINOMA AFTER LIVER …
- Grapefruit Juice Increases Bioavailability of mTOR Inhibitor; Turning a Problem with Oral Therapies into an Advantage
- mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma
- Role of Rapamycin as mTOR inhibitor in vitro and its use in the treatment of recurrent hepatitis C after liver transplantation
- mTOR-Inhibitors and CMV Infection after Solid Organ Transplantation-Is CMV Prophylaxis Still Necessary?: 2146
- mTOR Inhibitors Reduce Cerebral Vasospasm in a Subarachnoid Double‐Hemorrhage Canine Model
- P073. Dermatological follow-up of patients with non melanoma skin cancer after solid organ transplantation switched to an mTOR inhibitor
- The Significance of mTOR Inhibitor, Everolimus in TGF-β-Induced Regulatory T cells from Cord Blood
- Germline single nucleotide polymorphisms influence survival status in patients with stage IV renal cell carcinoma receiving VEGF or mTOR inhibitor therapy
- Anti-Proliferative Actions of the mTOR Inhibitor Temsirolimus in Primary Human Retinal Pigmentepithelium (RPE) and Vascular Endothelial Cells
- Diffusion-weighted Magnetic Resonance Imaging of Response to PI3-Kinase/mTOR Inhibition Studied in Human Ovarian Cancer Xenografts
- Cucurbitacin B as a direct mTOR inhibitor synergizes with methotrexate for treatment of human osteosarcoma
- Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
- Abstract B58: The ATP-competitive mammalian target of rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired rapamycin resistant …
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells
- Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors.
- Effects of two classes of immunosuppressive agents, mTOR inhibitors vs. calcineurin inhibitors, on the generation and function of human alloreactive T helper cells …
- Adverse events associated with mTOR inhibition: Results from the A2310 study comparing everolimus and mmf in de novo heart transplant recipients
- Investigation of the role of chondroitin sulfate proteoglycan in causing treatment resistance in melanoma to PI3k/mTOR inhibition.
- Predictive Value of Time to Best Response for Efficacy MTOR Inhibitors (MTORI) in Metastatic Renal Cell Carcinoma (MRCC) Patients (PTS)
- mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
- Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure–activity relationships of a series of quinoline and …
- Baicalein induces tumor suppression in triple negative breast cancer by mTOR inhibition mediated through DDIT4 expression
- Targeting PI3K/mTOR inhibitor induced survival programs abrogates resistance to cell death in ECM-attached cancer cells
- Effect of PIK3CA and KRAS mutations on sensitivity to ATP-competitive mTOR inhibitors in a primary xenograft model of colorectal carcinoma.
- Combination treatment with hypoxia-activated prodrug TH-302 and the mTOR inhibitor everolimus results in enhanced antitumor efficacy in preclinical models
- mTOR-Inhibitor-Attributed Events: Review of 2-Year Safety Data in Heart Transplant Recipients Receiving Everolimus Vs MMF in the Randomised Multi-Centre 2310 …
- Abstract MS1-3: Clinical Development of mTOR Inhibitors in Breast Cancer
- Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation
- Abstract LB-124: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s …
- Phase I Trial of the mTor Inhibitor Rapamycin in Combination with Short-course Radiotherapy in Operable Rectal Cancer
- Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line.
- The ATP-competitive mTOR inhibitor Torin2 enhances sensitivity of the ALK F1174L mutation to crizotinib in neuroblastoma
- … Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced Apoptosis in …
- Targeted PI3K/mTOR inhibition impairs tumor cell motility and bone metastatic outgrowth via modulation of p27
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, suppress tumorigenicity of ovarian clear cell carcinoma cells.
- Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
- An endogenous mTOR inhibitor, PRAS40, is upregulated in lung cancer and contributes to tumor cell invasion and chemoresistance
- Interim results of a phase II study of the mTOR inhibitor everolimus in patients with pretreated metastatic gastric and esophageal adenocarcinoma.
- Brief Report: A Phase II” Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an …
- Risk of rash and stomatitis with everolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
- A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer
- ImmunoPET Imaging of VEGF Response To mTOR Inhibition With 64Cu-Radiolabeled Bevacizumab
- The mTOR-‐inhibitor Rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response
- mTOR Inhibition and Hepatic Artery Thrombosis inde NovoLiver Transplant Recipients-Mitigation Strategy with Everolimus: 12 Month Results from Study H2304: 1563
- Effects of two classes of immunosuppressive agents, mTOR inhibitors vs. calcineurin inhibitors, on the generation and function of human alloreactive T helper …
- Observation of Morphology and Proliferative Density for Cashmere Goat Fetal Fibroblasts after mTOR Inhibition with Optical Microscope Cell Imaging
- Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA, Tyr3-octreotate
- … toxicity study of the immunosuppressant mTOR inhibitors everolimus and sirolimus in combination with the calcineurin inhibitors cyclosporine and tacrolimus
- … Cyclosporine A with Experimental Ischemia-Reperfusion Injury on Pro-Fibrotic Epithelial-Mesenchymal Transition Is not Reversible by Switching to the mTOR Inhibitor …
- Chronic inhibition of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
- Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph+ Leukemia Cells
- Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
- Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor …
- The proteasome inhibitor MG-132 induces AIF nuclear translocation through down-regulation of ERK and Akt/mTOR pathway
- … Combinations of a Selective MEK 1/2 Inhibitor (Pimasertib) With PI3K/MTOR Inhibitors or With Multi-Targeted Kinase Inhibitors in Pimasertib-Resistant …
- Mammalian Target of Rapamycin (mTOR) Inhibition Attenuates Angiotensin II-Induced Hypertension and Endothelial Dysfunction
- Inhibitors of Mtor and PI3K Synergistically Block Plasmacytoma Cell Growth
- … a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR …
- Six-Year Survival after Orthotopic Liver Transplantation (OLTtx) UsingDe NovoCombination Treatment of Mtor Inhibitor Everolimus (ERL) with Mycophanolate Sodium …
- Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC)
- Combination of antiangiogenic therapy using the mTOR inhibitor RAD001 (everolimus) and low-dose chemotherapy for locally advanced and/or metastatic pancreatic …
- mTOR inhibition in macrophages of asymptomatic HIV+ persons reverses the decrease in TLR4-mediated TNFα release through prolongation of MAPK …
- Combining whole transcriptome expression with SILAC to investigate mTOR inhibition in cultured baboon fetal proximal tubule cells
- Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines
- … Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor
- Abstract PR-11: Pharmacogenomics of mTOR inhibitors: A genome-wide association approach of biomarker identification.
- WITHDRAWN: Mammalian target of rapamycin (mTOR) inhibition in polycystic kidney disease (PKD): From bench to bedside
- Activity of a novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 to enhance antitumor activities of gemcitabine and EMAP II in pancreatic cancer.
- The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases
- Gemcitabine combined with the MTOR Inhibitor Temsirolimus (CCI-779) in Patients with Inoperable or Metastatic Pancreatic Cancer (He 3/07). A Phase I …
- Abstract LB-201: Prostate cancer stem cells display low mTOR activity and resistance to mTOR inhibitors in hypoxia
- Functional genetic screens to find modulators of sensitivity to inhibitors of the PI3K/mTOR pathway
- Drug Interaction Between Cyclosporine and Mtor Inhibitors in Experimental Model of Chronic Cyclosporine Nephrotoxicity and Pancreatic Islet Dysfunction: 1857
- Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian …
- DEPTOR, an mTOR inhibitor, is a novel substrate of SCFαTrCP E3 ubiquitin ligase upon S6K1/RSK1 phosphorylation and regulates survival and autophagy
- … from hR1, a humanized anti-insulin-like growth factor receptor-I monoclonal antibody, are enhanced in renal cell carcinoma and synergistic with an mTOR inhibitor
- Activity of insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic refractory …
- Synergistic Control of Acute GvHD: Effectively Down-Regulating T Cell Proliferation and Cytotoxicity with Combined mTOR Inhibition and CD28: CD80/86 …
- Abstract P4-08-02: Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations.
- Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
- 145 Novel Immunoassay for Therapeutic Drug Monitoring of mTOR-Inhibitors after Heart and Lung Transplantation
- The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells
- Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells
- Sensitivity of gastric cancer cell lines against 2-deoxy-D-glucose is independent of PI3K/mTOR inhibition
- 321 HDAC BLOCKADE COUNTERACTS RESISTANCE DEVELOPMENT CAUSED BY CHRONIC MTOR INHIBITION
- 416 IMPACT OF COMBINED HDAC AND MTOR INHIBITION ON THE INVASIVE POTENTIAL OF PROSTATE CANCER CELLS
- 935 iMPaCt of CoMbined hdaC and Mtor inhibition on the invasive Potential of Prostate CanCer Cells
- Abstract A57: Chondroitin sulfate proteoglycan 4 (CSPG4) Mediates Melanoma Cell Survival During PI3K and mTOR Inhibition
- The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas
- Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel® (MoTOR) phase II trial by the …
- Treatment effects of the novel mTOR kinase inhibitor AZD8055 in prostate cancer cell models
- Inhibition of mTOR and AKT as a potential strategy for the treatment of basal-like breast cancer
- Abstract B161: PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
- Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma
- Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR
- Inhibition of Mammalian Target of Rapamycin (mTOR) Complex 1 and 2 by PP242 Induces G1 Growth Arrest in Pancreatic Ductal Adenocarcinoma and when …
- Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative …
- Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors
- Structure–activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6, 5-heterocycles …
- Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
- NVP-BEZ235, a dual inhibitor of phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), is a potent inhibitor of lymphoma cell growth and …
- Inhibition of mTOR promotes dendritic cell activation and survival and enhances therapeutic autologous vaccination in mice (52.4)
- A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
- Coordinate autophagy and PI3K/Akt/mTOR pathway inhibition enhances cell death in melanoma
- Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors
- Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on …
- Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma
- Inhibition of mTOR with everolimus (RAD001) and silencing by vascular endothelial cell growth factor specific siRNA induces additive antitumor activity in …
- Inhibition of Notch and mTOR by nelfinavir as a novel approach for T cell acute lymphoblastic leukemia (T-ALL)
- Combined inhibition of JAK2 and mTOR signaling results in enhanced efficacy in in-vitro and preclinical mouse models of JAK2V617F-driven …
- Docosahexaenoic acid-induced cell death may be related to inhibition of mTOR through AMPK activation and PI3K/Akt inhibition in human non-small cell lung cancer …
- Targeting mTOR by a New Generation of Kinase Inhibitors Sensitizes Leukemia Cells for Chemotherapy Via Suppressing FANCD2 Expression
- Study of mTOR signaling inhibitors as potential treatment for TSC
- … negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial …
- Sirolimus plus MEC chemotherapy has significant activity in high risk AML patients especially those who exhibit in vivo inhibition of the mTOR pathway
- The director’s cut: a genome-wide characterization of active translation of messenger RNA following inhibition of mTOR will transform our view of this signalling …
- RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR
- Inhibitors of phosphatidylinositol 3-kinase and mTOR but not Akt enhance replication of bovine ephemeral fever virus
- … to the BRAF inhibitor GSK2118436, mediated by NRAS or MEK mutation, can be overcome with combinations that inhibit BRAF and MEK, BRAF and PI3K/mTOR, or …
- Correction: inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease
- Pulsatilla saponin D suppresses angiogenesis and induces apoptosis via inhibition of PI3K/Akt/mTOR signaling pathway in hepatocellular carcinoma
- Growth-Inhibitory Effects of a Class I PI3K Inhibitor GDC-0941 Are Modulated by Hypoxia-Induced mTOR Pathway Activation in Mantle Cell Lymphoma
- … , induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell …
- Mammalian target of rapamycin (mTOR) sigaling pathway involved in the inhibition of silence information regulator1 (Sirt1) on fat deposition of mice.
- Abstract LB-383: Translational studies of the novel prodrug PI3K/mTOR/PIM1 inhibitor SF1126 in DLBCL
- Inhibition of Histone Deacetylases (HDACs) and mTOR Signaling: Novel Strategies Towards the Treatment of Prostate Cancer
- Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer
- Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.
- Tangeretin and its metabolite 4′‐hydroxytetramethoxyflavone attenuate EGF‐stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR …
- Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor, in vitro in clear cell renal cell carcinoma (RCC)
- Nuclear factor of activated T-cells (NFAT) c3 inhibition of mTOR signaling through induction of REDD1 in human intestinal cells
- Discovery and SAR exploration of a novel series of imidazo [4, 5-b] pyrazin-2-ones as potent and selective mTOR kinase inhibitors
- Erratum to: Inhibition of mTOR in carcinoid tumors
- Design and synthesis of small-molecule inhibitors of two cancer targets: mTor and MDM2/p53
- Abstract B160: PWT33597 promotes apoptosis in tumor cells through balanced dual inhibition of PI3K alpha and mTOR.
- Abstract P6-04-11: Combination of PI3K-AKT-mTOR and MEK-ERK pathway inhibitors overcome acquired resistance to letrozole in ER+ breast cancer models
- Untersuchung der Proliferationshemmung von Brustkrebszellen durch Chloroquin in Kombination mit dem mTOR-Inhibitor Everolimus (RAD001)
- Abstract CN02-02: Dual inhibition of mTOR and IGFR pathways.
- Gezielte molekulare Therapie des Mantelzell-Lymphoms In vitro Wirksamkeit von mTOR-Inhibitor RAD001 und PNP-Inhibitor Forodesin+ dGUO in Mono-und …
- Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor
- mTOR pathway links suppressed autophagy to HDAC inhibitor-induced apoptosis in myeloid leukemia
- Differential effects of mTOR and PI3K inhibition on the phosphorylation of polysome-associated proteins
- The identification of the mTOR-regulated phosphoproteome and a mediator of feedback inhibition to P13K-Akt
- MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling via PRAS40
- Abstract B25: The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines
- Competitive inhibition of mTOR results in tumor specific radiosensitization
- In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL).
- Abstract A165: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
- Inhibition of Mammalian Target of Rapamycin (mTOR) in Epidermis
- HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34
- Prostate Cancer Radiation Enhancement Through mTOR Pathway Inhibition: The Role of Tumor and Vascular Compartments
- Discovery and optimization of potent and selective benzonaphthyridinone analogs as dual mTOR/ATR small molecular inhibitors for treatment of cancer
- Targeting of endocrine therapy resistance through combined mTOR and histone deacetylase inhibition.
- Abstract PR6: A cooperative molecular response to combined mTOR/HDAC inhibition revealed by transcriptional co-expression analysis
- Tumor regression in a 3-D melanoma model by the dietary flavonoid fisetin is associated with inhibition of Akt/mTOR signaling
- Erprobung einer Kombinationstherapie aus dem Histondeacetylaseinhibitor Valproat und dem mTOR-Inhibitor Temsirolimus für das fortgeschrittene …
- Target-Therapie mit dem mTOR-Inhibitor Temsirolimus (Torisel®)
- Inhibition of the PI3K and mTOR pathways reverses gemcitabine resistance in pancreatic cancer
- Curcumin Potentiates Antitumor Activity of Imatinib via Inhibition of the AKT/mTOR Signaling Pathway and Down-Regulation of Bcr-Abl Gene in Philadelphia …
- Activation of AMP-activated protein kinase (AMPK) enhances Radiosensitization via inhibition of mTOR pathway in Rapamycin-resistant non-small cell lung cancer …
- PIM kinase inhibition blocks activation of mTOR pathway components and enhances rapamycin-mediated tumor growth inhibition in prostate cancers
- Targeting PI3K/mTOR/MAPK pathway in inhibition of cell growth and dissemination of glioblastoma multiforme
- Untersuchung der Proliferationshemmung von Brustkrebszellen durch das Bioflavonoid Quercetin in Kombination mit dem mTOR-Inhibitor Everolimus (RAD001 …
- Ciclopirox induces autophagy through reactive oxygen species-mediated inhibition of mTOR signaling pathway
- Enhancement of Autophagy by Simvastatin through Inhibition of Rac1‐mTOR Signaling Pathway
- Dual Inhibition of mTOR in hepatocellular carcinoma induces tumor regression, return to normal liver gene expression and autophagy
- Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma
- Nebivolol‐mediated Inhibition of Nutrient Sensor mTOR‐and Inflammatory Marker JAK2‐mediated Signaling in Myocardium: Involvement of Angiotensin II Receptors
- Interrelations between roles of phospholipase C-gamma 1 inhibition, mTOR and glycolytic enzymes in growth and survival of glioblastoma cells
- Inhibition thérapeutique de mTOR dans la polykystose rénale autosomique dominante
- Ex vivo analysis of the mTOR/PI3K & MEK/ERK inhibitors, BEZ235 & AZD6244, alone and in combination in human tumor primary culture micro-spheroids: Exploration …
- … inhibitor, Olaparib with pathway-targeted drug, vandetanib (Caprelsa™) in TNBC: A proof of principle study to determine the role of PI3K-AKT-mTOR or RAS-MAPK …
- The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway
- Abstract LB-20: mTOR kinase inhibition relieves feedback suppression of receptor tyrosine kinase leading to a biphasic regulation of AKT signaling in breast cancer …
- Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors
- P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic …
- HM-032, a novel PI3K/mTOR dual inhibitor, is active on K-Ras/Raf mutation tumors through up-regulation of Bim
- Preclinical activity of INK128, a TORC1/2 inhibitor, in triple negative breast cancer: A combination of PARP inhibitor with PI3K-mTOR pathway-targeted inhibitor
- … trägt zur Entstehung der Insulin-induzierten Hepatokarzinogenese bei und lässt sich effektiv durch Gabe des dualen PI3K/mTOR Inhibitors NVP-BEZ235 zurückführen
- Abstract B163: First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on …
- Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer
- P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor …
- Etp-47187 a novel potent and efficacious dual inhibitor of phosphoinositide-3-kinases and mTOR
- P3-18-03: In Vitro Potency of mTOR Kinase (TOR1/TOR2) Inhibitor, INK128 in ER+ and HER2 Overexpressing Breast Cancer Cells.
- Steigerung der Apoptoserate durch kombinierte PI3K/mTOR-und Proteasom-Inhibition bei kolorektalen Karzinomzelllinien
- Abstract P6-11-02: Inhibition of mTOR and Fatty Acid Synthase (FASN) overcome acquired resistance to Trastuzumab, Lapatinib and both in HER2+ breast cancer
- Intratumoral delivery of rapamycin: advantages on mTOR pathway inhibition through direct delivery of intratumoral rapamycin in squamous cell carcinomas (초)
- Strategies for the management of adverse events associated with mTOR inhibitors
- Adverse events associated with mTOR inhibitors
- Rapalogs and mTOR inhibitors as anti-aging therapeutics
- mTOR inhibition improves immune function in the elderly
- Differentiating mTOR inhibitors in renal cell carcinoma
- mTOR inhibitors in the treatment of breast cancer
- mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques
- A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
- The role of mTOR inhibitors in liver transplantation: reviewing the evidence
- A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials
- The pros and the cons of mTOR inhibitors in kidney transplantation
- Metabolic complications with the use of mTOR inhibitors for cancer therapy
- Clinical development of mTOR inhibitors in breast cancer
- mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome
- mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review
- Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy
- Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
- Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors
- mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms
- Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis
- Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
- mTOR inhibitors as a new therapeutic option for epilepsy
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- mTOR inhibition: from aging to autism and beyond
- Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation
- Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
- Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
- Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition
- Is mTOR inhibition a systemic treatment for tuberous sclerosis?
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
- Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo
- mTOR inhibitors in pediatric kidney transplantation
- Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts
- Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath …
- Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment
- FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
- Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
- Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes
- Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates
- mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target
- Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
- TBK1 regulates prostate cancer dormancy through mTOR inhibition
- mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy
- Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor
- Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway
- mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
- Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
- mTOR inhibition increases cell viability via autophagy induction during endoplasmic reticulum stress–An experimental and modeling study
- Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells
- Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma
- From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches
- Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence
- Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines
- Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced …
- mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis
- Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
- PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response
- Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic …
- … anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in …
- Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy
- A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
- Non‐melanoma skin cancer is reduced after switch of immunosuppression to mTOR‐inhibitors in organ transplant recipients
- Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
- Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells
- PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
- Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP‐BEZ235 in renal cell carcinoma cells
- Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
- mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA
- PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt …
- The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
- Novel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions
- Predicting mTOR inhibitors with a classifier using recursive partitioning and naive Bayesian approaches
- mTOR inhibitors and renal allograft: Yin and Yang
- The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
- mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis
- Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
- Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition
- Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
- Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer
- NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant …
- Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
- Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3‐kinase inhibitor BEZ235 and the PI3‐kinase inhibitor BKM120 in hepatocellular carcinoma
- mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids
- Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions
- mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical …
- Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors
- Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative …
- Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses
- Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
- mTOR inhibitors in advanced breast cancer: ready for prime time?
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck …
- The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells
- The dual PI3K/mTOR inhibitor NVP‐BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial‐lysosomal cross‐talk
- NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
- Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer
- Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven
- Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP‐BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal …
- Inhibition of adipogenesis by oligonol through Akt-mTOR inhibition in 3T3-L1 adipocytes
- Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
- Role of mTOR inhibitor in cholangiocarcinoma cell progression
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
- Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors
- Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer
- Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid
- Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule
- Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
- Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms
- Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant …
- Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy
- Optimising the use of mTOR inhibitors in renal transplantation
- mTOR Inhibition ameliorates cognitive and affective deficits caused by Disc1 knockdown in adult-born dentate granule neurons
- A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition
- Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
- Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
- Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition
- Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and …
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
- mTOR Inhibitors induce cell-cycle arrest and inhibit tumor growth in epstein–barr virus–associated T and natural killer cell lymphoma cells
- PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
- The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1
- Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1
- Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus …
- The effect of mTOR-inhibition on NF-κB activity in kidney ischemia-reperfusion injury in mice
- mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma
- PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats
- mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma
- Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition
- Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 …
- Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen
- Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423
- Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma
- mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines
- The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer
- MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1
- mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
- An in silico protocol for identifying mTOR inhibitors from natural products
- Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression
- The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line
- The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis
- Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection
- Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer
- Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis
- … inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of …
- Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
- Mammalian target of rapamycin (mTOR) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: Predictors, management, and outcomes
- The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
- Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition
- Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models
- mTOR inhibitors radiosensitize PTEN‐deficient non‐small‐cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
- HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
- Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis
- Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition
- Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation
- PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy …
- Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis
- mTOR inhibition of cardamonin on antiproliferation of A549 cells is involved in a FKBP12 independent fashion
- Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib …
- mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
- Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition
- The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling
- Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications
- Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling
- Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
- Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis
- Dual PI3K/mTOR inhibitors: does p53 modulate response?
- Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer
- Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy
- mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice
- The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer
- Effects of mTOR inhibition on normal retinal vascular development in the mouse
- Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment
- mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells
- mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death
- Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF …
- The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
- Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis
- Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
- Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice
- Interstitial pneumonitis as an adverse reaction to mTOR inhibitors
- mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells
- Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor
- Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain …
- mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers
- Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene
- Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors
- Adaptation to chronic mTOR inhibition in cancer and in aging
- A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors
- Objective monitoring of mTOR inhibitor therapy by three-dimensional facial analysis
- Long‐term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients
- Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells
- Inhibition of mTOR affects protein stability of OGT
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype
- Antitumor efficacy of the dual PI3K/mTOR inhibitor PF-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a …
- Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
- Enhanced antitumor activity with combining effect of mTOR inhibition and microtubule stabilization in hepatocellular carcinoma
- Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo
- Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas
- Adverse Event Management of mTOR Inhibitors during treatment of hormone receptor–positive advanced breast cancer: considerations for oncologists
- A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma
- … expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors
- Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials
- Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status
- Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis
- Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South …
- mTOR-inhibitors may aggravate chronic hepatitis E
- Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin
- BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition
- Prospective, multicenter study of the Mtor inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia
- Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis
- Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
- Are calcineurin inhibitors safer than mTOR inhibitors?
- P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice
- PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors
- Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their …
- Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development
- mTOR inhibitors: changing landscape of endocrine-resistant breast cancer
- A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of …
- Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
- Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant
- Use of mTOR inhibitors in the treatment of malignancies
- Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer
- Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors
- The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
- Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
- Inhibition of mTOR signaling by quercetin in cancer treatment and prevention
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope
- Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics
- MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
- Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma
- mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open
- Safety and efficacy of BEZ235, a dual PI3-kinase/mTOR inhibitor, in adult patients with relapsed or refractory acute leukemia: results of a phase I study
- Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer
- Final results of a prospective multi-institutional phase II study of everolimus (RAD001), an mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade …
- Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
- 18F-FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model …
- Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a …
- Rapamycin and mTOR inhibitors probably have therapeutic effects for post-operative cognitive dysfunction
- Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma
- Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
- Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
- Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
- Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001
- Recent developments of small molecule PI3K/mTOR dual inhibitors
- 20‐O‐β‐d‐Glucopyranosyl‐20(S)‐Protopanaxadiol Suppresses UV‐Induced MMP‐1 Expression Through AMPK‐Mediated mTOR Inhibition as a Downstream of the …
- Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors
- Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma
- Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor
- Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5–and Integrin β3 …
- Kanser tedavisinde mTOR sinyal yolagi ve mTOR inhibitörleri/mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
- Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway: potential for novel anticancer therapeutics
- Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism
- The mTOR inhibitor revolution rolls on
- Effects of Chronic Akt/mTOR Inhibition by Rapamycin on Mechanical Overload–Induced Hypertrophy and Myosin Heavy Chain Transition in Masseter Muscle
- Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
- Species difference in glucuronidation formation kinetics with a selective mTOR inhibitor
- Exploring the selectivity of PI3Kα and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition
- Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.
- JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition
- Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia
- Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7, 8-dihydro-5H-thiopyrano [4, 3-d] pyrimidine derivatives as mTOR inhibitors
- Influenza vaccines: mTOR inhibition surprisingly leads to protection
- Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR
- Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice
- Synthesis of 5-substituted-1H-pyrazolo [4, 3-d] pyrimidin-7 (6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors
- The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype
- Reversion of hormone treatment resistance with the addition of an mTOR inhibitor in endometrial stromal sarcoma
- Inhibition of the mTOR pathway: a possible protective role in coronary artery disease
- Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells
- Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
- Neferine from Nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells
- Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non–small-cell lung cancer
- Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors
- 3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors
- mTOR inhibitors and their role in modern concepts of immunosuppression
- In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
- Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma
- In Silico Investigation of Potential mTOR Inhibitors from Traditional Chinese Medicine for Treatment of Leigh Syndrome
- Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
- mTOR inhibitor-related pulmonary toxicity; incidence even higher
- Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma
- … women with HR+/HER2–locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.
- Proteinuria associated with mTOR inhibitors after kidney transplant.
- mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction?
- mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes
- EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry
- Inhibition of Akt/mTOR attenuates age-related changes in mesenchymal stem cells
- Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation
- Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
- mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
- Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells
- Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma
- Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer
- Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
- Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition
- Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors
- Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
- Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models
- Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness
- Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
- Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR)
- … , a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway
- Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)
- Painful crural ulcerations and proteinuria as complications after several years of therapy with mTOR inhibitors in the renal allograft recipient: a case report
- Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition
- The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells
- Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death
- Inhibitory effect of the CDK4/6 inhibitor, PD 0332991, is enhanced by mTOR inhibition in Non-Small Cell Lung Cancer (NSCLC).
- Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)
- Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin
- mTOR inhibitors as primary immunosuppression after heart transplant: confounding factors in clinical trials
- “TRIMing” the patient population to increase the benefit of mTOR inhibition
- The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas
- Improvement of quality of life in patients with steroid‐refractory chronic graft‐versus‐host disease treated with the mTOR inhibitor everolimus
- Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
- … -independent apoptosis and cell cycle arrest in hematological malignancies and leukemic stem/progenitor cells by inducing ER stress and mTOR inhibition
- Hormone therapy plus mTOR inhibitors in the treatment of endometrial carcinoma
- Kidney transplant recipients receiving mTOR inhibitors experienced twice as many thrombotic events: a single cohort observational study
- Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602
- Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle
- Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma‐induced malignant pleural effusion
- Dual Inhibition of PI3K-AKT-mTOR-and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
- Phase 1b study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with carboplatin (carbo)/paclitaxel (pac)±bevacizumab (bev) and cisplatin (cis) …
- Final results of phase I/II trial of the oral mTOR inhibitor everolimus (RAD001) in combination with bortezomib and rituximab (RVR) in relapsed or refractory …
- Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition
- Amino-functionalized nanoparticles as inhibitors of mTOR and inducers of cell cycle arrest in leukemia cells
- Treatment of muscle invasive urinary bladders tumors: a potential role of the mTOR inhibitors
- Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells
- Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
- CNIs to mTOR inhibitors—effects on allosensitization?
- Subependymal giant cell astrocytoma associated with tuberous sclerosis complex-pharmacological treatment using mTOR inhibitors
- Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
- Inhibition of PI3K/Akt/mTOR signaling by natural products
- Initial evaluation of novel dual PIM/PI3K and triple PIM/PI3K/mTOR inhibitors in multiple myeloma
- Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes
- … Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor
- Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC).
- Patient-derived xenografts reveal limits to PI3K/mTOR-and MEK-mediated inhibition of bladder cancer
- The mTOR inhibitors and the skin wound healing.
- Evaluation of subchronic toxicity of GRD081, a dual PI3K/mTOR inhibitor, after 28-day repeated oral administration in Sprague–Dawley rats and beagle dogs
- Can the risk of skin cancer after transplantation be reduced by mTOR Inhibitors?
- Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer
- Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro
- AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake
- Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling
- Treating mitochondrial diseases with mTOR inhibitors—a potential treatment for Leigh syndrome?
- Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque
- Benzofuran derivatives as a novel class of inhibitors of mTOR signaling
- Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor …
- Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod
- Abstract PD1-6: a randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple …
- BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition
- The PI3K/AKT/MTOR signaling pathway: the role of PI3K and AKT inhibitors in breast cancer
- Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma
- Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation
- Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
- Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance
- PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
- Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients
- Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition
- ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change
- Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.
- Efficacy and mechanisms of the mTOR inhibitor AZD2014 combined with L-asparaginase or JAK2 inhibitor TG101348 in ALL
- Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
- Reversal of acquired resistance to pazopanib in soft tissue sarcoma with addition of an mTOR inhibitor: A case report.
- Difference in adverse-event profiles between mTOR inhibitors, temsirolimus, and everolimus for advanced renal cell carcinoma.
- Influence of the blood-brain barrier on drug distribution and efficacy of PI3K/mTOR inhibitors
- mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia
- GNB1 activating mutations promote myeloid and lymphoid neoplasms targetable by combined PI3K/mTOR inhibition
- Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis
- Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy
- A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer
- … cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
- Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
- Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B‐cell lymphoma
- Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway
- Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)
- Abstract LB-260: Combination of Foxp3+ T cells depletion and mTOR inhibitor enhances immune memory and controls cancer growth
- … ) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor …
- Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma
- Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design
- Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer
- Imaging parameters and molecular correlates as predictive markers of treatment response to mTOR inhibition in adults with recurrent low-grade gliomas.
- A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer …
- Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
- Identification of two novel inhibitors of mTOR signaling pathway based on high content screening
- Exploration of a plucked hair gene signature as a potential pharmacodynamic marker for the dual PI3K/mTOR inhibitor VS-5584.
- Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
- Proteasome inhibitors activate autophagy involving inhibition of PI3K-Akt-mTOR pathway as an anti-oxidation defense in human RPE cells
- Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor (PNET) metastatic progression
- Risk of serious infection with mTOR inhibitors everolimus and temsirolimus in the treatment of cancer: A meta-analysis of randomized controlled trials.
- Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature
- What Does the Future Hold for PI3K/AKT/mTOR Inhibitors in Breast Cancer?
- Benzofuran derivatives as anticancer inhibitors of mTOR signaling
- Long Term Follow Up ofDe NovoUse of mTOR Inhibitors (mTORi) After Kidney Transplantation.: Abstract# B979
- First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
- Advancements in mTOR inhibitors for the management of hormone receptor-positive breast cancer
- Merckel cell carcinoma of the skin treated with somatostatin analogue and mTOR inhibitor exhausted after primary surgery, adjuvant radiotherapy and palliative …
- 4′, 6-dihydroxy-4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation
- A phase I/II study of mTOR inhibitor temsirolimus in patients with unresectable hepatocellular carcinoma (HCC)
- Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma
- Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling
- Ph II study of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (PNET) after mTOR inhibitor therapy failure: stage I interim results
- Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model
- Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.
- The Impact of Hemi-brain Irradiation on Accumulation of PI3K/mTOR Inhibitors With Limited (GDC-0980) and Robust (GNE-317) Blood–Brain Barrier Penetration
- Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series
- Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
- Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
- PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim …
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro
- A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus …
- Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF …
- Inhibition of mTOR prevents ROS production initiated by ethidium bromide-induced mitochondrial DNA depletion
- The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma
- Abstract CT403: A Phase I study of oral administration of mTOR inhibitor everolimus (E) in association with cisplatin (C) and radiotherapy (R) for the treatment of locally …
- Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis
- Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in …
- Perivascular epithelioid cell tumors (PEComas) refractory to mTOR inhibitors
- Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway
- New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway
- Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth
- Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) …
- Dihydromyricetin induces autophagy in HepG2 cells involved in inhibition of mTOR and regulating its upstream pathways
- Pharmacological inhibition of the mTOR pathway impairs hippocampal development in mice
- Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway
- PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway
- Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR …
- PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of …
- Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition
- Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
- Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity
- Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells
- Increased eIF4E phosphorylation prevents response of prostate cancer cells to mTOR inhibitors.
- Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling …
- Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer
- Radiation enhancement of head and neck squamous cell carcinoma by the Dual PI3K/mTOR inhibitor PF-05212384
- Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors …
- Inhibition of mTOR kinase via rapamycin blocks persistent predator stress-induced hyperarousal
- Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma …
- … sylvestris (L.) Hoffm. inhibits the growth of breast cancer cells by inhibiting Akt/mTOR signaling, and its apoptotic effects are enhanced by autophagy inhibition
- Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events.
- Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells
- Advances in mTOR Inhibitors
- mTOR inhibitor-associated noninfectious pneumonitis in patients with metastatic renal cell cancer: A single-center experience.
- Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM‐5 leukemia cells
- mTOR inhibitor therapy for metastatic sarcomatoid clear cell renal cell carcinoma (ccRCC).
- MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
- … of four active compounds alleviates cerebral ischemia–reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways
- Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors …
- … the response of non-Hodgkin’s lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR …
- Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors alone or together with AR antagonists in advanced prostate cancer
- SC-31RATIONAL DESIGN OF A PI3-KINASE/mTOR INHIBITOR CYTOTOXIC TO BRAIN CANCER STEM CELLS UNDER HYPOXIA
- Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells
- AB98. The study of cell proliferation and apoptosis and autophagy in renal cell carcinoma cells influence by the PI3K/AKT/mTor inhibitor NVP-BEZ235
- Effect of the combination of the dual mTOR/pI3K inhibitor NVP-BEZ235 with gemcitabine on growth inhibition in pancreatic cancer cells in vitro and in vivo.
- Combined BCL-2/XL and mTor inhibition promotes apoptosis in small cell lung cancer
- Abstract A48: Anti-tumor activity of the MEK inhibitor pimasertib in combination with the PI3K/mTOR inhibitor SAR245409 in low-grade serous ovarian cancer
- GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
- Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance
- VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
- Autophagy inhibition with monensin enhances cell cycle arrest and apoptosis induced by mTOR or epidermal growth factor receptor inhibitors in lung cancer …
- PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways
- mTOR inhibition protects diabetic heart against ischemia/reperfusion injury through STAT3 activation (1078.5)
- Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells
- Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells
- LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway
- Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced …
- Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2
- Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibition
- … , a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and …
- … amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
- Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin
- Synthesis and structure–activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido [2, 3-d] pyrimidine derivatives
- Cdc-like/dual-specificity tyrosine phosphorylation–regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: Implication for Alzheimer’s disease
- Systemic inhibition of mTOR kinase via rapamycin disrupts consolidation and reconsolidation of auditory fear memory
- Abstract B24: Inhibition of mTOR induces multidrug resistance in B-progenitor acute lymphocytic leukemia
- Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway
- Pimasertib (Pim) and Sar245409 (Sar)-a Mek and Pi3K/Mtor Inhibitor Combination: a Phase Ib Trial with Expansions in Selected Genotype-Defined Solid …
- Integration of different “-omics” technologies identifies inhibition of the IGF1R-Akt-mTOR signaling cascade involved in the cytotoxic effect of shikonin against …
- Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma
- Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector
- Inhibition of mTOR and HIF pathways diminishes chondro-osteogenesis and cell proliferation in chondroblastoma
- Dual targeting of JAK2 signaling with a type II JAK2 inhibitor and of mTOR with a TOR kinase inhibitor induces apoptosis in CRLF2-rearranged Ph-like acute …
- mTOR inhibition increases learning/memory (684.16)
- Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy
- Research on mTOR inhibitors used in radio-sensitization
- New insights into mTOR inhibitors: spotlight on tolerability
- Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide …
- Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells
- Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in …
- How to Maximize the Potential of mTOR Inhibitors in Breast Cancer–More Questions than Answers
- Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis.
- The Evaluation of Dual PI3K/mTOR Inhibitors as a Superior Alternative to mTOR Inhibitors in Pre-B Acute Lymphoblastic Leukaemia
- Managing mTOR Inhibitor Side Effects in Breast Cancer
- Inhibition of ovarian cancer cell proliferation by Pien Tze Huang via the AKT‑mTOR pathway
- mTOR inhibition in MDR acute myeloid leukemia.
- … Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplantation: A Single Centre Experience Renal Transplantasyonda Kalsinörin İnhibitörlerinden mTOR
- Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signaling
- Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
- Hypothalamic nesfatin-1/NUCB2 knockdown augments hepatic gluconeogenesis that is correlated with inhibition of mTOR-STAT3 signaling pathway in rats
- mTOR Inhibitors in Liver Transplantation
- Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptor with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental …
- mTOR Inhibition Enhances the Efficacy of Aurora Inhibitors Liu et al. Page 1326
- Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells
- A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced …
- Expression of mTOR in breast cancer and the effect of mTOR inhibitor on the cell prolofera-tion and apoptosis of breast cancer cells
- Upregulation of HIF-1α protein induces mitochondrial autophagy in primary cortical cell cultures through the inhibition of the mTOR pathway
- … pathway activation mapping guided biomarker development to identify optimal combinations of MEK inhibitor with PI3K/mTOR pathway inhibitors for the treatment of …
- Imidazopyrazine derivatives as inhibitors of mTOR
- Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model
- Inhibition of protein synthesis or mTOR in the basolateral amygdala blocks retrieval-induced memory strengthening
- Reply to “mTOR inhibitor-related pulmonary toxicity; incidence even higher”
- Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic …
- mTOR inhibitors protect from apoptosis in B-ALL cells treated with chemotherapeutic drugs
- Successful treatment of four patients with severe hyperinsulinaemic hypoglycaemia with a novel therapy using mTOR inhibitor
- Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
- Clinical pharmacokinetics and pharmacodynamics of mTOR inhibitors in renal transplantation
- The Effect and Tolerability of MTOR Inhibitors for Metastatic Renal Cell Carcinoma
- mTOR Inhibition and Tuberous Sclerosis Prevention
- Role of mTOR Inhibitors in Heart Transplant Immunosuppressive Regimens
- Discovery of Novel Quinazolinone Based mTOR Inhibitors Endowed with Antifibrotic Properties
- Characterization of mTOR Inhibition and Autophagy Inhibition in Non-Small Cell Lung Cancer
- The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR …
- Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model
- Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors
- Risk of Metabolic Complications in Kidney Transplantation After Conversion From Calcineurin Inhibitor to mTOR Inhibitor: A Systematic Review and Meta-Analysis …
- Beneficial Effect of Mtor Inhibitors on Inflammation in Human Neutrophils
- Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells
- There is a correlation between interleukin-1beta and endothelial dysfunction in patients with mTOR inhibitor-eluting stent implantation
- In vitro and in vivo tumor cell radiosensitization by the competitive mTOR inhibitor INK128.
- Natural killer cell maturation is blocked by mTOR inhibition in C57Bl/6 mice
- mTOR inhibition, AKT proteins and chronic kidney disease
- Effects of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 on HCC
- Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models…
- Determinants of acquired resistance to PI3K/mTOR inhibition in cells refractory to EGFR inhibition.
- Penta-O-galloyl-β-d-glucose Suppresses EGF-Induced eIF3i Expression through Inhibition of the PI3K/AKT/mTOR Pathway in Prostate Cancer Cells
- Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers.
- AB110. Efficacy and safety of mTOR inhibitor in the treatment of renal cell cancer: a meta-analysis
- The mTOR inhibitor RAD001 exhibited more efficacy against ovarian cancer ascites after pharmacologic inhibition of Mirk kinase
- NEWS FROM THE AAN ANNUAL MEETING: Should mTOR Inhibitors Replace Surgery as the First-Line Treatment of Tuberous Sclerosis-SEGA?
- 13, 14‑bis (cis‑3, 5‑dimethyl‑1‑piperazinyl)‑β‑elemene, a novel β‑elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast …
- Risk of serious anemia with mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
- Combination HDACi and mTOR inhibitor therapy in poor-risk de novo and refractory elderly patients with AML.
- mTOR Inhibitors in Pediatric Heart Transplantation: Do the Potential Benefits Outweigh the Risks, Clues from the ISHLT Registry
- Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
- Inhibition of compensatory survival and proliferative pathway activation induced by mTOR inhibition in renal cell carcinoma
- Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response.
- Combination of mTOR Inhibitor and Calcineurin Inhibitor in EBV-positive and EBV-negative B-lymphocytes
- The dual PI3K/mTOR inhibitor VS-5584 preferentially targets cancer stem cells in vitro and in vivo.
- A Dual PI3K-mTOR Inhibitor Induced Cardiac Hypertrophy in Mice
- Use of a mouse model of constitutive mTOR inhibition to identify molecular modulators of acquired resistance.
- Biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors.
- A Dual PI3K-mTOR Inhibitor Induced Hyperglycemia and Increased Insulin Signals in the Heart
- Dual inhibition of PI3K and mTOR shows preferential antileukemic activity in MLL-rearranged AML
- Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
- PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma …
- Incidence and risk of stomatitis to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
- mTOR inhibition leads to decrease of breast cancer progression in vitro via cytoskeleton remodeling
- HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm
- Inactivation of mTor arrests bovine oocytes in the metaphase‐I stage, despite reversible inhibition of 4E‐BP1 phosphorylation
- MTOR Inhibitor MLN0128 has Antitumor Efficacy in Cell Lines With Intrinsic and Acquired Rapamycin-Resistance.
- Sunitinib-resistant ccRCC cell lines subjected to TKI/mTOR inhibitors as a model for sequence therapy
- Abstract A068: Targeting Akt reactivation following mTOR inhibition in breast cancer treatment
- In vitro and in vivo effects of the mTOR inhibitors everolimus (EVE) and temsirolimus (TEM).
- Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells
- GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells
- Testing the effects of Hsp90 inhibitor and mToR inhibitor on HPIV3 and RSV replication in lung epithelial cells
- mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids
- mTOR inhibitor MLN0128 Has antitumor efficacy in cell lines with intrinsic and acquired rapamycin resistance in vitro and in vivo.
- Conversion of calcineurin inhibitors by mTOR inhibitors contributes to the treatment of intraepithelial neoplasms in the cervix in women with renal …
- First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.
- mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression
- Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation
- THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER.
- Does the mTOR inhibitor everolimus influence the course of epilepsy in children with tuberous sclerosis complex?
- Reduction of fat mass with the mTOR inhibitor, sirolimus, in humans: from transplantation to lipodystrophies
- Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds
- Everolimus-retrospective analysis of therapy with mTor-inhibitors of 38 patients after pediatric HTX
- Effects of two mTOR inhibitors on in-vitro models of GH-secreting pituitary adenomas
- Abstract LB-359: Inhibition of DNA repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a novel radiosensitization strategy for glioblastoma.
- Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase
- Double mutation of KRAS and PIK3CA affects the efficacy of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in regulating the PI3K/mTOR pathway in colorectal cancer.
- The Role of Autophagy and Translation Initiation Factors in Overcoming Resistance to mTOR Inhibitors in Prostate Cancer
- CLK/DYRK kinases inhibitor Leucettine L41 induces mTOR-dependent autophagy. Implication for Alzheimers’ disease
- The role of mTOR inhibitors in the prevention of organ rejection in adult liver transplant patients: a focus on everolimus
- Medical Management with mTOR Inhibitors vs. Surgical Resection: Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytoma (SEGA) in Tuberous …
- Multifactorial mechanisms of resistance to the aminopeptidase inhibitor prodrug CHR2863 provoke marked sensitization to the mTOR inhibitor rapamycin
- Risk of pneumonitis with mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus.
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo
- Cancer stem cell-selected patient-derived xenograft models with sensitivity to FAK and Pan-PI3K/mTOR inhibitors.
- mTOR inhibition is required for conversion of invariant NKT cells into immunosuppressive regulatory cells.
- Long-term resistance to PI3K/mTOR inhibition requires increased expression of c-myc and YAP.
- Hsp90 inhibitor AUY922 abrogates mTOR inhibitor AZD8055-induced up-regulation of HER2/HER3 and potentiates antiproliferative activity in human breast cancer …
- Dual mTOR inhibition demonstrates antiproliferative and chemosensitizing effects in chemoresistant high-grade papillary serous ovarian cancer
- Abstract P5-11-06: Combination of insulin-like growth factor 1 receptor and PI3K/mTOR inhibition in triple-negative breast cancers
- Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients
- mTOR Inhibitors Everolimus and Sirolimus Influence Leukocyte Migration After Ischemia.: Abstract# C2080
- Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase
- Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma
- The novel PI3K/mTOR dual inhibitor PQR309 in pre-clinical lymphoma models: Demonstration of anti-tumor activity as single agent and in combination and …
- BEZ235, a selective PI3k/mTOR inhibitor, enhances the therapeutic efficacy of doxorubicin in pancreatic cancer (655.7)
- The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ …
- Different patterns of Akt and ERK feedback activation in response to allosteric and active-site mTOR inhibitors in comparison to metformin in pancreatic cancer cells.
- Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.
- Monitoring of glioblastoma response to a dual PI3K/mTOR inhibitor using hyperpolarized 13C MRSI and 1H MRS
- Effects of novel PI3K/mTOR inhibitors BKM120 and BEZ235 in comparison to everolimus in Head & Neck Squamous cell carcinomas (HNSCC).
- Lumen LPS inhibits HCO3− absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ exchange
- The Impact of mTOR Inhibition on Evolution of Renal Function and Urinary Protein Excretion-24 Months Data from 719 De Novo LTx Recipients.: Abstract# O-78
- Polycystic Kidney Disease: Literature Review on the Mechanism of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Reduction of Cyst Growth in Patients …
- mTOR Inhibition by Rapamycin Alleviates Mitochondrial Disease in the Ndufs4-Mouse Model of Leigh Syndrome
- A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: The Effect Of Mtor Inhibition On Fibrotic Function Of Systemic Scleroderma-Derived Mesenchymal Cells
- PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with 1 rapamycin in rats 2
- 73. Neurobehavioral consequences of acute mTOR inhibition
- Effects of mTOR Inhibition On IR/IGF-1R Signalling in PIK3CA-Mutated, Tamoxifen Resistant Breast Cancer
- Characterization of BK viral responses to the dual-PI3K/MTOR inhibitor dactolisib (NVP BEZ-235) in a renal cell culture model
- … activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant …
- Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423
- Abstract A15: HDAC6 inhibitor C1A abrogates the recruitment of the autophagic machinery and synergizes with proteasome, src kinase, and PI3K-mTOR inhibition.
- Evaluation of novel combinations of PI3K-mTOR inhibitors with dacomitinib (dac) or chemotherapy in PTEN-deficient genomically characterized patient-derived tumor …
- Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.
- MTOR KINASE INHIBITORS AND APOPTOSIS IN GLIOBLASTOMA
- FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model of …
- Combined Treatment of the PI3k/mTOR Inhibitor BEZ235 With Doxorubicin Does Not Increase Cardiotoxicity While Improving Efficacy in Breast Cancer Cells
- T-Cell Transcriptome Analysis Reveals the Mechanisms Controlling Synergy Between Costimulation Blockade and mTOR Inhibition during Graft Versus Host …
- … COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT PI3K/MTOR INHIBITORS
- Physiologically based pharmacokinetic model and correlative in vitro assessment of metabolism-based interaction between Everolimus and PI3K/mTOR inhibitor …
- Intracerebroventricular administration of ouabain, a Na/K-ATPase inhibitor, activates mTOR signal pathways and protein translation in the rat frontal cortex
- Impact of mTOR inhibition on expression of immune regulatory molecules by circulating dendritic cells and regulatory T cells in stable liver transplant patients
- Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy
- Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models Ian Powley1, Sara Galavotti1, Xiao-Ming Sun1
- Abstract A63: NVP-BEZ235, a dual PI3K/mTOR inhibitor, elicits an alternate route for induction of cell death in PTEN null prostate cancer cells.
- A subset of non-small cell lung cancers with wild-type EGFR are sensitized to Erlotinib (EGFR TKI) by mTOR inhibition.
- Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor.
- Stem Cell‐Based Combination Therapies for Cancer: Systemic Delivery of a PI3K/mTOR Inhibitor (PI‐103) and Stem Cell‐Mediated Delivery of TRAIL in Brain Tumors
- The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances dexamethasone induced apoptosis in models of T-cell ALL with PTEN dysfunction and hyperactivated PI3K/Akt …
- Final Results and Biomarker Correlation of a Phase II Study of the MTOR Inhibitor Everolimus in Patients with Pre-Treated Metastatic Esophagus, Gastro-Esophageal …
- … cancer cells to ABT888 in the presence of carboplatin by impairing DNA-damage repair: A proof of concept combination of PI3K/mTOR inhibitor with PARP inhibitor.
- Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By …
- 158 PRE-CLINICAL TRIAL OF A NEW DUAL MTOR INHIBITOR: INK128 FOR RENAL CELL CARCINOMA
- Abstract LB-36: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer.
- Review of research on dual PI3K-mTOR small molecular inhibitors
- Abstract A166: A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily …
- Abstract C267: Sequential combination of the novel allosteric MEK1/2 inhibitor BAY 86-9766 (RDEA119) with the mTOR inhibitor rapamycin decelerates relapse of …
- 4EVER: The Impact of mTOR Inhibition on Bone Health in Postmenopausal Women With Hormone Receptor Positive (HR+) Advanced Breast Cancer Treated …
- Synergistic Control of Acute GvHD: Effectively Down-Regulating T Cell Proliferation and Cytotoxicity with Combined mTOR Inhibition and CD28: CD80/86 …
- Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
- MP24-14 METABOLIC SHIFT UNDER HYPOXIC ENVIRONMENT CAUSES RESISTANCE TO MTOR INHIBITOR IN HUMAN CASTRATION RESISTANT PROSTATE …
- Abstract LB-224: mTOR inhibition can overcome cetuximab resistance in head and neck cancer.
- DR-08 MSK1/β-CATENIN SIGNALING MEDIATES RESISTANCE TO PI3K/mTOR INHIBITORS IN GLIOBLASTOMA
- PI3K inhibition potentiates ABT-737 induced apoptosis in colorectal cancer cells independent of MCL1 downregulation or AKT/mTOR inhibition.
- 297 Adverse Event Management of mTOR Inhibitors During Treatment of Hormone ReceptorePositive Advanced Breast Cancer: Considerations for Oncologists
- Abstract LB-314: Preclinical investigation of antitumor effects of dual PI3K/mTOR inhibitor PF-04691502 in human xenograft and murine Pten/Tgfbr1 deficient head …
- Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
- MP35-17 COMBINATION OF MTOR INHIBITION AND CD4 DEPLETION GENERATES ANTITUMOR IMMUNITY
- Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway
- Identification of novel 7-amino-5-methyl-1, 6-naphthyridin-2 (1H)-one derivatives as potent PI3K/mTOR dual inhibitors
- Thrombospondin-1 Is a Key Mediator of mTOR Inhibitor-Associated Induction of T and B Lymphocyte Regulatory Phenotype in Kidney Transplanted Patients.: Abstract …
- DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway
- Inhibition of the mammalian Target of Rapamycin (mTOR) does not alter nitric oxide or superoxide levels in human skin
- Antiproliferative effects of PI3K-mTOR pathway inhibitors alone or in combination with MEK inhibitor GSK1120212 in pancreatic cancer cell lines are not correlated …
- Preclinical efficacy of GNE-317, a dual PI3K/mTOR inhibitor, with or without bevacizumab in EGFR and/or PTEN-mutated glioblastoma multiforme
- mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer
- Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma
- Dual inhibition of the androgen receptor and PI-3K/mTor pathways has significant antitumor activity in castrate-resistant prostate cancer
- Dual mTOR/PI3K inhibitors induce ERK pathway overactivation in pancreatic cell lines: Rationale for combinatory therapy
- B58 EXPERIMENTAL MODELS OF PULMONARY HYPERTENSION II: Inhibition Of Mtor By Rapamycin Blocks Systemic Angiogenesis
- Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM).
- Neferine from Nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells.
- Abstract P6-06-32: 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) …
- Abstract A283: PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.
- An evaluation of molecular changes in non-small cell lung cancer (NSCLC) cell lines with acquired resistance to NVP-BEZ235, a novel P13K/mTOR dual inhibitor
- SPR965: an oral PI3K/mTOR C1/C2 inhibitor for the treatment of solid tumors
- Benzofuran derivatives as a novel class of mTOR signaling inhibitors
- Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal …
- Inhibition of mTOR Kinase and Cancer Treatment
- Evidence that chronic inhibition of the mammalian Target of Rapamycin (mTOR) reduces skin blood flow in humans
- Inhibition of mTOR signaling induces cumulus expansion and stimulates meiotic maturation of oocytes in mice
- Combined inhibition of mTOR and AKT activity induces potent apoptosis in epithelial ovarian cancer cells.
- … , O’-acac)(γ-acac)(DMS)] Alters SH-SY5Y Cell Migration and Invasion by the Inhibition of Na+/H+ Exchanger Isoform 1 Occurring through a PKC-ε/ERK/mTOR …
- Inhibition of mTOR Pathway and Induction of Autophagy Block Lymphoma Cell Growth: Role of AMPK Activation
- MLN0128, a second-generation mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML
- Effect of inhibition of the PI3K/Akt/mTOR pathway on AR splicing and downstream targets.
- mTOR or VEGFR inhibition—get the order right
- Integral role of the PI3K-AKT-mTOR pathway in DDR-mediated antitumor actions of PARP inhibitor in triple-negative breast carcinogenesis
- PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human …
- Inhibition of the PI3K/mTOR pathway potentiates irradiation effects in paediatric glioblastoma inducing metabolic alterations detected by MRS.
- Dopamine-induced regulation and deregulation of the catabolism of cyclic ADP-ribose, an intrinsic mTOR signal inhibitor, during development in the rodent striatum
- Abstract A165: Antitumor activity of mTOR kinase inhibitor CC-223 in a mouse model of prostate cancer.
- adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors
- Correction: AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake
- Inhibition of PI3K/mTOR by BEZ235 dramatically potentiates panobinostat-induced lethality in diffuse large B-cell lymphoma through multiple mechanisms
- Abstract PD1-8: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
- Abstract number 14: mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer
- Defining optimal combinations of pi3k/akt/mtor and ras/raf/mapk pathway inhibitors for use in endometrial cancer
- Inhibition of mTOR Pathway Reduces Senescence of Corneal Epithelial Cells in Culture.
- Identifying a mechanism of acquired resistance to the combined inhibition of PI3K/mTOR and MEK in colorectal carcinoma
- Inhibition of mTOR in Neuroendocrine Neoplasms of the Digestive Tract
- Effect of evodiagenine mediates photocytotoxicity on human breast cancer cells MDA-MB-231 through inhibition of PI3K/AKT/mTOR and activation of p38 pathways
- Systems Biology Approach for Targeted Therapy of Liver Cancer P13k/Akt/Mtor Pathway Inhibitors: An Ally or Rival for Sorafenib
- Roles of selective inhibition of PI3K/Akt/mTOR signaling pathway on rabbit primary macrophage autophagy and possible pechnism
- Dual mTOR/HDAC Inhibition: Preclinical Development of a Novel Breast Cancer Therapy
- Kawain, a kavalactone, inhibits urinary bladder carcinogenesis in the UPII-mutant Ha-ras transgenic model and associated with inhibition of the mTOR pathway.
- … Mutations in the IL7-Receptor Signaling Pathway in T-Cell Acute Lymphoblastic Leukemia Respond to Combined Inhibition of MEK/ERK and PI3K/AKT/mTOR …
- … evaluation of molecular changes in non-small cell lung cancer (NSCLC) cell lines with acquired resistance to NVP-BEZ235, a novel PI3K/mTOR dual inhibitor
- The rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
- Dual PI3K/Akt/mTOR Pathway Inhibitor Potentiate Cytarabine Cytotoxicity For Acute Myeloid Leukemia
- Anti-proliferative Activity of NVP-BEZ235, a Dual Inhibitor of PI3K and mTOR, in Colorectal Cancer Cells
- Pitavastatin regulates mTOR Complex 1 signaling through inhibition of Rheb in T cells
- A systems pharmacogenomic approach to identify synergistic molecular mechanisms of combined mTOR/HDAC inhibition.
- A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584, Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma
- … cardiac hypoxiareoxygenation injury by Suppressed Autophagy and Reduced Cell Death via inhibition of the activation of AMPK-mTOR signalling pathway in rat …
- INHIBITION OF mTOR KINASE AFFECTS ASTROCYTES GFAP mRNA EXPRESSION IN IN VITRO CONDITIONS
- Cell Growth Inhibition of Her2 Positive Trastuzumab Resistant Gastric Cancer Cell Lines By Combined Inhibition of Pi3K/Akt/Mtor and Mapk
- Sorafenib Suppresses Translation in Desmoid Tumors via Inhibition of mTOR Signaling
- Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
- Combined Use of a PI3K-mTOR Dual Inhibitor and Doxorubicin Induced Cardiac Hypertrophy and Early Death in Mice
- The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185–induced Glycolysis/Gluconeogenesis, Enhancing Antitumor …
- Research Article Integration of Different ”-omics”Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of …
- A systems approach to understand the molecular synergy of combined mTOR/histone deacetylase (HDAC) inhibition in the treatment of cancer
- Multimodality Imaging End-Points on mTOR and HSP Inhibition in Pancreatic Cancer: A Pre-Clinical PET/MRI/MRS Study
- Rapamycin, an inhibitor of mTOR signaling pathway, reverses lithium‐induced cell proliferation in renal collecting ducts
- Lapatinib Reduced Cardiac Hypertrophy Induced By Combined Use Of A Pi3k-mtor Dual Inhibitor And Doxorubicin
- Combating lapatinib resistance of HER2 positive breast cancer cells by combined inhibition of mTOR and autophagy.
- Cationic polystyrene nanosphere induces autophagy through inhibition of the Akt/mTOR and activation of the AMPK signaling pathways in macrophage and epithelial …
- Targeting PI3K and mTOR with BEZ235, a dual inhibitor, is efficacious in trastuzumab refractory and HER2+/PIK3CA-mutated breast cancer models
- Inhibition of mTOR attenuates tumor lactate production & enhances cisplatin/radiation induced immune mediated clearance of HPV-positive head & neck squamous …
- Retraction: PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and …
- EFFECTS OF SMALL MOLECULE INHIBITORS TARGETING PI3K, EGFR, IGF-1R, MTOR, SMAD3 AND MEK IN TUBE FORMATION AND 3-D SPHEROID …
- 335 Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
- NVP-BYL719, a novel PI3K-alpha selective inhibitor, overcomes acquired erlotinib resistance via upregulation of the PI3K/Akt/mTOR pathway in pancreatic ductal …
- … distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR pathway inhibition
- … : Lumen LPS inhibits HCO3− absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ …
- AB0276 Methotrexate therapy monitoring by MTOR, autophagy-related ULK1, caspase 3, CDK-inhibitor p21, TNF alpha, and osteoclast-specific cathepsin K and …
- AB0529 Rituximab therapy monitoring by mtor, autophagy-related ULK1, caspase 3, CDK-inhibitor P21, TNF alpha, and osteoclast-specific cathepsin K and …
- Abstract B274: Discovery and characterization of a highly selective inhibitor of B-RAF, PI3K, and mTOR kinases with antitumor activity in B-RAF and B-RAF/PI3K …
- Proteomic analysis of effects of MEK inhibition with BAY86-9766 on LKB1/AMPK and mTOR pathway in lung cancer cell lines.
- … mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition …
- Omega-3 polyunsaturated fatty acids induce apoptotic and autophagic cell death through inhibition of Akt/mTOR pathway in human oral cancer cells
- Chemopreventive effect of omega-3 fatty acid, EPA, in non-small cell lung cancer through formation of PGE3 and inhibition of PI3kinase/mTOR pathways.
- Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR
- … 2030: Slide Session; K-LG-01: Lower GI Tract; The Inhibition of MDSC and M2 Macrophage by Metformin is Mediated by AMPK-mTOR and Cholesterole Metabolism …
- BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway.
- … FACTOR-1 RECEPTOR (IGF-1R) SIGNAL TRANSDUCTION PATHWAYS WITH INHIBITORS OF IGF-1R, EGFR, PI3K, MEK, AND MTOR IN BREAST CANCER …
- mTOR inhibitors in cancer therapy
- PI3K/Akt/mTOR inhibitors in breast cancer
- mTOR inhibitors and diabetes
- mTOR inhibitors at a glance
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- Gerosuppression by pan-mTOR inhibitors
- Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
- The therapeutic potential of mTOR inhibitors in breast cancer
- Role of mTOR inhibitors in kidney disease
- Potential therapeutic effects of mTOR inhibition in atherosclerosis
- mTOR inhibition in epilepsy: rationale and clinical perspectives
- New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
- Cellular and molecular effects of the mTOR inhibitor everolimus
- Safety of mTOR inhibitors in adult solid organ transplantation
- Role of mTOR inhibitors in epilepsy treatment
- SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells
- Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review
- Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
- Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
- mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
- mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation?
- The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions
- Management of side effects of mTOR inhibitors in tuberous sclerosis patients
- mTOR inhibitors in children: current indications and future directions in neurology
- Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice
- mTOR inhibitors effects on regulatory T cells and on dendritic cells
- Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
- mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
- Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
- Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients
- mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast …
- Muscle wasting associated with the long-term use of mTOR inhibitors
- Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
- Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells
- Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
- mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm
- Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration
- Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review
- Place of mTOR inhibitors in management of BKV infection after kidney transplantation
- mTOR inhibitors for the treatment of severe congenital hyperinsulinism: perspectives on limited therapeutic success
- mTOR inhibitors in urinary bladder cancer
- mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC
- Is mTOR inhibitor good enough for treatment all tumors in TSC patients?
- Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
- Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays
- Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition
- Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria‐related disorders
- mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors
- SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)
- Mutant HRAS as novel target for MEK and mTOR inhibitors
- A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
- Inhibition of autophagy increases proliferation inhibition and apoptosis induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in breast cancer cells.
- mTOR inhibition rescues osteopenia in mice with systemic sclerosis
- A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition
- mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia
- Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
- Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology
- mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
- Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature
- Radiation enhancement of head and neck squamous cell carcinoma by the dual PI3K/mTOR inhibitor PF-05212384
- The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy
- Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
- Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma
- Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner
- … alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
- Dual mTOR inhibition is required to prevent TGF-β-mediated fibrosis: implications for scleroderma
- Practical considerations for the use of mTOR inhibitors
- Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling
- A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth
- Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
- PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
- Review of PI3K/mTOR inhibitors entering clinical trials to treat triple negative breast cancers
- mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- Therapeutic potential of mTOR inhibitors for targeting cancer stem cells
- Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
- The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway …
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade …
- Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth
- Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2
- mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
- Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
- Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells
- A phase I/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft‐versus‐host disease
- Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions
- Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
- mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer
- Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
- The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
- In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
- Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma
- MR studies of glioblastoma models treated with dual PI3K/mTOR inhibitor and temozolomide: metabolic changes are associated with enhanced survival
- Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
- ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP
- Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors
- Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
- mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
- Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients
- eCF309: a potent, selective and cell-permeable mTOR inhibitor
- Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial
- Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
- Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with …
- Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell …
- Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
- Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition
- The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth
- mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
- A novel covalent mTOR inhibitor, DHM25, shows in vivo antitumor activity against triple-negative breast cancer cells
- mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease
- Age-related neurodegeneration prevention through mTOR inhibition: potential mechanisms and remaining questions
- The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
- A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
- The role of 18F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
- MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates antitumor effects in human head and neck squamous cell …
- 3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer
- Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: a systematic review
- Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex—a comprehensive review of the literature
- Oscillatory mTOR inhibition and Treg increase in kidney transplantation
- mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a …
- Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines
- Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts
- Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
- mTOR inhibitors in cancer: what can we learn from exceptional responses?
- Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
- Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
- Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients
- Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma
- Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy
- CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating …
- Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of …
- Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and …
- Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization
- Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
- Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid
- Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors
- Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer
- Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling
- mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures
- Celastrus orbiculatus extract triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in human colorectal cancer cells
- The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
- A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors
- Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
- Silencing Nrf2 impairs glioma cell proliferation via AMPK-activated mTOR inhibition
- mTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg profile
- Risk of metabolic complications in patients with solid tumors treated with mTOR inhibitors: meta-analysis
- mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model
- Dual-modal imaging-guided theranostic nanocarriers based on indocyanine green and mTOR inhibitor rapamycin
- Potential molecular targeted therapeutics: role of PI3-K/Akt/mTOR inhibition in cancer
- Immunosuppressive minimization with mTOR inhibitors and belatacept
- The AMPK agonist PT1 and mTOR inhibitor 3HOI-BA-01 protect cardiomyocytes after ischemia through induction of autophagy
- mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α
- Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated
- High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 …
- MSK1-mediated β-catenin phosphorylation confers resistance to PI3K/mTOR inhibitors in glioblastoma
- Future perspectives for mTOR inhibitors in renal cell cancer treatment
- Successful everolimus treatment of kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: clinical efficacy and adverse effects of mTOR inhibitor …
- Bivalent mTOR inhibitors—the next generation
- mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration
- Cytotoxic properties of a DEPTOR-mTOR inhibitor in multiple myeloma cells
- siRNA-mediated knockdown of the mTOR inhibitor RTP801 promotes retinal ganglion cell survival and axon elongation by direct and indirect mechanisms
- The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
- β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
- Assessing metabolic changes in response to mTOR inhibition in a mantle cell lymphoma xenograft model using acidoCEST MRI
- The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
- Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive …
- Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1
- mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
- Rapamycin-Mediated mTOR Inhibition Reverses Drug Resistance to Adriamycin in Colon Cancer Cells.
- The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis …
- Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models
- Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma
- Antiinflammatory activity of a novel folic acid targeted conjugate of the mTOR inhibitor everolimus
- Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer
- A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I
- Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
- Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 …
- Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
- Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa
- Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis
- Abrogation of autophagy by chloroquine alone or in combination with mTOR inhibitors induces apoptosis in neuroendocrine tumor cells
- mTOR inhibition curbs colorectal cancer
- Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic …
- Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness
- Enhanced antitumor activity of an anti-5T4 antibody–drug conjugate in combination with PI3K/mTOR inhibitors or taxanes
- Mechanistic target of rapamycin (mTOR) inhibition synergizes with reduced internal ribosome entry site (IRES)-mediated translation of cyclin D1 and c-MYC …
- CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model
- Effects of mTOR inhibitors in prevention of abdominal adhesions
- mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase …
- Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- Higher risk of infections with PI3K–AKT–mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials
- … small GTPase DIRAS3 in human white adipose progenitor cells, which negatively regulates adipogenesis and activates autophagy via Akt–mTOR inhibition
- Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
- … induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid …
- Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
- Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel
- Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor
- Differential reponses of hematopoietic stem and progenitor cells to mTOR inhibition
- mTOR inhibition for cancer therapy: past, present and future
- Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
- mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity
- mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
- FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition
- Stomatitis associated with use of mTOR inhibitors: implications for patients with invasive breast cancer
- Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation–experiences from a prospective, clinical …
- Proteomic analysis of mTOR inhibition-mediated phosphorylation changes in ribosomal proteins and eukaryotic translation initiation factors
- Long‑lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review
- Safety of mTOR inhibitors in breast cancer
- Hypoxia increases IGFBP-1 phosphorylation mediated by mTOR inhibition
- Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of …
- 1 T moderate intensity static magnetic field affects Akt/mTOR pathway and increases the antitumor efficacy of mTOR inhibitors in CNE-2Z cells
- Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma
- Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer
- Procyanidins, from Castanea mollissima Bl. shell, induces autophagy following apoptosis associated with PI3K/AKT/mTOR inhibition in HepG2 cells
- Inhibition of mTOR induces a paused pluripotent state
- mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
- Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell
- Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological …
- Anandamide suppresses proinflammatory T cell responses in vitro through type-1 cannabinoid receptor–mediated mTOR inhibition in human keratinocytes
- Dose‐level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma
- Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
- Phase Ib trial of the PI 3K/mTOR inhibitor voxtalisib (SAR 245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell …
- Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention
- Activation of both the calpain and ubiquitin-proteasome systems contributes to septic cardiomyopathy through dystrophin loss/disruption and mTOR inhibition
- mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells
- Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment
- Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer
- Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.
- Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal …
- Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
- mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis
- Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma
- The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma
- Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor
- mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat
- Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.
- Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor
- Differential effects of PI3K and dual PI3K/mTOR inhibition in rat prolactin-secreting pituitary tumors
- mTOR inhibition per se induces nuclear localization of FOXP3 and conversion of invariant NKT (iNKT) cells into immunosuppressive regulatory iNKT cells
- Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
- mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
- The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
- A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
- Role of mTOR inhibitors in growth hormone-producing pituitary adenomas harboring different FGFR4 genotypes
- Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells
- A novel quinoline based second-generation mTOR inhibitor that induces apoptosis and disrupts PI3K-Akt-mTOR signaling in human leukemia HL-60 cells
- Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer
- Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
- Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients
- Intensified antineoplastic effect by combining an HDAC‐inhibitor, an mTOR‐inhibitor and low dosed interferon alpha in prostate cancer cells
- The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration
- mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience
- Blockage of autophagy rescues the dual PI3K/mTOR inhibitor BEZ235-induced growth inhibition of colorectal cancer cells
- MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
- Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells
- An mTOR‐inhibitor‐based protocol and calcineurin inhibitor (CNI)‐free treatment in kidney transplant recipients from donors after cardiac death: good renal function …
- BEZ235 (PIK3/mTOR inhibitor) overcomes pazopanib resistance in patient-derived refractory soft tissue sarcoma cells
- Loss of tuberous sclerosis complex 2 (TSC2) as a predictive biomarker of response to mTOR inhibitor treatment in patients with hepatocellular carcinoma
- Impact of mTOR inhibitors on cancer development in kidney transplantation recipients: a population-based study
- mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
- mTOR inhibition: reduced insulin secretion and sensitivity in a rat model of metabolic syndrome
- Pro-apoptotic activity of ruxolitinib alone and in combination with hydroxyurea, busulphan, and PI3K/mTOR inhibitors in JAK2-positive human cell lines
- Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells
- … mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition
- Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany
- A Practical, Protecting-Group-Free Synthesis of a PI3K/mTOR Inhibitor
- Characterization of LY3023414, a novel PI3K/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth
- Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
- Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report
- Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers
- First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer
- mTOR inhibition attenuates glucose deprivation-induced death in photoreceptors via suppressing a mitochondria-dependent apoptotic pathway
- mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
- REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury
- A dose-escalation (DE) study with expansion evaluating safety, pharmacokinetics and efficacy of the novel, balanced PI3K/mTOR inhibitor PQR309 in patients …
- Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
- … evaluation and docking studies of novel 2-substituted-4-morpholino-7, 8-dihydro-5H-thiopyrano [4, 3-d] pyrimidine derivatives as dual PI3Kα/mTOR inhibitors
- Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial …
- Incidence and risk of rash to mTOR inhibitors in cancer patients–a meta-analysis of randomized controlled trials
- PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin …
- Activity of pan-class I isoform PI3K/mTOR Inhibitor PF-05212384 in combination with crizotinib in ovarian cancer xenografts and PDX
- Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl) quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents
- Structure-based grafting and identification of kinase–inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma
- Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials
- Inhibition of the PI3K/AKT/mTOR pathway in solid tumors
- mTOR inhibition suppresses posttransplant alloantibody production through direct inhibition of alloprimed B cells and sparing of CD8+ antibody-suppressing …
- Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture
- Inhibition of mTOR reduces lipotoxic cell death in primary macrophages through an autophagy-independent mechanism
- Monitoring of CD8 (+) T-cell activity in mTOR inhibitor-treated cancer patients for successful immunotherapy
- PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells
- Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor
- mTOR inhibition by rapamycin increases ceramide synthesis by promoting transforming growth factor‐β1/Smad signaling in the skin
- mTOR inhibition beyond rapalogs
- Streptococcus pneumoniae Induces Autophagy through the Inhibition of the PI3K-I/Akt/mTOR Pathway and ROS Hypergeneration in A549 Cells
- Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
- mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
- PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
- A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
- Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation
- A dual PI3K/mTOR inhibitor as potential therapeutic option for vulvar cancer
- The imidazo [1, 2-a] pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors
- PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing …
- Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers
- Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution
- Inhibition of the mechanistic target of rapamycin (mTOR)–rapamycin and beyond
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
- PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
- … and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition …
- PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability
- New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer
- Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant
- … /AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
- Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
- Current use of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas and epilepsy in patients with TSC
- PQR309: structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor
- mTOR Inhibitors in the Treatment of Cancer
- mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside
- LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro
- Efficacy and safety of sirolimus (mTOR inhibitor) in two patients with diazoxide-unresponsive hyperinsulinemic hypoglycemia
- … with HR+/HER2–locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.
- Inhibitors of mTOR in aging and cancer
- Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation
- The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines
- Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors.
- An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease
- mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy
- Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition
- Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
- Anticancer mammalian target of rapamycin (mTOR) signaling pathway inhibitors: current status, challenges and future prospects in management of epilepsy
- … tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
- Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
- Inhibition of AMP-activated protein kinase alleviates focal cerebral ischemia injury in mice: Interference with mTOR and autophagy
- A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma
- Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma
- Doubling down on mTOR inhibition: Harnessing ZEBRA for insights
- PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer
- Combination of mTOR inhibitors augments potency while activating PI3K signaling in pituitary tumors
- Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and-Resistant Models of Burkitt …
- Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate
- Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression
- Docosahexaenoic acid induces cell death in human non-small cell lung cancer cells by repressing mTOR via AMPK activation and PI3K/Akt inhibition
- bULKing up mTOR inhibition
- mTOR inhibition in diffuse large B-cell lymphoma: new hope?
- Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents
- Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate
- Resistance mechanisms to mTOR inhibition in renal cancer
- DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600
- The role of mTOR inhibitors in solid organ transplantation
- Crosstalk between Ca2+ signaling and mitochondrial H2O2 is required for rotenone inhibition of mTOR signaling pathway leading to neuronal apoptosis
- Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen–glucose deprivation and reoxygenation
- Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells
- Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
- Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma
- Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer
- Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human acute lymphoblastic leukemia
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid …
- Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).
- MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
- A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid …
- … Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer …
- A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell …
- Early initiation of mTOR inhibitors in children with heart transplantation: a propensity-based registry analysis
- Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
- Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells
- FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies
- The role of mTOR inhibitors in breast cancer
- Drug sensitivity research of mTOR inhibitor on breast cancer stem cells
- Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.
- α-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway
- mTOR inhibition in T-cell lymphoma: a path (way) forward
- Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt
- Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells
- Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside
- mTOR kinase inhibitors enhance efficacy of TKIs in preclinical models of Ph-like B-ALL
- Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways
- Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells
- Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115
- The mTOR kinase inhibitor INK128 blunts migration of cultured retinal pigment epithelial cells
- Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia
- The dual PI3K/mTOR inhibitor PQR309 has synergistic activity with other targeted agents in diffuse large B cell lymphomas
- A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Rapamycin inhibition of mTOR reduces levels of the Na+/H+ exchanger 3 in intestines of mice and humans, leading to diarrhea
- Upstream and downstream co-inhibition of mitogen-activated protein kinase and PI3K/Akt/mTOR pathways in pancreatic ductal adenocarcinoma
- MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells
- 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
- Phase Ib trial of the mTOR inhibitor everolimus given in combination with multiagent chemotherapy in relapsed acute lymphoblastic leukemia
- pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
- Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1, 25 (OH) vitamin D (VITD) reverts everolimus (EVE) …
- Somatostatin agonist and mTOR inhibitors as potential radioprotectors or radiosensitizers in neuroendocrine tumor cells
- Commentary: mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia
- Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients
- Inhibition of mTOR pathway by rapamycin reduces brain damage in rats subjected to transient forebrain ischemia
- Neuroprotective effects of DAHP and Triptolide in focal cerebral ischemia via apoptosis inhibition and PI3K/Akt/mTOR pathway activation
- The role of PI3K/AKT/mTOR inhibitors in the treatment of hematological malignancies
- A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
- Polyphyllin VII induces an autophagic cell death by activation of the JNK pathway and inhibition of PI3K/AKT/mTOR pathway in HepG2 cells
- Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy
- PI 3K/Akt/mTOR pathway dual inhibitor BEZ 235 suppresses the stemness of colon cancer stem cells
- Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
- A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches
- Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
- Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
- Structure–activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches
- Subependymal giant cell astrocytoma in pediatric patients with tuberous sclerosis complex treated with mTOR inhibitors: One center experience.
- Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling
- Factors influencing the CNS distribution of a novel PI3K/mTOR inhibitor GSK2126458: implications for overcoming resistance with combination therapy for …
- Current management of mTOR inhibitor-associated stomatitis
- Comment on “mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT …
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic …
- Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical …
- Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer
- The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
- Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 …
- Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling
- Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors
- Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway
- AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
- Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway
- mTOR inhibitor interactions with azole antifungals
- In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway
- Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
- Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model
- Inhibition of aerobic glycolysis represses Akt/mTOR/HIF-1α axis and restores tamoxifen sensitivity in antiestrogen-resistant breast cancer cells
- Inhibition of Notch signaling promotes the adipogenic differentiation of mesenchymal stem cells through autophagy activation and PTEN-PI3K/AKT/mTOR …
- AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell
- PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
- A group of novel HIF‐1α inhibitors, glyceollins, blocks HIF‐1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding
- Salidroside induces apoptosis and autophagy in human colorectal cancer cells through inhibition of PI3K/Akt/mTOR pathway
- Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma
- Synergistic targeted inhibition of MEK and dual PI 3k/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical …
- Andrographolide analogue induces apoptosis and autophagy mediated cell death in U937 cells by inhibition of PI3K/Akt/mTOR pathway
- Inhibition of mTOR improves the impairment of acidification in autophagic vesicles caused by hepatic steatosis
- Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway
- Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309
- FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells
- Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic …
- The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer
- Triggering PIK3CA mutations in PI3K/Akt/mTOR axis: exploration of newer inhibitors and rational preventive strategies
- Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: Involvement of the Akt–mTOR signaling pathway
- … Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
- Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223
- 161P Discovery of novel 1, 3, 5-triazine-thiourea based dual PI3K/mTOR inhibitor against non-small cell lung cancer (NSCLC)
- Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition-a Warburg-reversing effect
- The Role of mTOR Inhibitors and PI3K Pathway Blockade in Renal Cell Cancer
- PI3K-Akt-mTOR signal inhibition affects expression of genes related to endoplasmic reticulum stress
- Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite Formation In Vitro
- mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells
- Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical …
- Probucol inhibits neural cell apoptosis via inhibition of mTOR signaling pathway after spinal cord injury
- Effects of mTOR and calcineurin inhibitors combined therapy in Epstein–Barr virus positive and negative Burkitt lymphoma cells
- Long-term follow-up of de novo use of mTOR and calcineurin inhibitors after kidney transplantation
- 8-Chloroadenosine sensitivity in renal cell carcinoma is associated with AMPK activation and mTOR pathway inhibition
- mTOR inhibitors preserve fertility in a murine model: a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy
- Cognitive and functional outcomes after a trial of an mTOR inhibitor in an adolescent with neuropsychiatric sequelae of TSC
- The’enablers’: Inhibitors of mTOR, PI3K and CDK that prolong endocrine sensitivity
- Che‐1‐induced inhibition of mTOR pathway enables stress‐induced autophagy
- … inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK …
- FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid …
- Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
- Carnosic acid induces autophagic cell death through inhibition of the Akt/mTOR pathway in human hepatoma cells
- Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan
- Enhanced anti-tumor activity of an Auristatin-based antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes: Translational implications and …
- AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells
- Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation
- Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells
- Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
- Novel mTOR inhibitor MLN0128 inhibits imatinib-resistant GIST more potently than rapalogues by abrogating AKT and 4EBP1 activation
- G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell Carcinoma
- Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells
- Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma
- Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration …
- NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in head and neck squamous cell carcinoma
- P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway
- MTOR inhibition favors the differentiation of human in vitro-induced regulatory T cell through selective protein synthesis
- The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT–mTOR signaling pathway
- A dual PI3K/mTOR inhibitor, PI-103, cooperates with TRAIL in laryngeal squamous carcinoma cells in vitro
- mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells
- Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
- Anticancer activity of the mTOR inhibitor (everolimus) and dual mTORC1/mTORC2 Inhibitor (AZD2014) on mouse lymphocytic leukemia both in vitro and in vivo
- Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
- In silico prediction of the clinical response to the mTOR inhibitor everolimus using a Boolean model: validation from a cohort of the SHIVA trial
- In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
- Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
- … agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK …
- Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
- FGFR4 Polymorphism as Molecular Determinant of the Efficacy of mTOR Inhibitors In GH-Secreting Pituitary Adenomas
- Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling
- MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
- Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer
- Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin
- Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma
- p53 inhibition provides a pivotal protective effect against ischemia-reperfusion injury in vitro via mTOR signaling
- Potent efficacy of combined PI3K/mTOR and JAK or SRC/ABL inhibition in Philadelphia chromosome-like acute lymphoblastic leukemia
- Fucoxanthin activates apoptosis via inhibition of PI3K/Akt/mTOR pathway and suppresses invasion and migration by restriction of p38-MMP-2/9 pathway in human …
- Inhibition of mTOR signaling protects photoreceptor cells against serum deprivation by reducing oxidative stress and inducing G2/M cell cycle arrest
- Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
- The involvement of mutual inhibition of ERK and mTOR in PLCγ1-mediated MMP-13 expression in human osteoarthritis chondrocytes
- … and improves immuno-regulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR …
- CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
- Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell …
- Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, RET) in children, adolescents, and …
- FP-208, a novel mTOR inhibitor with potent antitumor activities
- CXCR2 inhibition in human pluripotent stem cells induces predominant differentiation to mesoderm and endoderm through repression of mTOR, β-catenin, and …
- Comparative effectiveness of first-line (1st) VEGF TKI followed by second-line (2nd) therapy with either a VEGF TKI or an mTOR inhibitor in patients (pts) with …
- ATPS-94THIRD GENERATION mTOR INHIBITORS IN GLIOBLASTOMA
- … Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human …
- Predictive Biomarkers of Response to mTOR Inhibitors
- Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway
- mTOR inhibition in breast cancer
- Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice
- Correction: mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile
- Fascaplysin induces caspase mediated crosstalk between apoptosis and autophagy through the inhibition of PI3K/AKT/mTOR signaling cascade in human leukemia …
- Muscle wasting in fasting requires activation of NF-κB and inhibition of AKT/mechanistic target of rapamycin (mTOR) by the protein acetylase, GCN5
- Unfolded protein response promotes doxorubicin-induced nonsmall cell lung cancer cells apoptosis via the mTOR pathway inhibition
- Final results of the pharmacodynamic (PD) data of PQR309-001, a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors
- Research progress of mTOR inhibitors in the treatment of breast cancer
- Small molecule inhibition of miR-544 biogenesis disrupts adaptive responses to hypoxia by modulating ATM-mTOR signaling
- … leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL …
- Effects of metformin and a mammalian target of rapamycin (mTOR) ATP-competitive inhibitor on targeted metabolomics in pancreatic cancer cell line
- PI3K/AKT/mTOR Inhibitors in Breast Cancer
- … -containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR …
- PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137
- A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG‑1 dependent on …
- Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in …
- Primary cross-resistance to BRAFV600E-, MEK1/2-and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway …
- Aspirin-triggered resolvin D1 inhibits TGF-β1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely …
- Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR
- Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer
- Combined targeting of JAK2 with a type II JAK2 inhibitor and mTOR with a TOR kinase inhibitor constitutes synthetic activity in JAK2-driven Ph-like acute …
- A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks
- Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR …
- Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia
- Rational combinations of mTOR inhibitors as anticancer strategies
- mTOR inhibitors in cancer therapy [version 1; peer review: 3
- … of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR …
- mTOR inhibitors in liver transplantation for HCC
- Down-regulation of Homer1b/c protects against chemically induced seizures through inhibition of mTOR signaling
- Solanum nigrum Suppress Angiogenesis-Mediated Tumor Growth Through Inhibition of the AKT/mTOR Pathway
- … via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibition of autophagy contributes to the …
- Discovery of a 6-(pyridin-3-yl) benzo [d] thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors
- Role of mTOR inhibition in triple-negative breast cancer
- Abstract IA16: Mechanisms of resistance to mTOR inhibitors in leukemia and lymphoma
- transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning
- Malignant PEComas: a rare sarcoma responding to mTOR inhibitors
- New Indications of mTOR Inhibitors in Rare Tumors
- Quinones derived from polychlorinated biphenyls induce ROS-dependent autophagy by evoking an autophagic flux and inhibition of mTOR/p70S6k
- Mtor inhibitors responsiveness associates with Akt/Mtor pathway activation in pancreatic neuroendocrine tumors
- Effect of mTOR inhibitors on the risk of cancer development after kidney transplantation in Chinese population
- Proceedings of the 13th international transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning
- The Role of mTOR Inhibitors in Neuroendocrine Tumors
- Effects of mTOR Inhibition on Immunosenescence in the Elderly
- Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2
- SP833 MTOR INHIBITORS IN RENAL TRANSPLANTATION: A FIFTEEN YEAR, SINGLE-CENTER EXPERIENCE
- The inhibition of microRNA-128 on IGF-1-activating mTOR signaling involves in temozolomide-induced glioma cell apoptotic death
- RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
- Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation
- Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemia …
- Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review
- Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- Loss of muscle mass associated with the long term use of mTOR inhibitors
- Cinnamtannin D1 from Rhododendron formosanum Induces Autophagy via the Inhibition of Akt/mTOR and Activation of ERK1/2 in Non-Small-Cell Lung Carcinoma …
- Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
- mTOR Inhibition Per Se Induces Nuclear
- VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
- Diabetes-accelerated experimental osteoarthritis is prevented by MTOR inhibition
- Transcriptional Effects of mTOR Inhibitors on Vascular Smooth Muscle Cells
- Application of mTOR inhibitor everolimus for the treatment of renal cell carcinoma
- Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway
- Research Article Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition
- Prediction and Optimization of the Therapeutic Effect of mTOR Inhibitors in Aggressive B-Cell Lymphomas
- Correction: eCF309: a potent, selective and cell-permeable mTOR inhibitor
- mTOR Inhibition remodels extracellular matrix components of human osteoarthritic cartilage
- Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway
- Characterization of MicroRNA Expression during the Development of Resistance to a mTOR-Inhibitor in renal cell carcinoma
- Abstract IA25: Autophagy: A potentially druggable resistance mechanism to PI3K/mTOR inhibitors
- Is It Time to Use De Novo mTOR Inhibitors Posttransplant?
- MEK inhibition sensitizes precursor B-cell acute lymphoblastic leukemia (B-ALL) cells to dexamethasone through modulation of mTOR activity and stimulation …
- Direct evidence of target inhibition with anti-VEGF, EGFR, and mTOR therapies in a clinical model of wound healing
- Progress of research on mTOR inhibitor in endocrine and HER 2 targeted therapy resistance in breast cancer
- PI3-kinase, Akt, and mTOR Inhibitors in RCC
- Abstract B33: Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems
- mTOR inhibitors effects on regulatory T cells and on dendritic cells
- L-Glutamate deficiency can trigger proliferation inhibition via down regulation of the mTOR/S6K1 pathway in pig intestinal epithelial cells
- Abstract IA28: PI3K and mTOR inhibitors in lymphoid malignancies: Clinical data
- Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells
- Differential cell cycle control protein profiles characterise bronchial carcinoids sensitive to mTOR inhibitors
- Norepinephrine transporter as a predictive marker of response to PI3K/mTOR inhibition in phaeochromocytoma
- Abstract A45: In depth molecular characterization of novel PI3K-mTOR inhibitor resistant NSCLC cell lines
- Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
- B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors
- … of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast …
- Ribavirin inhibits the activity of mTOR/eIF4E, ERK/Mnk1/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl …
- Safety and Efficacy of Radiation Therapy Concurrent With VEGF and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- … kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR …
- The role of mTOR inhibitors in targeting a putative cancer stem cell-like population in esophageal cancer.
- Downregulation of RGS10 induces PI3K/mTOR inhibitor resistance by Ras activation in glioblastoma
- Cell-specific regulation of immediate early gene BZLF1 in Epstein-Barr virus under mTOR inhibition
- Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309
- Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245709) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway
- New Treatment Options in Gynecologic Malignancy The PI3K/AKT/mTOR Inhibitor in Gynecologic Malignancy
- SP097 PATHOLOGICAL FINDINGS OF PROTOCOL BIOPSY IN KIDNEY TRANSPLANT RECIPIENTS USING MTOR INHIBITOR
- L10 Two novel mtor and PI3K/mTOR inhibitors induce autophagy and reduce the amount of aggregated mutant huntingtin in cell models of HD
- Blockade of mTOR pathway inhibition in the neointimal hyperplasia and promoting macrophage autophagy—Effect of statin-eluting stents to reduce in-stent restenosis
- Chronic mTOR Inhibition by Rapamycin and Diabetes: What is the Role of Mitochondria?
- G115 (P) Use of mTOR inhibitors in children with tuberous sclerosis complex for renal angiomyolipomatosis–does it have secondary benefits on seizures and …
- Genomic analysis of PI3K/AKT/mTOR pathway in mesothelioma and treatment of mesothelioma cell lines in vitro using PI3K/mTOR inhibitor PKI-587
- β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
- Abstract PR01: Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition
- In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
- The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma
- Inhibition of mTOR enhances radiosensitivity of lung cancer cells and protects normal lung cells against radiation
- Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
- Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
- Dual P13K/mTOR Inhibition in Combination With Radiation in a Murine Model of Head and Neck Squamous Cell Carcinoma
- Inhibition of mTOR promotes hyperthermia sensitivity in SMMC-7721 human hepatocellular carcinoma cell line
- Mechanisms of transcriptional regulation of FOXO3 by cofactors upon PI3K/AKT/mTOR inhibition
- Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids
- Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
- Abstract A56: A dual PI3K-mTOR inhibitor induced cardiac hypertrophy in mice: Role of the insulin signaling
- β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
- Abstract B46: Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation
- Radiosensitization of bladder cancer cells by the mTOR inhibitor, RAD001: a novel strategy for treatment
- Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
- Abstract A34: Therapeutic potential of the novel mTOR inhibitor Torin-2 to overcome AKT reactivation in B-precursor acute lymphoblastic leukemia (B-pre ALL).
- CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors
- The ATP-Competitive mTOR Inhibitor AZD8055 Reduces Cell Proliferation and Tumour Load in Chronic Lymphocytic Leukaemia
- ID: 74: Interleukin-6 globally influences stress-signaling by reducing the expression of the mTOR-Inhibitor REDD1 in a STAT3-dependent manner
- mTOR Inhibitors Ameliorate Ischemia-Reperfusion Injury through Endothelin-A Modulation and Reduction of Free Radical Production
- Inhibition of the PI3K/AKT/mTOR pathway leads to down-regulation of c-Myc and overcomes resistance to ATRA in acute myeloid leukemia
- In vivo molecular imaging of the impact of mTOR inhibition on hypoxia signaling in mouse tumor model
- Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic …
- Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
- The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
- Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway
- Cytotoxic activity of the novel dual PI3K/mTOR inhibitor NVP-BGT226 in both normoxic and hypoxic hepatocarcinoma cells
- Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors alone or together with AR antagonists in advanced prostate cancer
- Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by …
- Loss of Tuberous Sclerosis Complex 2 (TSC2) Confers Sensitivity to mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
- Norepinephrine transporter (NET) as a predictive marker of response to PI3K/mTOR inhibition in pheochromocytoma
- Proliferation inhibition and autophagy induction of PI3K/mTOR inhibitor NVP-BEZ235 in human breast cancer cells
- Ligustrazine suppresses the growth of HRPC cells through the inhibition of cap-dependent translation via both the mTOR and the MEK/ERK pathways
- The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene …
- Abstract C199: PI3K/AKT/mTOR inhibitors enhance the anti-tumor activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGF-dependent breast cancer models
- Drug-related pneumonitis during mTOR inhibitor therapy in patients with neuroendocrine tumors: A radiographic pattern-based approach
- Abstract P5-07-07: Combination of IGF1R/FAK inhibition and PI3K/mTOR inhibition in triple-negative breast cancers
- … /mTOR inhibition in cancer models using dual dissociative TORC1/TORC2 (P529), single dissociative TORC1 (rapalogs) and catalytic inhibitors (PI3K/Akt, PI3K/mTOR …
- Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
- Abstract B193: Ibrutinib potentiates the effects of mTOR inhibitors and pazopanib in renal cell carcinoma in vitro and in vivo
- mTOR Inhibition With Rapamycin Mitigates Radiation-Induced Pulmonary Fibrosis in a Murine Model
- Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer
- Abstract A67: The mTOR inhibitor, everolimus, enhances the cytotoxicity of pseudomonas-based immunotoxins: Mechanistic insights
- The mammalian target of rapamycin (mTOR) inhibitor rapamycin improves postoperative cognitive dysfunction (POCD)
- Everolimus as Targeted mTOR Inhibition in Neonates and Infants with Tuberous Sclerosis
- Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
- EPT-17PHASE I STUDY OF BRAF INHIBITOR (VEMURAFENIB) IN COMBINATION WITH THE MTOR INHIBITOR (EVEROLIMUS) IN BRAFV600E POSITIVE …
- Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
- Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
- The activity of HDAC and mTOR inhibitors in three dimensional in-vitro model of BRCA-2 mutated breast cancer cell line.
- The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration [Retraction]
- Combination of Metformin and a Dual mTOR Inhibitor Shows Enhanced Inhibitory Effects on Cell Proliferation of Glioblastoma Cells
- A Phase I dose-escalation study of the BRAF inhibitor vemurafenib in combination with the MTOR inhibitor everolimus in subjects with advanced cancer
- The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma-Compassionate Use in 8 Centers in Brazil
- The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia
- INAUGURAL ARTICLE by a Recently Elected Academy Member: mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as …
- The dual mTOR inhibitor, AZD2014, and castration increase intra-tumoral immune cell infiltration and anti-tumour activity in a genetically engineered mouse model of …
- Discovery and Process Development of Class I PI3K and Class I PI3K/mTOR Inhibitors GDC-0941 and GDC-0980
- The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
- Preclinical data supporting the flavone baicalein as a novel mTOR inhibitor with potent activity against endometrial cancer cells
- OOTR-N006: mTOR inhibition with everolimus in invasive breast cancer patients after pre-operative use of anthracycline and/or taxane-based chemotherapy.
- OP53–2462: The role of mTOR inhibitors in TSC associated epilepsy
- Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in …
- Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma …
- T-Cell Transcriptome Analysis Reveals the Mechanisms Controlling Synergy Between Costimulation Blockade and mTOR Inhibition during GVHD Prevention
- Abstract B11: A dual PI3K/mTOR inhibitor, BEZ235 blocks tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment
- Defining the Role of Autophagy Kinase ULK1 Signaling in Therapeutic Response of Tuberous Sclerosis Complex to mTOR Inhibitors
- p21 WAF1/Cip1-mediated radiosensitization of bladder cancer cells by mTOR inhibitor, RAD001 disrupts the balance between autophagy and apoptosis
- Abstract PR03: The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition
- Pneumocystis Jirovecii pneumonia (PJP) in metastatic breast cancer (MBC) patients (pts) treated with mTOR inhibitor everolimus (EVE) and exemestane (AI).
- Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus
- … : HCC Recurrence after Liver Transplantation; Preventive Treatment for HCC Recurrence after Liver Transplantation: Role of mTOR Inhibitor and Adjuvant Treatment
- The impact of cetuximab plus AKT-or mTOR-inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.
- FP018 MTOR INHIBITORS PROMOTE AUTOPHAGIC NOT APOPTOTIC CELL DEATH IN PROXIMAL TUBULAR RENAL CELLS, VIA P75NTR ACTIVATION
- Combinatorial Testing of an ERK Inhibitor, SCH-772984 with PI3K/AKT/mTOR Inhibitors in Melanoma
- The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators …
- Dual-Modal Imaging-Guided Theranostic Nanocarriers Based on Indocyanine Green and mTOR Inhibitor Rapamycin
- Abstract P3-05-06: Evolution of genomic alterations on endocrine therapy and mTOR inhibition in estrogen receptor (ER)-positive breast cancer
- … -based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc …
- Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a …
- … enumeration and characterization has predictive and prognostic implications in patients with metastatic breast cancer treated with exemestane plus the mTOR inhibitor …
- Dual PI3K/mTOR inhibition with BEZ235 augments the therapeutic efficacy of doxorubicin in cancer without influencing cardiac function
- Knock-in of Dnmt3a R878H Recapitulates Human Acute Myeloid Leukemia Harboring DNMT3A Mutation and Is Highly Responsive to mTOR Inhibitor …
- Robust differentiation of human embryonic stem cells into definitive endoderm using Activin A coupled with mTOR inhibition.
- CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway
- A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 …
- Targeting Rac-Gtpases Reverses Stroma-Induced Resistance to Notch and mTOR-Inhibition in Acute T-Cell Leukemia
- Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models
- Mcl-1-mediated resistance to ABT-263 is combated by mTOR inhibition in luminal breast cancers
- Abstract B07: Mcl-1-mediated resistance to ABT-263 is combated by mTOR inhibition in luminal breast cancers
- AB0061 MTOR Inhibition by Rapamycin is Associated with Downregulation of Pro-Infammatory Cytokine TNFα, and Genes Involved in Bone Resoption (MMP-9 and …
- Anti CD20 Radioimmunotherapy and mTOR Inhibition in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B Cell …
- Abstract LB-040: mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction upon 4E-BP1 dephosphorylation
- Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid …
- Addition of mTOR inhibition to HER2 blockade results in improved antitumor activity in a preclinical model of uterine serous carcinoma with HER2 gene amplification …
- Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors
- Response to Comment on “mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive …
- Autophagy and mTOR inhibition as mechanisms for combatting chemoresistance to standard chemotherapy: Final results of a phase I study of infusional …
- Fisetin suppresses lipid accumulation in mouse adipocytic 3T3-L1 cells by repressing GLUT4-mediated glucose uptake through inhibition of mTOR-C/EBPα signaling
- Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway
- MB-20EVALUATING THE ONCOGENIC POTENTIAL OF TSC1/2 MUTATIONS AND EFFICACY OF MTOR INHIBITORS IN HIGH RISK PEDIATRIC …
- Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.
- EPN-26ONCOLOGY DRUG SCREEN IDENTIFIES EPENDYMOMA-SELECTIVE POTENCY OF 5-FU ANALOGS AND mTOR INHIBITORS
- Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.
- VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells
- Abstract A15: Dual inhibition of the PI3K-mTOR signaling in combination with HER2 inhibitor is necessary for maximal antitumor activity in HER2+ breast cancer cells
- D23 PEDIATRIC RARE DISEASES AND LUNG DEVELOPMENT: A Phase 2 Clinical Trial Assessing Efficacy And Safety Of The Mtor Inhibitor Sirolimus In The …
- DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys
- Phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitors demonstrate broad efficacy and synergy in head and neck cancer cell lines and patient-derived xenografts
- Abstract A34: GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating …
- CLINICAL PHARMACOKINETICS AND BRAIN PENETRATION OF GDC-0084, AN ORAL PI3K/mTOR INHIBITOR, IN PATIENTS WITH HIGH-GRADE GLIOMA.
- Approaches to mTOR pathway inhibition in acute leukemic cell lines
- Abstract B09: Targeting the anti-apoptotic protein Mcl-1 with the mTOR inhibitor RAD001 sensitizes luminal breast cancers to the Bcl-2/Bcl-xL inhibitor ABT-263
- Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax
- Abstract B53: Effects of metformin and ATP-competitive inhibitor of mTOR on targeted-metabolomic profile in HPAF-II pancreatic cancer cell lines
- Abstract P3-06-04: 4EVER: The impact of mTOR inhibition on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer …
- ATPS-46 Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
- Integrative drug sensitivity analysis of PI3K/mTOR pathway inhibitors in Head and Neck Squamous Cell Carcinoma (HNSCC)
- … -3 promotes proprioceptive axon regeneration when combined with activation of the mTor intrinsic growth pathway but not with reduction of myelin extrinsic inhibitors
- Lysine-specific demethylase 1 (LSD1) inhibitor S2101 induces autophagy via the AKT/mTOR pathway in SKOV3 ovarian cancer cells
- Advances in inhibitors of PI3K/Akt/mTOR pathway in treatment of advanced breast cancer
- MP88-09 PRECLINICAL MODEL OF DUAL-SPECIFIC, MTOR COMPLEX 1 (TORC1) AND MTOR COMPLEX 2 (TORC2) INHIBITORS FOR BLADDER CANCER …
- Abstract A109: Dual mTOR/PI3K inhibitors induce compensatory MEK/ERK activation in human pancreatic cancer cells: A mechanism contributing to drug resistance
- Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro
- Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma
- Abstract P6-02-01: Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors
- … triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with …
- Inhibition of mTOR induces chemoresistance in B-cell acute lymphoblastic leukemia
- Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer
- Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent
- … exerts antiproliferative effect and downregulates vegf signaling in caco‐2 human colon carcinoma cell line through a selective ppar‐α‐dependent inhibition of akt/mtor …
- Abstract B57: Effects of MEK inhibition alone or in combination with PI3K-mTOR pathway inhibitors in pancreatic ductal adenocarcinoma in vitro and on an innovative …
- Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in …
- Inhibition of 11β-Hydroxysteroid dehydrogenase type II suppresses lung carcinogenesis by blocking tumor COX-2 expression as well as the ERK and mTOR …
- The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab …
- Abstract A53: Dual inhibition of mTOR in hepatocellular carcinoma: Autophagy friend or foe?
- Involvement of mTOR in type 2 CRF receptor inhibition of insulin signaling in muscle cells
- Abstract A16: DDR-mediated antitumor actions of PARP inhibitor: Can PI3K-mTOR pathway inhibitor be combined with PARP inhibitor in TNBT?
- Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway
- Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells
- Inhibition of TK better than MTOR
- … derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR/p70s6k signaling pathway
- Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways
- The discovery and process chemistry development of GDC-0084, a brain penetrating inhibitor of PI3K and mTOR
- MTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in…
- Identification of a novel long intergenic noncoding RNA-LINC00936, with significant impact on multiple myeloma cell growth via mtor pathway inhibition
- A cocktail of specific inhibitors of HER-2, PI3K, and mTOR radiosensitises human breast cancer cells
- Management of Advanced Endometrial Cancer and Inhibitors of the PI3K/AKT/mTOR Pathway
- Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
- PI3K/Akt/mTOR pathway inhibition in chemotherapy-sensitive and-resistant models of Burkitt Lymphoma
- Inhibition of DNA nanotube-conjugated mTOR siRNA on the growth of pulmonary arterial smooth muscle cells
- Design and development of novel mTOR and SRC family kinase inhibitors via a phenotypic drug discovery approach
- Abstract A35: Proteomic and transcriptional profiling reveal differential responses to combined MEK and PI3K-mTOR network inhibition in basal-like and mesenchymal …
- Mechanisms of resistance to PBK-Akt-mTOR signaling pathway inhibitors
- TARGETED INHIBITION OF PI3K, MTOR, AND IGF1R FOR THE TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
- Abstract B59: Dual mTOR kinase inhibitor reverses rapamycin resistance in prostate cancer cells
- Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
- Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple …
- Inhibition of mTOR Signaling Protects Against Myocardial Reperfusion Injury, Acute Myocardial Infarction
- Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.
- Dual inhibition of the PI3K/mTOR and MAPK pathways in Non-Hodgkin Lymphoma
- Effect of PI3K inhibitor LY294002 combined with RAD001, a mTOR specificity inhibitor, on proliferation and apoptosis of triple-negative breast cancer cell lines MDA …
- … chromosome positive acute lymphoblastic leukemia cells are also resistant to ABL inhibitors, which can be overcome by targeting the PI3K/AKT/mTOR …
- Cranberry proanthocyanidins induce autophagic cell death via ROS generation and inhibition of AKT/mTOR/MAPK signaling pathways in esophageal …
- Inhibition of mTOR as Antiangiogenic Strategy in Multiple Myeloma
- Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination
- Abstract B50: Targeting KRASG12D colorectal cancer with combined inhibition of PI3K/mTOR and MAPK signaling
- Research Article Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite …
- Dual mTOR kinase inhibitor overcomes rapamycin resistance in vitro
- Metformin Sensitizes Glucose Starved Microvascular Endothelial Cells to Death by Inhibition of the mTOR Pathway and Autophagy
- Targeting glioblastoma and its stem cells using novel small molecule inhibitors of the mTOR pathway
- HG-121THE EFFECTS OF MTOR COMPLEX 1/2 INHIBITION ON DIFFUSE INTRINSIC PONTINE GLIOMA CELLS
- Abstract A36: Combined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584
- Dual targeting of PI3K/mTOR leads to MEK/ERK over-activation in leiomyosarcoma through suppression of mTORC2 inhibition
- … 08 SYNERGISTIC ANTICANCER EFFECT OF COMBINATION TREATMENT WITH MEK INHIBITOR AND PI3K/MTOR DUAL INHIBITOR IN CASTRATION-RESISTANT …
- Targeting therapy-resistant gastric and esophageal cancers with mTOR ATP site inhibitors
- A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study
- MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR …
- Evaluation of small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 for their radiomodulatory effects in human breast cancer cell lines
- Inhibition of mTOR Increases the Severity of Lung Inflammation in Mice Infected With Influenza A Virus
- Abstract B02: mTOR/S6K pathway-dependent metabolic reprogramming in cancer cells mediates resistance to glycolytic inhibitors
- Protein phosphatase 4 regulates cell survival and responses to PI3K/AKT/mTOR pathway inhibitors in breast cancer cell lines
- CHLOROQUINE DOES NOT CANCEL E1A+ cHa-Ras TRANSFORMANTS’DEATH INDUCED BY mTOR KINASE INHIBITOR pp242..
- … A41: Automated immunohistochemistry of phosphobiomarkers: Case study of MTOR (MLN0128) and PI3Kα (MLN1117) investigational inhibitors, single agent and in …
- mTOR signaling pathway for regulating inhibition of 1, 25 dihydroxyvitamin D3 on Hep-2 cells proliferation in laryngeal carcinoma
- Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
- mTOR Pathway Inhibition Prevents Neuroinflammation and Neuronal Death in a Mouse Model of Spinal Cord Injury
- Genetic and pharmacologic inhibition of mTOR delays mortality due to thymc lymphoma formation in mice and is associated with decreases in cell cycle proteins
- Effect of Rapamycin as an Inhibitor of the mTOR Cell Cycle Entry Complex on the Selective Lysis of Human Leukemia Cells Lines in Vitro Using 20 kHz Pulsed Low …
- … suppresses systemic autoimmunity in Roquinsan/San mice through inhibition of B cell differentiation into plasma cells VIA AMPK/MTOR/Stat3 Pathway Regulation
- Inhibition of the PI3K/AKT/mTOR pathway in a murine model attenuates primordial follicle depletion during gonadotoxic chemotherapy
- Evaluation of the effect of selected Pl3K/Akt/mTOR and RAF/MEK/ERK pathways inhibitors on proliferation and apoptosis in human H295R adrenocortical …
- Glutamine PET to Predict Response to Dual Pharmacological Inhibition of BRAFV600E and PI3K/mTOR Pathway Activity in vivo.
- … derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR …
- … VARIANT-TARGETED COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER USING EPI-002 AND A PI3K/MTOR DUAL INHIBITOR
- Cell-based screening identifies gene expression signature correlated with sensitivity to PI3K-mTOR dual inhibitor BEZ235
- Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001
- Sequential treatment of HCC cells with PI3K/Akt/mTOR pathway inhibitors prior to sorafenib attenuates cancer stem cell population
- Paclitaxel exerts anticancer bioactivity on SGC7901 human gastric adenocarcinoma cell line through inhibition of Akt/mTOR signaling pathway
- Fibroblast-induced switching to the invasive phenotype and PI3K-mTOR signaling protects melanoma cells from BRAF inhibitors
- Metformin Mediated Inhibition of the mTOR Pathway Promotes Death in Glucose Starved Micro-Vascular Endothelial Cells
- Abstract P6-07-01: Anti-tumor efficacy of PI3K-mTOR pathway inhibitors in combination with PARP inhibitor plus carboplatin in BRCA1-competent TNBC, beyond …
- 133P The mTOR kinase inhibitor AZD-2014 enhances the antitumor effects of XPO1 antagonist KPT-185 in mantle cell lymphoma
- GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab
- Inhibition of mTOR signaling by everolimus has concurrent anti-tumor and bone-protective effects in murine osteolytic cancer models
- Peer review report 1 on “P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway”
- Pharmacological Inhibition Of Mtor Kinase Activity Reverses Sugen/hypoxia-Induced Pulmonary Hypertension, Right Ventricular Hypertrophy, And Improves Heart …
- PTPS-22 Dual mTOR kinase inhibitor (MLN0128) markedly induces growth suppression and apoptosis in diffuse intrinsic pontine glioma cell lines
- mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies
- … Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors
- … changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR …
- Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia
- Abstract LB-C22: Acquired resistance to the cMET inhibitor savolitinib in lung cancer models through EGFR/mTOR/MYC deregulation and adoption of PIM signaling
- A66 PH: MOLECULES, CELLS AND ANIMAL MODELS: Pharmacological Inhibition Of Mtor Kinase Activity Reverses Sugen/hypoxia-Induced Pulmonary Hypertension …
- The energy sensor AMP-activated protein kinase (AMPK) signals neuronal death in glaucoma through inhibition of the mammalian target of rapamycin (mTOR).
- MP92-14 INHIBITION OF MTOR/AKT PATHWAY ENHANCES CELL DEATH VIA AUTOPHAGY IN RENAL CELL CARCINOMA
- Targeted inhibition of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) sensitizes pancreatic cancer cells to doxorubicin without exacerbating …
- Abstract B107: Targeting PI3K and mTOR with GDC-0980, a dual inhibitor, is efficacious in trastuzumab refractory and HER2+/PIK3CA-mutated breast cancer models
- … : [Pt(O,O’-acac)(γ-acac)(DMS)] Alters SH-SY5Y Cell Migration and Invasion by the Inhibition of Na+/H+ Exchanger Isoform 1 Occurring through a PKC-ε/ERK/mTOR …
- Peer review report 2 on “P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway”
- Cancer and mTOR inhibitors in transplant recipients
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- mTOR inhibitor therapy and metabolic consequences: where do we stand?
- mTOR inhibition role in cellular mechanisms
- The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress
- The role of mTOR inhibitors in the management of viral infections: a review of current literature
- mTOR inhibition and kidney diseases
- mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis
- Therapeutic use of mTOR inhibitors in renal diseases: advances, drawbacks, and challenges
- Clinical development of mTor inhibitors for renal cancer
- Deptor: not only a mTOR inhibitor
- PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
- Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
- Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review
- MTOR inhibitor-based combination therapies for pancreatic cancer
- mTOR inhibitors in castration-resistant prostate cancer: a systematic review
- Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
- PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy
- Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex
- Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy
- Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
- Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid …
- … the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with …
- … for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition
- mTOR inhibition and cardiovascular diseases: cardiac hypertrophy
- mTOR inhibition and clinical transplantation: heart
- Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
- PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
- mTOR inhibition rejuvenates the aging gingival fibroblasts through alleviating oxidative stress
- Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
- Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
- Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells
- mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2
- A novel mTOR inhibitor; anthracimycin for the treatment of human hepatocellular carcinoma
- The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
- Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
- Additive cytotoxic effects of radiation and mTOR inhibitors in a cervical cancer cell line
- Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers
- Emerging perspectives on mTOR inhibitor‐associated pneumonitis in breast cancer
- A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in …
- The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)
- Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
- Selective effects of mTOR inhibitor sirolimus on naïve and CMV-specific T cells extending its applicable range beyond immunosuppression
- Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition
- Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition
- Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor
- Discovery and development of ATP-competitive mTOR inhibitors using computational approaches
- Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression
- Exploiting radiation-induced signaling to increase the susceptibility of resistant cancer cells to targeted drugs: AKT and mTOR inhibitors as an example
- mTOR inhibition and clinical transplantation: pancreas and islet
- The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in …
- Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia
- A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer
- The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma
- RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition
- Protection by mTOR inhibition on zymosan-induced systemic inflammatory response and oxidative/nitrosative stress: contribution of mTOR/MEK1/ERK1/2/IKKβ/IκB-α …
- CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
- mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus
- MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
- NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with …
- Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms
- CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
- The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous …
- Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells
- Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer
- Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism
- Anti-cancer effects of radix Angelica sinensis (Danggui) and N-butylidenephthalide on gastric cancer: Implications for REDD1 activation and mTOR inhibition
- Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition
- Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation
- mTOR inhibition in glioblastoma: requiem for a dream?
- … in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor …
- Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma
- The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
- … inhibits cell growth and pro-inflammatory response in IL-1β-stimulated fibroblast-like synoviocytes by enhancement of autophagy via PI3K/AKT/mTOR inhibition
- Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells
- A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma
- Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis
- MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells
- Everolimus as an mTOR inhibitor suppresses endometriotic implants: an experimental rat study
- Adeno-associated viral vector-mediated mTOR inhibition by short hairpin RNA suppresses laser-induced choroidal neovascularization
- The dual PI3K/mToR inhibitor omipalisib/GSK2126458 inhibits clonogenic growth in oncogenically-transformed cells from neurocutaneous melanocytosis
- Impact on autophagy and ultraviolet B induced responses of treatment with the MTOR inhibitors rapamycin, everolimus, torin 1, and pp242 in human …
- Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity
- mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease …
- Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
- mTOR inhibition via displacement of phosphatidic acid induces enhanced cytotoxicity specifically in cancer cells
- The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8
- PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
- Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma
- Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site
- 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors
- Early LC3 lipidation induced by d-limonene does not rely on mTOR inhibition, ERK activation and ROS production and it is associated with reduced clonogenic …
- Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
- On the pathogenesis of mTOR inhibitor‐associated stomatitis (mIAS)—studies using an organotypic model of the oral mucosa
- Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
- mTor inhibitors for the treatment of endometriosis
- Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity
- Improved Fetal Hemoglobin With mTOR Inhibitor–Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease
- Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
- In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
- Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen
- Highly selective, potent, and oral mTOR inhibitor for treatment of cancer as autophagy inducer
- … atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition
- Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS
- The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
- Neuroimaging biomarkers of mTOR inhibition on vascular and metabolic functions in aging brain and Alzheimer’s disease
- mTOR inhibition mitigates molecular and biochemical alterations of vigabatrin-induced visual field toxicity in mice
- Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation
- mTOR inhibition and clinical transplantation: kidney
- The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus
- mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro
- PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4
- Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
- Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma
- The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
- A review of mTOR pathway inhibitors in gynecologic cancer
- The return of the mTOR inhibitors: getting it right in patients after cardiac transplantation
- Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with …
- Expert opinion on the metabolic complications of mTOR inhibitors
- mTOR inhibitors for treatment of low-risk prostate cancer
- Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
- Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide‑induced autophagic death of U251 glioma cells
- Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome
- Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer
- mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
- Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A hellenic cooperative oncology group …
- Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: A case report
- Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
- Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
- Potential natural mTOR inhibitors screened by in silico approach and suppress hepatic stellate cells activation
- Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study
- The impact of cetuximab plus AKT-or mTOR-inhibitor in a patient-derived colon cancer cell model with wild-type RAS and PIK3CA mutation
- Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced …
- Effect of dual mTOR inhibitor on TGFβ1-induced fibrosis in primary human urethral scar fibroblasts
- Triggering of eryptosis, the suicidal erythrocyte death by mammalian target of rapamycin (mTOR) inhibitor temsirolimus
- Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
- … carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors
- In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and …
- Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
- Intermittent mTOR inhibition reverses kidney aging in old rats
- Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1
- Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors
- Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors
- Immunosuppression with mTOR inhibitors prevents the development of donor‐specific antibodies after liver transplant
- The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
- The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
- … -1, 3, 5-triazin-2-yl)-4-(trifluoromethyl) pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate …
- Nanosecond pulsed electric fields enhance the anti-tumour effects of the mTOR inhibitor everolimus against melanoma
- Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
- Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
- Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
- Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients
- The influence of mTOR inhibitors on the incidence of CMV infection in high‐risk donor positive–recipient negative (D+/R−) kidney transplant recipients
- Controlled release of second generation mTOR inhibitors to restrain inflammation in primary immune cells
- Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
- Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
- The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous …
- Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism
- Evidence of the immunomodulatory role of dual PI 3K/mTOR inhibitors in transplantation: an experimental study in mice
- Calcineurin and mtor inhibitor–free post-transplantation cyclophosphamide and bortezomib combination for graft-versus-host disease prevention after …
- Discovery of an orally bioavailable dual PI3K/mTOR inhibitor based on sulfonyl-substituted morpholinopyrimidines
- mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions
- Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition
- Critical analysis of graft loss and death in kidney transplant recipients treated with mTOR inhibitors
- Presurgical administration of mTOR inhibitors in patients with large subependymal giant cell astrocytoma associated with tuberous sclerosis complex
- Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
- mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines
- PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro
- Renal cell carcinoma associated with Xp11. 2 translocation/TFE3 gene-fusion: a long response to mammalian target of rapamycin (mTOR) inhibitors
- MANTA-a randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor …
- A system to identify inhibitors of mTOR signaling using high-resolution growth analysis in Saccharomyces cerevisiae
- Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition
- Recent advances in targeting mTOR signaling pathway using small molecule inhibitors
- Phosphoramide mustard induces autophagy markers and mTOR inhibition prevents follicle loss due to phosphoramide mustard exposure
- High incidence of ovarian cysts in women receiving mTOR inhibitors after renal transplantation
- VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute …
- HIF is not essential for suppression of experimental tumor growth by mTOR inhibition
- Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
- HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
- Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis
- The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes
- Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic …
- Overcoming palbociclib resistance by combined treatment with PI3K/AKT/mTOR inhibitors in mesothelioma cells
- Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas—an ENITEC Group Initiative
- Synergistically suppressive effects on colorectal cancer cells by combination of mTOR inhibitor and glycolysis inhibitor, Oxamate
- Pharmacological inhibition of mTOR kinase reverses right ventricle remodeling and improves right ventricle structure and function in rats
- Drug repurposing: Targeting mTOR inhibitors for anticancer activity
- The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
- The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/-mice through suppression of cell proliferation and induction …
- Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment
- Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis
- 3D-QSAR, virtual screening, docking and design of dual PI3K/mTOR inhibitors with enhanced antiproliferative activity
- Design, synthesis, and biological evaluation of imidazo [1, 2-b] pyridazine derivatives as mTOR inhibitors
- Is there a role for mTOR inhibitors in renal transplantation?
- Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures
- Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
- Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
- Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition
- Cancer and mTOR inhibitors in kidney transplantation recipients
- Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling
- Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives
- Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials
- Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
- Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia
- Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma
- PI3K–mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models
- G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer
- Discovery of pyridopyrimidinones as potent and orally active dual inhibitors of PI3K/mTOR
- mTOR signalling pathway-protein expression in post-transplant cutaneous squamous-cell carcinomas before and after conversion to mTOR-inhibitors
- Inhibition of mTOR complexes protects cancer cells from glutamine starvation induced cell death by restoring Akt stability
- mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
- Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
- Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1
- Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
- Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report
- Inhibition of the mTOR pathway in abdominal aortic aneurysm: implications of smooth muscle cell contractile phenotype, inflammation, and aneurysm expansion
- … synthesis, cytotoxicity evaluation and docking studies of 1, 2, 4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors
- The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: Clinical evidence and current challenges
- New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation
- Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis
- FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor
- OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by deubiquitinating the mTORC1 inhibitor DEPTOR
- Abstract GS2-07: MANTA-A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in …
- Inhibition of the AKT/mTOR pathway augments the anticancer effects of sorafenib in thyroid cancer
- Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and …
- PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
- Consensus scoring model for the molecular docking study of mTOR kinase inhibitor
- Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
- Effects of resveratrol, lovastatin and the mTOR-inhibitor RAD-001 on insulin-induced genomic damage in vitro
- mTOR (mechanistic target of rapamycin) inhibition decreases mechanosignaling, collagen accumulation, and stiffening of the thoracic aorta in elastin-deficient mice
- The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Bruton’s tyrosine kinase (BTK) inhibitor PLS‐123 on Mantle cell lymphoma
- Beneficial effects of resveratrol-mediated inhibition of the mTOR pathway in spinal cord injury
- mTOR inhibition subdues milk disorder caused by maternal VLDLR loss
- Breast cancer patients have increased risk of developing mTOR inhibitor‐associated stomatitis
- mTOR inhibition by everolimus does not impair closure of punch biopsy wounds in renal transplant patients
- Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma
- Effects of mTOR Inhibitor Rapamycin on Burkitt’s Lymphoma Cells
- The long journey of mtor inhibitors and the long path that is still ahead
- Potent Anticancer and mTOR Inhibitor Activities of Some Synthesized Linear and Macrocyclic Pyridine Derivatives
- hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells
- Phase 2 trial of single agent gedatolisib (PF-05212384), a dual PI3K/mTOR inhibitor, for adverse prognosis and relapse/refractory AML: clinical and …
- Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities
- mTOR masters monocyte development in bone marrow by decreasing the inhibition of STAT5 on IRF8
- Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines
- Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
- Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
- Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease
- Anti-proliferative effect of metformin on a feline injection site sarcoma cell line independent of Mtor inhibition
- Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR
- Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors
- GSK458 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in T Cell lymphomas as a single agent and in combination therapy
- Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer
- Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes
- Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors
- Combined inhibition of PI3Kβ and mTOR inhibits growth of PTEN-null tumors
- Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted …
- Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
- Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication
- Acid suspends the circadian clock in hypoxia through inhibition of mTOR
- mTOR inhibitors in uterine and extra-uterine malignant PEComas: a multicenter international case series retrospective analysis
- mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors
- Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation
- Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells
- SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
- Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer
- Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor–positive breast cancer
- The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia
- Effect and mechanism of inhibition of PI3K/Akt/mTOR signal pathway on chronic neuropathic pain and spinal microglia in a rat model of chronic constriction …
- In vivo evaluation of the synergic effect of metformin and mTOR inhibitors on the endothelial healing of drug-eluting stents in diabetic patients
- c‑Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway
- The role of antioxidant proteins in improvement of autism core symptoms in two patients with tuberous sclerosis treated with mTOR inhibitor everolimus
- NLRC3 mediated PI3K-mTOR inhibition takes a toll on colon cancer
- Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition
- Design, synthesis and biological evaluation of novel 3H-imidazole [4, 5-b] pyridine derivatives as selective mTOR inhibitors
- Glycolysis inhibition via mTOR suppression is a key step in cardamonin-induced autophagy in SKOV3 cells
- Tetrandrine, an activator of autophagy, induces autophagic cell death via PKC-α inhibition and mTOR-dependent mechanisms
- Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1
- mTOR Inhibition for Transplantation: More May Not Be Better
- Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
- PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium
- Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
- Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight
- Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
- PI3K/mTOR dual inhibitor, LY3023414, demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model
- Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition
- Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma
- Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors
- Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
- Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer
- UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism
- Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
- Evaluating the effectiveness of MAPK, AKT, and mTOR inhibitors in reducing proliferation in cellular models of papillary and follicular thyroid cancer
- The macrolide toxin mycolactone promotes bim-dependent apoptosis in Buruli ulcer through inhibition of mTOR
- Clinical Outcomes after switch to mTOR inhibitors in kidney transplant recipients
- Maternal folate deficiency causes inhibition of mTOR signaling, down-regulation of placental amino acid transporters and fetal growth restriction in mice
- Efficiency of an mTOR inhibitor in Kasabach-Merritt phenomenon with indolent tufted angioma: a case report
- Preserving Treg Function: Beyond mTOR Inhibitors
- Inhibition of mTOR signaling pathway delays follicle formation in mice
- Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy of articular chondrocytes and attenuates inflammatory response in rats with osteoarthritis
- mTOR inhibition decreases mechanosignaling, collagen accumulation, and stiffening of the thoracic aorta in elastin-deficient mice
- Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival
- Inhibition of mTOR pathway decreases the expression of pre‐meiotic and meiotic markers throughout postnatal development and in adult testes in mice
- DIPG-29. Preclinical efficacy of combined ACVR1 and PI3K/mTOR inhibition in diffuse intrinsic pontine glioma (DIPG)
- Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition
- Neuroprotective strategy in retinal degeneration: suppressing ER stress-induced cell death via inhibition of the mTOR signal
- mTOR Inhibition to Prevent Posttransplant Malignancies—Don’t Stop Believin’
- Inhibition of human lung cancer cell proliferation and survival by post-exercise serum is associated with the inhibition of Akt, mTOR, p70 S6K, and Erk1/2
- Combined inhibition of autophagy with mTOR inhibitor to enhance cell death in renal cell carcinoma.
- ROS promote Ox-LDL-induced platelet activation by up-regulating autophagy through the inhibition of the PI3K/AKT/mTOR pathway
- Natural cyclopeptide RA-XII, a new autophagy inhibitor, suppresses protective autophagy for enhancing apoptosis through AMPK/mTOR/P70S6K pathways in HepG2 …
- The mTOR kinase inhibitor CZ415 inhibits human papillary thyroid carcinoma cell growth
- A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055
- STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of …
- HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression
- … characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
- Inhibition of autophagy via activation of PI3K/Akt/mTOR pathway contributes to the protection of hesperidin against myocardial ischemia/reperfusion injury
- … -tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular …
- Inhibition of the PI3K-Akt-mTOR signaling pathway in T lymphocytes in patients with active tuberculosis
- Interaction between mTOR pathway inhibition and autophagy induction attenuates adriamycin-induced vascular smooth muscle cell senescence through decreased …
- Inhibition of Akt/mTOR/p70S6K signaling activity with Huangkui capsule alleviates the early glomerular pathological changes in diabetic nephropathy
- Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
- Experience of Using mTOR Inhibitor in Lung Transplant at Recipients With Lymphangioleiomyomatosis
- Cap-independent translation ensures mTOR expression and function upon protein synthesis inhibition
- PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis
- Pharmacological inhibition of O-GlcNAcase enhances autophagy in brain through an mTOR-independent pathway
- Correction: the dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
- Exploring the effects and effectors of mTOR inhibition in oncolysis and TOP mRNA translation
- MEDU-44. TARGETING SHH SIGNALING VIA PI3K/MTOR INHIBITION IN MEDULLOBLASTOMA AND EWING SARCOMA
- The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma
- Inhibition of mast cell function and proliferation by mTOR activator MHY1485
- Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma
- Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib
- The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
- Leucine can modulate the expression of proteins related to protein degradation signalling under mTOR inhibition in C2C12 cells
- PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy
- Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway
- microvascular integrity can be preserved by anti-platelet therapy and in combination with mTOR inhibitor
- Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
- Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
- mTOR inhibition prolongs reproductive longevity in a murine model of physiologic ovarian aging
- Matrine induces Akt/mTOR signalling inhibition‐mediated autophagy and apoptosis in acute myeloid leukaemia cells
- Activated cMyc/PIM kinase promotes resistance to PI3K/mTOR inhibition in NSCLC
- Inhibition of mammalian target of rapamycin (mTOR) signaling in the insular cortex alleviates neuropathic pain after peripheral nerve injury
- Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis
- 20 (S)-Protopanaxadiol-induced apoptosis in MCF-7 breast cancer cell line through the inhibition of PI3K/AKT/mTOR signaling pathway
- Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation
- QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents
- QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents
- Brg1 aggravates airway inflammation in asthma via inhibition of the PI3K/Akt/mTOR pathway
- How Readily Available Are mTOR Inhibitors?
- Omipalisib (GSK458), a dual an-PI3K/mTOR inhibitor, exhibits in vitro and in vivo activity in chemotherapy-sensitive and-resistant models of Burkitt lymphoma
- Gax suppresses chemerin/CMKLR1‐induced preadipocyte biofunctions through the inhibition of Akt/mTOR and ERK signaling pathways
- Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in …
- Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients.
- Inhibition of mTOR signaling confers protection against cerebral ischemic injury in acute hyperglycemic rats
- mTOR kinase inhibition effectively decreases progression of a subset of neuroendocrine tumors that progress on rapalog therapy and delays cardiac impairment
- CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study
- The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415
- AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: Implications …
- Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells
- Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR.
- Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
- The novel mTOR complex 1/2 inhibitor P529 inhibits human lung myofibroblast differentiation
- Synthesis and biological activity of imidazo [4, 5-c] quinoline derivatives as PI3K/mTOR inhibitors
- Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p‑IGF‑1R/PI3K/AKT/mTOR signaling pathway
- Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass …
- mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition
- Sex-specific dimorphism in cellular stress response upon mTOR inhibition revealed by podocyte specific RNA sequencing
- Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway
- A first-in-human phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer
- Gambogic acid improves non-small cell lung cancer progression by inhibition of mTOR signaling pathway
- mTOR Inhibitors Maintain low levels of immune activation, immune senescence and EBV load in kidney transplant patients
- Lycium barbarum polysaccharide protects diabetic peripheral neuropathy by enhancing autophagy via mTOR/p70S6K inhibition in Streptozotocin-induced diabetic …
- Silibinin induced human glioblastoma cell apoptosis concomitant with autophagy through simultaneous inhibition of mTOR and YAP
- Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent
- Curcumin suppresses epithelial–mesenchymal transition of renal tubular epithelial cells through the inhibition of Akt/mTOR pathway
- An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway
- PI3K/mTOR pathway inhibition induces Aurora B mediated cell death in NOTCH1 mutant head and neck squamous (HNSCC) cells
- Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like …
- Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway
- Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib
- Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR …
- Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27
- The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia
- … Elevated MTORC1 signature in B cells from sjÖgren’s syndrome patients correlates with B cell hyperactivity that is abrogated by MTOR inhibition: a novel therapeutic …
- Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
- The Coefficient of Variability is the Same in the mTOR-inhibitors?
- Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway
- Design, Synthesis and biological evaluation of novel phenylsulfonylurea derivatives as PI3K/mTOR dual inhibitors
- Inhibition of the mTOR pathway exerts cardioprotective effects partly through autophagy in CLP rats
- Inhibition of PI3K/AKt/mTOR signaling pathway protects against d-galactosamine/lipopolysaccharide-induced acute liver failure by chaperone-mediated autophagy in …
- Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-κB and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264. 7 …
- Inhibition of Gli1‑mediated prostate cancer cell proliferation by inhibiting the mTOR/S6K1 signaling pathway
- Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition
- Dioscin ameliorates cardiac hypertrophy through inhibition of the MAPK and Akt/GSK3β/mTOR pathways
- Discovery, Process Development, and Scale-Up of a Benzoxazepine-Containing mTor Inhibitor
- Nutmeg extract increases skeletal muscle mass in aging rats partly via IGF1-AKT-mTOR pathway and inhibition of autophagy
- Discovery of novel 1, 3, 5-triazine-thiozolidine (DDDL-251) based dual PI3K/mTOR inhibitor against breast cancer
- Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC)
- Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation
- Deoxypodophyllotoxin induces cytoprotective autophagy against apoptosis via inhibition of PI3K/AKT/mTOR pathway in osteosarcoma U2OS cells
- The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
- PO-505 Targeting PIM kinase to overcome resistance to PI3K-mTOR inhibition in NSCLC
- Triptolide suppresses glomerular mesangial cell proliferation in diabetic nephropathy is associated with inhibition of PDK1/Akt/mTOR pathway
- Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2-metastatic breast cancer
- The protective effects of Κ-opioid receptor stimulation in hypoxic pulmonary hypertension involve inhibition of autophagy through the AMPK-MTOR pathway
- Inhibition of miR-20 promotes proliferation and autophagy in articular chondrocytes by PI3K/AKT/mTOR signaling pathway
- Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
- Notoginsenoside R1 attenuates glucose-induced podocyte injury via the inhibition of apoptosis and the activation of autophagy through the PI3K/Akt/mTOR …
- Inhibition of ghrelin o-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPK–mTOR pathway
- EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells
- Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells
- Inhibition of mTOR/S6K1/4E-BP1 signaling by nutraceutical SIRT1 modulators
- Bigelovin, a sesquiterpene lactone, suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS …
- Metformin plus caloric restriction show anti-epileptic effects mediated by mTOR pathway inhibition
- Design, synthesis, and docking studies of new Torin2 analogs as potential ATR/mTOR kinase inhibitors
- Anti-fibrosis effect for Hirsutella sinensis mycelium based on inhibition of mTOR p70S6K phosphorylation
- Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP …
- mTOR inhibitors in kidney transplantation
- STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer
- miR-21 inhibitors modulate biological functions of gastric cancer cells via PTEN/PI3K/mTOR pathway
- mTOR inhibitors in epilepsy management: from bench to bedside
- Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex …
- Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations
- Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction
- Dietary α-mangostin provides protective effects against acetaminophen-induced hepatotoxicity in mice via Akt/mTOR-mediated inhibition of autophagy and apoptosis
- Research progress of mTOR inhibitors for anti-atherosclerosis
- Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
- Pharmacological inhibition of 2-arachidonoilglycerol hydrolysis enhances memory consolidation in rats through CB2 receptor activation and mTOR signaling …
- Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
- Abstract IA25: Third-generation inhibitors of mTOR
- mTOR Inhibitor-Corticoid Combination Therapy For Multiple Sclerosis
- Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma …
- … companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
- Early Conversion to mTOR Inhibitors Prevents Kidney Function Better Than Late Conversion
- Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 …
- Role of mTOR inhibitors in solid organ transplantation
- PI3kinase/mTOR Inhibition Alters Global Metabolism in IPF Patients: Exploratory Biomarker Analysis from a Phase I Proof of Mechanism Study
- Inhibition of Rac1 ameliorates neuronal oxidative stress damage via reducing Bcl-2/Rac1 complex formation in mitochondria through PI3K/Akt/mTOR pathway
- Companion diagnostic for predicting the efficacy of mTOR inhibitor in neuroendocrine tumor
- mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents
- Multitargeted kinase inhibition (AEE788) alleviates mTOR inhibitor drug resistance in triple-negative breast cancer
- Therapy monitoring of mTOR-inhibitors using 3D reconstruction of SEGA volume, DTI and SVS
- Chemical identification of a sulfated glucan from Antrodia cinnamomea and its anti-cancer functions via inhibition of EGFR and mTOR activity
- Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo
- Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells
- Docosahexaenoic Acid Attenuated Experimental Chronic Colitis in Interleukin 10–Deficient Mice by Enhancing Autophagy Through Inhibition of the mTOR Pathway
- Early use of mTOR inhibitors and risk of Cytomegalovirus infection in liver transplant patients
- … effects in human kidney tumor cells mediated via mitochondrial mediated apoptosis, inhibition of cell migration and invasion and targeting PI3K/AKT/mTOR …
- Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients
- Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway
- Anticancer activity of cucurbitacin-A in ovarian cancer cell line SKOV3 involves cell cycle arrest, apoptosis and inhibition of mTOR/PI3K/Akt signaling pathway
- Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the PI3K/AKT/mTOR pathway
- The pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
- Abstract A49: Transcription factor upregulation after mTOR inhibition by Torin1 induces growth factor receptor expression
- Lymphatically directed MAPK/PI3K/mTOR inhibitor for treatment of cancer growth and metastasis
- CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
- Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models
- Safety of mTOR Inhibitors in Infants with Tuberous Sclerosis Complex (TSC): Multicenter Clinical Experience (S35. 003)
- KLF15 protects against isoproterenol-induced cardiac hypertrophy via regulation of cell death and inhibition of Akt/mTOR signaling
- Mechanisms of secondary resistance to dual PI3K/mTOR inhibition in sarcomas with complex genetics
- SP757 COMBINATION OF CALCINEURIN INHIBITORS AND MTOR INHIBITORS FOLLOWING KIDNEY TRANSPLANTATION IN COMPARISON WITH …
- Understanding the biochemical alterations in cancer cells chronically treated with PI3K/mTOR inhibitors
- An anti‐cancer drug candidate OSI‐027 and its analog as inhibitors of mTOR: computational insights into the inhibitory mechanisms
- Controlled release of mTOR inhibitors to enhance CD8+ T cell memory
- … activity of caffeic acid n‑butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling …
- DIPG-61. HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT SYNERGIZES WITH DUAL MTOR INHIBITOR TAK228 TO POTENTIATE KILLING OF DIPG CELLS
- Combined PI3 K/mTOR Inhibition and Transcriptional Repression in Head and Neck Carcinoma
- mTOR Inhibitors Enhance Antitumor Activity of Liver Resident NK Cells
- Qianlie Xiaozheng decoction induces autophagy in human prostate cancer cells via inhibition of the Akt/mTOR pathway
- Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma
- Vitamin D increases glucocorticosteroid efficacy via mTOR-inhibition in Multiple Sclerosis (P3. 392)
- Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer
- Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
- Pediatric relapsed acute lymphoblastic leukemia patients display enrichment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR inhibitor PKI-587
- Immunotherapy and mTOR inhibitors a new perspective in the treatment of advanced and metastatic urothelial carcinomas.
- … Immunosuppression on Mineral Metabolism One Year after Kidney Transplantation: Differences Between a Mycophenolate-Based Regimen Versus an mTOR Inhibitor …
- Use of Antiepileptic Drugs among Patients with Tuberous Sclerosis Complex Related Epilepsy who Initiated an Oral mTOR Inhibitor (P6. 277)
- Clinical efficacy of mTOR inhibitor for Kaposiform hemangioendotheliomas with Kasabach-Merritt phenomenon
- SP769 RITUXIMAB AND MTOR INHIBITORS IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER. IS PROGNOSIS CHANGING?
- Consequences of mTOR inhibition on epileptogenesis and neuroprotection in lithium-pilocarpine model of epilepsy in rats
- Effect of dibutyltin dilaurate on triglyceride metabolism through the inhibition of the MTOR pathway in human HL7702 liver cells
- Microvascular Loss in Experimental Murine Tracheal Transplantation can be Prevented by Anti-Platelet Therapy and in Combination with mTOR Inhibitor
- Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
- differential effects of linsitinib and mtoR inhibitors on cell migration and proliferation of pancreatic neuroendocrine tumor cells
- Role of the Early Association of a mTOR Inhibitor and Tacrolimus in BK Polyomavirus Infection in Kidney Transplant Recipients
- Abstract P525: Mtor Inhibitor Everolimus Decreases Aortic Sensitivity To Phenylephrine In Normotensive Rats
- Abstract NTOC-110: UNEXPECTED ROLES FOR KDM4A: PROTEIN SYNTHESIS AND MTOR INHIBITOR SENSITIVITY
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
- Abstract B22: Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors together with AR antagonists in advanced prostate cancer
- Inhibition of mTOR pathway by rapamycin decreases P-glycoprotein expression and spontaneous seizures in pharmacoresistant epilepsy
- Pain-relieving effects of the mTOR inhibitor in the anterior cingulate cortex of neuropathic rats
- Radio sensitizing effect of double PI3K/mTOR inhibitor NVPBEZ235 on Hela cells of cervical cancer
- Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with …
- OP-MTOR INHIBITOR-ASSOCIATED STOMATITIS (MIAS) INDUCED BY EVEROLIMUS IN ADVANCED BREAST CANCER PATIENT-CASE REPORT
- CD44 positive and sorafenib resistant hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
- Phosphodiesterase-3 Inhibitor Regulates Endothelial Autophagy and Re-Endothelialization in Experimental Models of a First-Generation mTOR Inhibitor-Eluting Stent
- Precision Assessment of on-and Off-Target Effects of mTOR Kinase Inhibitors in a Mouse Model
- … of Immunosuppression on Metabolic Outcomes One Year after Kidney Transplantation: The Role of Mycophenolate and mTOR Inhibitors on Lipid Metabolism and …
- MP83-02 OVERCOMING PI3K/MTOR INHIBITOR RESISTANCE BY PIM1 INHIBITOR THROUGH REGULATION OF TYROSINE KINASE EXPRESSION.
- Cuprizone model of demyelination in the presence of mTOR inhibitor rapamycin
- Abstract B153: CDK4/6 inhibitor synergizes with mTOR inhibitor to suppress cholangiocarcinoma pathogenesis
- … on isoproterenol-induced myocardial injury in high-fat-fed rats involves modulation of PI3K/Akt/mTOR signaling pathway and inhibition of apoptosis: comparison to …
- A drug screening assay identifies mTOR inhibitors and SERMs as novel radiosensitizers for head and neck cancer
- BENEFICIAL EFFECTS OF THE MTOR INHIBITOR EVEROLIMUS IN PATIENTS WITH ADVANCED MEDULLARY THYROID CARCINOMA; SUB-GROUP …
- … liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation
- mTOR inhibitor augments the antitumor effect of p53-expressing oncolytic adenovirus in human neuroblastoma cells
- … 5, 8′-coupled naphthylisoquinoline alkaloid, eliminates the tolerance of cancer cells to nutrition starvation by inhibition of the Akt/mTOR/autophagy signaling pathway
- Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition
- Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway
- … effects of resveratrol on transforming growth factor β1-induced fibrogenesis in primary human lung fibroblasts through autophagy induction via Akt/mTOR inhibition
- TEMSIROLIMUS IS A CANDIDATE OF THE OPTIMAL MTOR INHIBITOR FOR PROTECTING HUMAN INTERVERTEBRAL DISC NUCLEUS PULPOSUS CELLS: 6
- Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells
- … Mutational Burden and Alterations to DNA Damage Repair Genes are Associated With Poor Prognosis and Sensitivity to PI3K-mTOR Inhibitors in Multiple Myeloma
- Arsenic trioxide sensitizes glioma stem cells to brain penetrant PI3K and mTOR inhibitor GDC-0084
- Assessing Impaired Oatp1b1-and Oatp1b3-Mediated Transport by Mtor Inhibitors, Multi-Kinase Inhibitor Vemurafenib and by Protein Kinase C Activation
- … shows preferential cytotoxicity to acidity-tolerant prostate carcinoma PC-3 cells through ROS-mediated mitochondrial damage and the inhibition of PI3K/Akt/mTOR …
- Xanthohumol induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI3K/Akt/mTOR-kinase in human gastric cancer cells
- UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA‑MB‑231 cells
- Inhibition of PI 3K‐Akt‐mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth
- TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma
- Anti-angiogenic efficacy of Bevacizumab alone and in combination with a dual PI3K/mTOR inhibitor in an orthotopic model of malignant glioma: A multimodal neuro …
- … resistance to an emibetuzumab analogue in MET-amplified gastric xenografts can be overcome by a MET-targeting antibody mixture or PIK3CA/AKT/mTOR inhibition
- Increased mTORC1 activation in salivary gland B cells and T cells from Sjögren’s syndrome patients: mTOR inhibition as a novel therapeutic strategy to halt …
- Eicosapentaenoic acid abolishes inhibition of insulin-induced mTOR phosphorylation by LPS via PTP1B downregulation in skeletal muscle
- Mutations in TSC1/TSC2 genes are prevalent in sporadic renal angiomyolipoma and insulinoma tumors, supporting their responsiveness to mTOR inhibitors
- Down‐Regulation of OATP1B1‐Mediated Transport by Mammalian Target of Rapamycin (mTOR) Inhibitors Everolimus and Sirolimus: Potential Mechanism and …
- Targeting Rac-GTPases reverses stroma-induced resistance to notch and mtor-inhibition in T-cell acute lymphoblastic leukemia
- EXTH-51. PI3K/mTOR INHIBITION LEADS TO REDUCTION IN 2HG PRODUCTION AND CELL PROLIFERATION IN IDH1 MUTANT CELLS
- P. 039 mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report
- Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition
- Proteomics and Network Analyses Reveal Inhibition of Akt‐mTOR Signaling in CD4+ T Cells by Mycobacterium tuberculosis Mannose‐Capped Lipoarabinomannan
- Abstract CT161: Clinical study of PD-1 inhibitor with mTOR inhibitor for relapsed and refractory brain tumors
- … 3 study of buparlisib (BKM120)+ fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2-ABC after progression on an mTOR inhibitor
- CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5‐FU‐induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway
- Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells
- Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells
- Dual inhibitory effects of novel naringenin analogue in tobacco-carcinogen induced lung cancer via inhibition of PI3K/Akt/mTOR pathway
- MP88-14 CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS
- … and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast …
- Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway
- Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung …
- Effect of HER3 dimer feedback upregulation via PI3K-AKT-mTOR pathway inhibition on androgen receptor (AR) stabilization in metastatic prostate cancer.
- Renal Cell Carcinoma Associated With Xp11. 2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
- In silico discovery of a small molecule suppressing lung carcinoma A549 cells proliferation and inducing autophagy via mTOR pathway inhibition
- EXTH-35. IN VIVO 1H MRS DETECTS REDUCED 2HG PRODUCTION IN IDH1 MUTANT GLIOMAS TREATED WITH A DUAL PI3K/MTOR INHIBITOR
- Low frequency magnetic fields induce autophagy-associated cell death in lung cancer through miR-486-mediated inhibition of Akt/mTOR signaling pathway
- P3. 02c-010 Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC: Topic: Targeted Therapy
- Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted …
- P2. 06-009 Combined PKCi and mTOR Inhibition in Advanced or Recurrent Lung Cancer, Preliminary Report of an Ongoing Phase I/II Trial: Topic: Phase I/II Trials
- Snail reduces the antitumor efficacy of mTOR kinase inhibitors by transcriptional repression of 4E-BP1
- Effect of inhibitors (PP242), PKI402 and (MTOR) in their combination with MEK cytometry on cancer cell cells
- A cyclometalated iridium (III) complex induces apoptosis and autophagy through inhibition of the PI3K/AKT/mTOR pathway
- Inhibitors Targeting IGF‐1r and mTOR Induce Synergistic Cell Growth Inhibition and Enhance Apoptotic Activity in Cancer Cell Lines
- Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3. 1 and inhibition of AKT/mTOR signaling
- Inhibition of Rabies Virus by 1,2,3,4,6-Penta-O-galloyl-β-d-Glucose Involves mTOR-Dependent Autophagy
- Design and synthesis of alkyl substituted pyridino [2, 3-D] pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent …
- Development of novel 1, 2, 4-triazole-thiol derivatives as dual PI3K/mTOR inhibitor against the non-small cell lung cancer (NSCLC)
- Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer
- Telmisartan induces osteosarcoma cells growth inhibition and apoptosis via suppressing mTOR pathway
- Cyclic ADP-ribose as an endogenous inhibitor of the mTOR pathway downstream of dopamine receptors in the mouse striatum
- Catalpol prevents denervated muscular atrophy related to the inhibition of autophagy and reduces BAX/BCL2 ratio via mTOR pathway
- CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA
- Discovery of a series of N-(5-(quinolin-6-yl) pyridin-3-yl) benzenesulfonamides as PI3K/mTOR dual inhibitors
- Inhibition of tissue transglutaminase attenuates lipopolysaccharide-induced inflammation in glial cells through AKT/mTOR signal pathway
- Combined 3D-QSAR and Molecular Docking Study on benzo [h][1, 6] naphthyridin-2 (1H)-one Analogues as mTOR Inhibitors.
- … of metformin, an antidiabetic drug, against ovarian cancer cells involves inhibition of cysteine-rich 61 (cyr61)/Akt/mammalian target of rapamycin (mTOR) …
- CSIG-29. THE DUAL PI3K/mTOR-PATHWAY INHIBITOR GDC-0084 ACHIEVES ANTITUMOR ACTIVITY IN BREAST CANCER BRAIN METASTASES IN VITRO AND …
- Inhibition of mTOR signaling pathway by aqueous extract of Siberian ginseng
- PI3K/AKT/mTOR pathway inhibition sensitizes ovarian cancer cells to anti-estrogen therapy
- Abstract PD4-04: combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long term growth inhibition in estrogen receptor …
- Inhibition of mTOR signalling: a potential anti-aging drug strategy
- Antifibrotic effect of rapamycin, an inhibitor of mTOR pathway, on the TGF-β2 induced proliferation of human tenon fibroblasts
- Pharmacological Inhibition Of Mtor Kinase Selectively Suppresses Rv-Specific Activation Of Mtorc1 Signaling, Reverses Rv Remodeling And Improves Rv Morphology …
- Essential signaling in NF2 loss-related tumours: The therapeutic potential of CRL4DCAF1 and mTOR combined inhibition
- Advances in Cardiovascular Geroscience: Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive …
- Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR
- Effect of PI3K/Akt/mTOR signal pathway-mediated N822K mutation on apoptosis induced by c-KIT inhibitor in AML cells
- PO-233 Chemoresistant NSCLC cells are hypersensitive to metabolic drugs due to mTOR-mediated inhibition of autophagy
- EIF4E Phosphorylation as a Mechanism of Resistance To mTOR and Androgen Receptor Inhibition in Advanced Prostate Cancer
- Bornyl cis-4-Hydroxycinnamate Suppresses Cell Metastasis of Melanoma through FAK/PI3K/Akt/mTOR and MAPK Signaling Pathways and Inhibition of the Epithelial …
- … of novel cardamonin analogues and identification of a highly active Cu (II)-cardamonin complex that inhibits migration and induces apoptosis via inhibition of mTOR …
- Effects of PI3K/AKT/mtor And VEGFR Pathway Inhibitors on Liver Cancer Stem Cells and Bioactivities of Novel Pyrazolic Chalcone Derivatives on Liver Cancer
- Inhibition of laryngeal cancer cell activity by pterostilbene via modulating AKT/mTOR signal pathway and related mechanisms
- … , Taiwanofungus camphoratus (Agaricomycetes), Induces Protective Autophagy in SPCA-1 Cells through AMPK Inhibition-Independent Blockade of the Akt/mTOR …
- Inhibition of Endothelial mTOR Drives Hematopoietic Stem Cell Aging
- MAPkinase and PI3K/mTOR pathways inhibition in conjunctival melanoma
- Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
- Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models
- Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
- Mechanisms resistance analysis of inhibitors involved in the PI3K/Akt/mTOR pathway in vitro and in cftDNA collected from patients with breast tumors
- The effect of selective tyrosine kinase inhibitors on the expression of HIF1α and mTOR in p16-positive and-negative squamous cell carcinoma (HNSCC)
- Discovery and evaluation of WX047, a potent and oral active phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitor
- Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation
- … PRETEND WE’RE MARRIED: THE RIGHT VENTRICLE AND THE PULMONARY VASCULATURE: Pharmacological Inhibition Of Mtor Kinase Selectively Suppresses …
- Combined inhibition of MEK and mTOR pathways is effective in NRAS Q61K mutant small cell lung cancer
- Characterization of a Novel Mouse Model for Angiosarcoma in Which Combined Inhibition of mTOR and MEK Results in Tumor Suppression
- Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation
- mTOR-and tyrosine kinase inhibitors reduce AKT-and IGF-R expression in squamous cell carcinoma (HNSCC), dependent on p16 status
- Advances in childhood T-cell acute lymphoblastic leukemia and inhibitors targeting PI3K-Akt-mTOR signaling pathway
- The Investigation of mTOR, JAK/STAT and Hedgehog pathways inhibitor effect on hematological cancer cell lines proliferation
- Abstract B175: Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer
- Oxidative Stress Induces Autophagy through Inhibition of mTOR in Corneal Epithelial Cells
- Antitumor effect by inhibition of PI3K/AKT/mTOR and RAS/MAPK pathways in human oral squamous cell carcinoma cells
- Epi-magnolin suppresses EGF-induced neoplastic cell transformation by inhibition of Akt/mTOR signaling pathway in JBC Cl41 cells
- PLGA-PEG nanoparticles for targeted delivery of an mTOR/PI3kinase inhibitor, NVP-BEZ235, to inflamed endothelium
- A dual mTOR-PI3K inhibitor DCB-HDG2-57 with Hedgehog signaling pathway antagonist activity
- Effects of Emodin against Renal Tubular Epithelial Cell Fibrosis via the Inhibition of Akt/mTOR Signal Pathway
- Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer when combined to PARP inhibition
- Fibroblast-Mediated Resistance to BRAF Inhibition in Metastatic Melanoma-Effect of drugs targeting PI3K/AKT/mTOR signaling pathway
- Inhibition of Upper Small Intestinal mTOR Lowers Plasma Glucose Levels by Inhibiting Hepatic Glucose Production
- Modulation of MEK/ERK and mTOR pathways by Na+‐K+‐ATPase and AMPK inhibitors in ovarian cancer cells
- Effect of silencing Notch1 gene on proliferation, apoptosis and Akt/mTOR pathyway inhibition in clear cell renal cell carcinoma
- Synergistic effect of alectinib and everolimus on anaplastic large cell lymphoma cells via ALK-mTOR pathway inhibition
- Inhibition of mammalian target of rapamycin (mTOR) signaling in the anterior cingulate cortex alleviates neuropathic pain
- Inhibition of mTOR Signaling Reduces Mesenchymal Cell Migration To Sites Of Injury And Eliminates Heterotopic Ossification In A Mouse Model
- Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells
- Pharmacological Inhibition of mTOR and ERK1/2 Resulted in Attenuated Protein Synthesis Rates in Differentiated C2C12 Myoblasts in a Similar Fashion to in vivo …
- Ribonuclease inhibitor interacts with integrin-linked kinase and inhibits bladder cancer growth in vitro and in vivo through ILK/AKT/mTOR pathway
- Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells
- Lysosome membrane permeabilization and disruption of mTOR-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a …
- Neuropathic Pain Relieving in Rats by the Inhibition of Monomer of Lamiophlomis Rotata on AKT-mTOR Signaling Pathway in Spinal Dorsal Horn
- Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid …
- Correction: Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation
- Antibody targeting PDZ domain of TIP-1 induces proliferation arrest through AKT/mTOR signaling inhibition in lung cancer and glioblastoma
- Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.
- Inhibition of Inositol hexakisphosphate Kinase 1 (IP6K1) Does Not Increase Akt or mTOR Activity in vitro.
- Soluble epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, represses human aortic smooth muscle cell proliferation and migration …
- Abstract PD4-08: a microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER+ breast …
- … and Undifferentiated Pleomorphic Sarcoma Sensitive to Mammalian Target of Rapamycin (mTOR) and Insulin-Like Growth Factor 1 (IGF1) Receptor Inhibitors
- … harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid …
- Abated microRNA-21 attenuates high glucose-induced autophagy inhibition in rat mesangial cells by PTEN/Akt/mTOR pathway
- … -Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway
- Research progress of mTOR inhibitors
- mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy
- Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors
- Mechanisms of resistance to mTOR inhibitors
- Exploring mTOR inhibition as treatment for mitochondrial disease
- The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives
- Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
- PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
- Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation
- Revisiting mTOR inhibitors as anticancer agents
- Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma?
- Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas)
- Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines
- Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age–a multicenter retrospective study
- PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
- mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19
- mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors
- mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases
- The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth
- Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
- Novel mTOR inhibitor enhances the sensitivity of hepatocellular carcinoma cells to molecular targeting agents
- Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
- mTOR inhibitors in advanced biliary tract cancers
- Inhaled biguanides and mTOR inhibition for influenza and coronavirus
- Phytochemicals as PI3K/Akt/mTOR inhibitors and their role in breast cancer treatment
- A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
- IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
- Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma
- Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition
- Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors
- Synergistic anti-tumor effect of mTOR inhibitors with irinotecan on colon cancer cells
- Second generation mTOR inhibitors as a double-edged sword in malignant glioma treatment
- Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition
- mTOR inhibitor everolimus in regulatory T cell expansion for clinical application in transplantation
- mTOR inhibitor everolimus reduces invasiveness of melanoma cells
- High sensitivity of circulating tumor cells derived from a colorectal cancer patient for dual inhibition with AKT and mTOR inhibitors
- 4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer
- PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
- Addition of antiestrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors
- Pharmacodynamic monitoring of mTOR inhibitors
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation
- First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma
- TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1
- Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells
- Overexpression of ABCB1 transporter confers resistance to mTOR inhibitor WYE-354 in cancer cells
- Pain-relieving effects of mTOR inhibitor in the anterior cingulate cortex of neuropathic rats
- Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
- Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
- In silico analyses and cytotoxicity study of asiaticoside and asiatic acid from malaysian plant as potential mTOR inhibitors
- A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment
- mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report
- Extracellular acidosis and mTOR inhibition drive the differentiation of human monocyte-derived dendritic cells
- Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy
- Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
- Dual-mTOR inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity
- Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
- The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma
- Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in Mycobacterium tuberculosis …
- Macropinocytosis renders a subset of pancreatic tumor cells resistant to mTOR inhibition
- Synergistic effects of combination therapy with AKT and mTOR inhibitors on bladder cancer cells
- Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
- PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
- Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma
- mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b+ Gr1+ cells
- mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy?
- Individual response to mTOR inhibition in delaying replicative senescence of mesenchymal stromal cells
- The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic …
- Effects of mTOR inhibitors on neuropathic pain revealed by optical imaging of the insular cortex in rats
- Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors
- PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer
- Discovery and SAR of novel disubstituted quinazolines as dual PI3Kalpha/mTOR inhibitors targeting breast cancer
- A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma …
- Hyperpolarized MRI visualizes Warburg effects and predicts treatment response to mTOR inhibitors in patient-derived ccRCC xenograft models
- Virtual screening and optimization of novel mTOR inhibitors for radiosensitization of hepatocellular carcinoma
- Use of human induced pluripotent stem cells and kidney organoids to develop a cysteamine/mTOR inhibition combination therapy for cystinosis
- Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
- mTOR inhibitors in pediatric liver transplant recipients
- Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT/pS6K/pS6 in triple negative breast cancer
- Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
- A conformational restriction strategy for the identification of a highly selective pyrimido-pyrrolo-oxazine mTOR inhibitor
- A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer
- Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70
- A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
- Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
- Dual PI3K/mTOR inhibitor NVP-BEZ235 enhances radiosensitivity of head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand …
- mTOR inhibitor INK128 attenuates dextran sodium sulfate‐induced colitis by promotion of MDSCs on Treg cell expansion
- The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver …
- Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus
- Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of rapamycin (mTOR) inhibition by reducing NIMA‐related kinase 7 …
- The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non–small cell lung cancer
- Use of de novo mTOR inhibitors in hypersensitized kidney transplant recipients: experience from clinical practice
- A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
- Chronic sulforaphane administration inhibits resistance to the mTOR-inhibitor everolimus in bladder cancer cells
- Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy
- Functional effects of cuprizone-induced demyelination in the presence of the mTOR-inhibitor rapamycin
- Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines
- Using SMOTE to deal with class-imbalance problem in bioactivity data to predict mTOR inhibitors
- Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit
- Radiosensitising cancer using phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT) or mammalian target of rapamycin (mTOR) inhibitors
- … , Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of …
- RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma
- Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system
- The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators
- The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma
- Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma
- Effects of neddylation and mTOR inhibition in acute myelogenous leukemia
- The mTOR inhibitor rapamycin prevents general anesthesia-induced changes in synaptic transmission and mitochondrial respiration in late postnatal mice
- Long-term follow-up of mTOR inhibition for Erdheim-Chester disease
- mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
- Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice
- Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
- Sex-dependent lifespan extension of ApcMin/+ FAP mice by chronic mTOR inhibition
- Electroacupuncture upregulated ghrelin in rats with functional dyspepsia via AMPK/TSC2/Rheb-mediated mTOR inhibition
- The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition
- Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell …
- Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
- UV damage induces G3BP1-dependent stress granule formation that is not driven by mTOR inhibition-mediated translation arrest
- Autophagy, lysosome dysfunction and mTOR inhibition in MNU-induced photoreceptor cell damage
- Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
- Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis
- Combined treatment with MEK and mTOR inhibitors is effective in in vitro and in vivo models of hepatocellular carcinoma
- PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo
- Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells
- Long‐term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle‐aged marmosets
- mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers
- Comparing the effects of the mTOR inhibitors azithromycin and rapamycin on in vitro expanded regulatory T cells
- Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
- A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor
- The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation
- Artesunate targets oral tongue squamous cell carcinoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition
- mTOR inhibitor use in head and neck squamous cell carcinoma: a meta‐analysis on survival, tumor response, and toxicity
- High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto) antibody production by human plasma cells
- Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
- mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development
- Combining PI3K/Akt/mTOR inhibition with chemotherapy
- Early adjuvant medication with the mTOR inhibitor sirolimus in a preterm neonate with compressive cystic lymphatic malformation
- Gemcitabine and selected mTOR inhibitors in uterine sarcomas and carcinosarcoma cells-an isobolographic analysis
- Haprolid inhibits tumor growth of hepatocellular carcinoma through Rb/E2F and Akt/mTOR inhibition
- Impact of minor structural modifications on properties of a series of mTOR inhibitors
- Anti‑proliferative effect of cardamonin on mTOR inhibitor‑resistant cancer cells
- Mtor inhibition leads to src-mediated egfr internalisation and degradation in glioma cells
- Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma
- mTOR inhibitors can enhance the anti-tumor effects of DNA vaccines through modulating dendritic cell function in the tumor microenvironment
- Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors
- The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following …
- Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration‐resistant prostate cancer
- Visualizing DC morphology and T cell motility to characterize DC-T cell encounters in mouse lymph nodes under mTOR inhibition
- Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin
- Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP‑BEZ235 in combination with cisplatin on drug‑resistant non‑small cell lung cancer cell
- Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia
- Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt …
- … carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated …
- The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)
- mTOR inhibitor therapy diminishes circulating CD8+ CD28− effector memory T cells and improves allograft inflammation in belatacept-refractory renal allograft …
- Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors
- Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) for CNS disorders
- A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells
- Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis
- Topical Application of a Dual PI3K/mTOR Inhibitor Prevents Anal Carcinogenesis in an HPV Mouse Model of Anal Cancer
- Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex
- Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
- ABI-009 (nab-Sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors
- A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter’s transformation and de novo diffuse …
- Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of …
- IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium
- Recent advances of mTOR inhibitors use in autosomal dominant polycystic kidney disease: is the road still open?
- COVID‐19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors
- A novel molecular mechanism of IKKε-mediated Akt/mTOR inhibition in the Cardiomyocyte autophagy after myocardial infarction
- Practical synthesis of vistusertib (AZD2014), an ATP competitive mTOR inhibitor
- Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer
- Mammalian target of rapamycin (mTOR) inhibitors and skin cancer risk in nonrenal solid organ transplant recipients: systematic review and meta‐analysis
- Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a …
- First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor
- Management of mTOR inhibitors oral mucositis: current state of knowledge
- PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges
- Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled …
- Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene
- Curcumin analog, WZ37, promotes G2/M arrest and apoptosis of HNSCC cells through Akt/mTOR inhibition
- The effects of different mTOR inhibitors in EGFR inhibitor resistant colon carcinoma cells
- Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors
- VicTORia: A randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line …
- Horizontal combination of MEK and PI3K/mTOR inhibition in BRAF mutant tumor cells with or without concomitant PI3K pathway mutations
- Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus
- Long-term redistribution of peripheral lymphocyte subpopulations after switching from calcineurin to mTOR inhibitors in kidney transplant recipients
- Low-level ionizing radiation induces selective killing of HIV-1-infected cells with reversal of cytokine induction using mTOR inhibitors
- mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
- … )-6-((R)-3-methylmorpholino)-1, 3, 5-triazin-2-yl) pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of …
- Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer
- ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation
- Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
- UV damage induces G3BP1-dependent stress granule formation that is not driven by translation arrest via mTOR inhibition
- Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma
- Rational discovery of a highly novel and selective mTOR inhibitor
- Preclinical evidence for targeting PI3K/mTOR signaling with dual-inhibitors as a therapeutic strategy against cutaneous T-cell lymphoma
- Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition
- Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu] Lu-DOTA-TATE in Lewis rats
- Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
- 18 mTOR Inhibitors: Sirolimus and Everolimus
- Inhibition of gastric cancer cell growth by a PI3K-mTOR dual inhibitor GSK1059615
- Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: a natural experiment
- Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1, 3, 5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors
- 2, 6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo
- Brain-Restricted mTOR Inhibition with Binary Pharmacology
- A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines
- Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma …
- Rapamycin-mediated mTOR inhibition impairs silencing of sex chromosomes and the pachytene piRNA pathway in the mouse testis
- Anti‐tumor effects of PIM/PI 3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
- Manganese-enhanced MRI depicts a reduction in brain responses to nociception upon mTOR inhibition in chronic pain rats
- Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway
- The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
- Preventive Role of mTOR Inhibitor in Post–Kidney Transplant Urothelial Carcinoma
- Combination effect of Notch1 and PI3K/AKT/mTOR signaling pathways inhibitors on T-ALL cell lines
- Repurposing potential of riluzole as an ITAF inhibitor in mTOR therapy resistant glioblastoma
- Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial
- Therapeutic Enhancement of Verteporfin‐mediated Photodynamic Therapy by mTOR Inhibitors
- A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
- Effect of mTOR inhibitors during CMV disease in kidney transplant recipients: Results of a pilot retrospective study
- Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and …
- Eosinophilic fasciitis triggered by nivolumab: a remarkable efficacy of the mTOR inhibitor sirolimus
- FUS contributes to mTOR-dependent inhibition of translation
- Inhibition of mTOR alleviates early brain injury after subarachnoid hemorrhage via relieving excessive mitochondrial fission
- Inhibition of mTOR by rapamycin aggravates corneal epithelial stem cell deficiency by upregulating inflammatory response
- mTOR inhibitor therapy for tuberous sclerosis complex: longitudinal study of muscle mass determined by abdominal cross-sectional imaging with CT and MRI
- Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma
- Topical delivery of mTOR inhibitor halts scarring
- Effects of mTOR inhibitor, everolimus, on proliferation, autophagy and temozolomide sensitivity of glioma cells
- Regulation of autophagy in chick skeletal muscle: effect of mTOR inhibition
- Accelerated regression of cardiac rhabdomyoma by mTOR inhibitors in a neonate with heart failure: A case report
- PI3K/mTOR pathway inhibition: opportunities in oncology and rare genetic diseases
- Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
- Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients
- Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
- Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
- Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: strategy for non-small cell lung cancer with mutant RAS gene
- Exploring molecular descriptors and fingerprints to predict mTOR kinase inhibitors using machine learning techniques
- Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis
- mTOR‐Inhibitor‐Based Immunosuppression Following Liver Transplantation for Hereditary Hemorrhagic Telangiectasia
- Abstract P5-13-02: neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 …
- Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with …
- Lipopolysaccharide promotes lung fibroblast proliferation through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway
- Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
- Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers
- Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and …
- Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
- CD4+ T cell activation and concomitant mTOR metabolic inhibition can ablate microbiota-specific memory cells and prevent colitis
- Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) …
- Advancement on clinical application of mTOR inhibitors in gastrointestinal cancers
- Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling
- PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
- Pharmacological inhibition of mTOR attenuates replicative cell senescence and improves cellular function via regulating the STAT3-PIM1 axis in human …
- Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production
- Laser-assisted delivery of topical rapamycin: mTOR inhibition for Birt–Hogg–Dube syndrome
- Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in …
- Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors
- … ‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors
- ABI-009, nab-sirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension
- Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer
- The Use of Geroprotective Agents (mTOR Inhibitors) in the Treatment of Cancer Patients
- Patients with severe pulmonary arterial hypertension treated with ABI-009, nab-sirolimus, an mTOR inhibitor: Interim results from a phase 1 clinical trial
- Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition
- CTNI-27. first-in-pediatrics phase I study of GDC-0084 (PAXALISIB), a CNS-penetrant PI3K/mTOR inhibitor, in newly diagnosed diffuse intrinsic pontine glioma (DIPG) …
- Overcoming Endocrine Resistance in Breast Cancer: mTOR Inhibitors and New Drugs
- Inhibition of mTOR signaling enhances maturation of cardiomyocytes derived from human-induced pluripotent stem cells via p53-induced quiescence
- The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
- Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
- The use of mTOR inhibitors is associated with improved survival in lung transplant recipients
- Beta-catenin mutations in hepatocellular cancer, tumor cell metabolism, and the response of these tumors to mTOR inhibition.
- Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer
- mTOR inhibitors for the management of difficult lymphangioma in adults
- Transient inhibition of mTOR in human pluripotent stem cells enables robust formation of mouse-human chimeric embryos
- Role of mTOR and VEGFR inhibition in prevention of metastatic tumor growth in the spine
- mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes
- First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy
- SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway
- Continuation of mTOR Inhibition in LAM Patients Listed for Lung Transplant is Safe
- Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) …
- A genome-scale CRISPR screen identifies the ERBB and mTOR signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer
- Inhibition of mTOR via an AAV-delivered shRNA tested in a rat OIR model as a potential antiangiogenic gene therapy
- Inhibition of mTOR delayed but could not prevent experimental collapsing focal segmental glomerulosclerosis
- Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
- Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches
- The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway
- Nanoparticles induce autophagy via mTOR pathway inhibition and reactive oxygen species generation
- Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells
- Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy
- Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition
- Retraction Note: HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
- Inhibition of mTOR in head and neck cancer cells alters endothelial cell morphology in a paracrine fashion
- Calycosin induces apoptosis in adenocarcinoma HT 29 cells by inducing cytotoxic autophagy mediated by SIRT 1/AMPK‐induced inhibition of Akt/mTOR
- Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region
- Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth
- Phase 2a study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) given to glioblastoma (GBM) …
- Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer‐signaling PI3K/AKT/mTOR pathway
- Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth
- p53-Mediated PI3K/AKT/mTOR Pathway Played a Role in PtoxDpt-Induced EMT Inhibition in Liver Cancer Cell Lines
- Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
- Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker …
- miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in …
- Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer …
- Correction to: Electroacupuncture Upregulated Ghrelin in Rats with Functional Dyspepsia via AMPK/TSC2/Rheb‑Mediated mTOR Inhibition
- mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors
- Casticin-induced inhibition of cell growth and survival are mediated through the dual modulation of Akt/mTOR signaling cascade
- Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
- Pharmacological treatment of Autoimmune Polyendocrine Syndrome type I with Rapamycin, a mTOR inhibitor
- In silico Analysis and Molecular Docking Studies of Novel 4-Amino-3-(Isoquinolin-4-yl)-1H-Pyrazolo [3, 4-d] Pyrimidine Derivatives as Dual PI3-K/mTOR Inhibitors
- Stomatitis in mTOR inhibitors treatment and other targeted cancer therapy, possibilities of infl uencing it, and the use of local corticotherapy.
- Novel Dual mTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity and Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer
- Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial‐lysosomal crosstalk
- ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis
- Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition
- Inhibition of the glutamine transporter SNAT1 confers neuroprotection in mice by modulating the mTOR-autophagy system
- The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
- Bupivacaine inhibits angiogenesis through oxidative stress‐dependent inhibition of Akt/mTOR and activation of AMPK
- Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway
- Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells
- PSORI-CM02 ameliorates psoriasis in vivo and in vitro by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway
- Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells
- Dual-inhibition of mTOR and Bcl-2 enhances the anti-tumor effect of Everolimus against renal cell carcinoma in vitro and in vivo
- Investigating the use of mTOR inhibitors in Tuberous Sclerosis Complex
- Thioredoxin‐interacting protein deficiency alleviates phenotypic alterations of podocytes via inhibition of mTOR activation in diabetic nephropathy
- Dexmedetomidine protects against lipopolysaccharide-induced acute kidney injury by enhancing autophagy through inhibition of the PI3K/AKT/mTOR …
- Characterization of Anti-Neovascularization Activity and Ocular Pharmacokinetics of PI3K/mTOR Inhibitor GNE-947
- mTOR inhibitors vs calcineurin inhibitors: A Catch‐22—preventing nephrotoxicity or acute allograft rejection after heart transplantation
- Dual mTOR/DNA-PK inhibitor CC-115 induces cell death in melanoma cells and has radiosensitizing potential
- The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human …
- Enhanced inflammatory response mediated by parenchymal cells associates with resistance towards mTOR inhibition
- DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects
- Discovery of 3-oxabicyclo [4.1. 0] heptane, a non-nitrogen containing morpholine isostere, and its application in novel inhibitors of the PI3K-AKT-mTOR pathway
- A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease
- Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer
- BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway
- Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer
- Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
- Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma
- Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa
- Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K/AKT/mTOR pathway and inhibition of topoisomerase II: in vitro …
- Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models
- Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors
- Targeting mTOR: up-to-date mTOR inhibitors.
- Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling
- Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt …
- Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
- Bisperoxovanadium mediates neuronal protection through inhibition of PTEN and activation of PI3K/AKT-mTOR signaling after traumatic spinal injuries
- Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric …
- Discovery and development of SPR519 as a potent, selective, and orally bioavailable inhibitor of PI3Kα and mTOR kinases for the treatment of solid tumors
- Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells
- … and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and …
- ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway
- Neuroprotective effect of ginkgetin in experimental cerebral ischemia/reperfusion via apoptosis inhibition and PI3K/Akt/mTOR signaling pathway activation
- Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy and relieves hyperalgesia in diabetic rats
- Synergistic antitumor effects of combined treatment with hsp90 inhibitor and pi3k/mtor dual inhibitor in cisplatin-resistant human bladder cancer cells
- AMP‐kinase inhibitor dorsomorphin reduces the proliferation and migration behavior of colorectal cancer cells by targeting the AKT/mTOR pathway
- DRAM1 regulates autophagy and cell proliferation via inhibition of the phosphoinositide 3-kinase-Akt-mTOR-ribosomal protein S6 pathway
- Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve …
- BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584
- Akt/mTOR-mediated autophagy confers resistance to BET inhibitor JQ1 in ovarian cancer
- Piperlonguminine and piperine analogues as TrxR inhibitors that promote ROS and autophagy and regulate p38 and Akt/mTOR signaling
- Synthesis and validation of [18F] mBPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on a benzofuran backbone
- Inhibition of autophagy attenuated intestinal injury after intestinal I/R via mTOR signaling
- Real-Life Experience With mTOR Inhibitors Treatment After Liver Transplantation
- mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
- GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway
- Repurposing of mTOR complex inhibitors attenuates MCL-1 and sensitizes to PARP inhibition
- mTOR inhibitor INK128 promotes diabetic wound healing by regulating MDSCs
- INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/MTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA …
- The vicious cycle between ferritinophagy and ROS production triggered EMT inhibition of gastric cancer cells was through p53/AKT/mTor pathway
- Epigallocatechin gallate suppresses premature senescence of preadipocytes by inhibition of PI3K/Akt/mTOR pathway and induces senescent cell death by regulation …
- Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy
- MTOR INHIBITORS ENHANCE ANTITUMOR ACTIVITY OF LIVER NATURAL KILLER CELLS IN MICE
- … Rb3 provides protective effects against cisplatin‐induced nephrotoxicity via regulation of AMPK‐/mTOR‐mediated autophagy and inhibition of apoptosis in vitro and …
- In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei
- Bee venom and its peptide component melittin suppress growth and migration of melanoma cells via inhibition of PI3K/AKT/mTOR and MAPK pathways
- The synergistic effect of an ATP-competitive inhibitor of mtor and metformin on pancreatic tumor growth
- Renin-angiotensin system inhibitor attenuates oxidative stress induced human coronary artery endothelial cell dysfunction via the PI3K/AKT/mTOR pathway
- Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD‑1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway
- mTOR inhibition in primary neurons and the developing brain represses transcription of cholesterol biosynthesis genes and alters cholesterol levels
- Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of …
- Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1< alpha> signaling pathway
- Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR
- … suppress doxorubicin-induced cardiotoxicity via inhibition of oxidative stress, MAP kinase activation, NF-κB pathway, PI3K/Akt/mTOR impairment, and cardiac …
- Dual inhibition of autophagy and PI3K/AKT/MTOR pathway as a therapeutic strategy in head and neck squamous cell carcinoma
- Use of human iPSCs and kidney organoids to develop a cysteamine/mTOR inhibition combination therapy to treat cystinosis
- Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway
- A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2/mTOR pathway in human ovarian cancer cells
- The Role of mTOR Inhibitors in Breast Cancer Treatment
- Effect of PI3K/mTOR signal pathway inhibitor XL765 on human leukemic KG-1 cells
- mTOR inhibitor Treats Autistic-like Behaviors in Tsc2+/-rats but not following Developmental Status Epilepticus
- mTOR inhibition in the treatment of resistant breast cancer
- Enhanced skeletal muscle insulin sensitivity after acute resistance-type exercise is upregulated by rapamycin-sensitive mTOR complex 1 inhibition
- ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM …
- Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition
- TGFβ Causes Postoperative Natural Killer Cell Paralysis Through mTOR Inhibition
- Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
- Inhibition of decidual IGF-1 signaling in response to hypoxia and leucine deprivation is mediated by mTOR and AAR pathways and increased IGFBP-1 …
- Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
- Inhibition of PLK4 might enhance the anti‐tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway
- Geroprotective drugs-mTOR inhibitors in the treatment of cancer patients.
- mTOR signalling in cancer-Is there a role for mTOR inhibitors in current anti-cancer therapies?
- Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway
- Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells
- Vanillic acid suppresses HIF-1α expression via inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK pathways in human colon cancer HCT116 cells
- KDM1A and mTOR inhibition is a novel therapeutic combination for the treatment of endometrial cancer
- Berberine attenuates cardiac hypertrophy through inhibition of mTOR signaling pathway
- Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway
- Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer
- APLNR is involved in ATRA‐induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K‐Akt‐mTOR signaling
- Targeting the PI3K/mTOR pathway augments CHK1 inhibitor–induced replication stress and antitumor activity in high-grade serous ovarian cancer
- Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells
- Structure-based design and biological evaluation of novel mTOR inhibitors as potential anti-cervical agents.
- Attenuation of free fatty acid (FFA)-induced skeletal muscle cell insulin resistance by resveratrol is linked to activation of AMPK and inhibition of mTOR and p70 S6K
- MSTN attenuates cardiac hypertrophy through inhibition of excessive cardiac autophagy by blocking AMPK/mTOR and miR-128/PPARγ/NF-κB
- Inhibition of CD133 overcomes cisplatin resistance through inhibiting PI3K/AKT/mTOR signaling pathway and autophagy in CD133-positive gastric cancer cells
- Long non-coding RNA MALAT1 enhances the apoptosis of cardiomyocytes through autophagy inhibition by regulating TSC2-mTOR signaling
- Safety and Efficacy of mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex under 2 Years of Age
- XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells
- Inhibition of dipeptidyl peptidase-4 accelerates epithelial–mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis
- Cytotoxic and antiproliferative effects of β-mangostin on rat C6 glioma cells depend on oxidative stress induction via PI3K/AKT/mTOR pathway inhibition
- Retracted: GABARAP promotes bone marrow mesenchymal stem cells‐based the osteoarthritis cartilage regeneration through the inhibition of PI3K/AKT/mTOR …
- TREATMENT OF B-CELL LYMPHOMAS AS CHARACTERISED BY MTOR INHIBITORS
- … stem cell-derived exosomal miRNA-29c decreases cardiac ischemia/reperfusion injury through inhibition of excessive autophagy via the PTEN/Akt/mTOR signaling …
- Sequential or concomitant inhibition of cyclin-dependent kinase 4/6 before mTOR pathway in hormone-positive HER2 negative breast cancer: biological …
- Inhibition of HIF1A-AS1 promoted starvation-induced hepatocellular carcinoma cell apoptosis by reducing HIF-1α/mTOR-mediated autophagy
- Combining the mTOR Inhibitor Everolimus and Gemcitabine in Relapsed/Refractory Peripheral T-Cell Lymphomas
- Doxorubicin‐induces NFAT/Fas/FasL cardiac apoptosis in rats through activation of calcineurin and P38 MAPK and inhibition of mTOR signalling pathways
- mTOR inhibitor enhances anti-tumor effect of BET bromodomain inhibitor in small cell lung cancer
- Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors
- Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
- Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway
- PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome
- Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism
- Tanc2-dependent direct and regulated mTOR inhibition balances mTORC1/2 signaling in developing mouse and human neurons
- Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression
- HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment
- Improvement of cerebral ischemia/reperfusion injury by daucosterol palmitate-induced neuronal apoptosis inhibition via PI3K/Akt/mTOR signaling pathway
- MECHANISMS OF NEUROPROTECTION BY MTOR INHIBITORS
- mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers
- Fate of Pediatric Renal Angiomyolipoma During mTOR Inhibitor Treatment in Tuberous Sclerosis Complex
- 18572 Relevant skin exposure after topical application of the pan-PI3K/mTOR inhibitor bimiralisib
- … contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/MAPK signaling pathway and suppressing the Akt/mTOR …
- Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK …
- Abstract IA04: Stroma-driven resistance to PI3K/mTOR inhibition
- Oral mucositis:’In Vitro’model and systematic review of treatment with natural mTOR inhibitors
- Pharmacological inhibition of O-GlcNAc transferase promotes mTOR-dependent autophagy in rat cortical neurons
- Novel Delivery of Mtor Inhibitor to Glioblastoma Cells
- Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment
- … and rapamycin attenuate isoflurane-induced cognitive impairment through inhibition of neuroinflammation by suppressing the mTOR signaling in the …
- A study on the protective mechanism of mTOR inhibitor Everolimus on brain injury after epilepsy
- Triclosan induces PC12 cells injury is accompanied by inhibition of AKT/mTOR and activation of p38 pathway
- Expanding the use of mtor inhibitors to high-risk kidney transplant recipients
- Opposite Effects of the Triple Target (DNA-PK/PI3K/mTOR) Inhibitor PI-103 on the Radiation Sensitivity of Glioblastoma Cell Lines MO59K and MO59J Differing in …
- Hif-Mediated suppression of DEPTOR confers resistance to mTOR kinase inhibition in renal cancer
- Genetic Analysis of PI3k and mTOR Inhibition in U87mg Glioblastoma Cell Line
- Yangxinkang tablet protects against cardiac dysfunction and remodelling after myocardial infarction in rats through inhibition of AMPK/mTOR-mediated autophagy
- Exploring mTOR Inhibition as Treatment for Mitochondrial Disease (P4. 6-060)
- … sirolimus reduces organic anion-transporting polypeptide (OATP) 1B1-and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing …
- Safety and efficacy of mTOR inhibitors following intestine and multivisceral transplantation
- Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex
- DDIS-33. SELECTIVE AND COMPLETE INHIBITION OF mTORC1 BY BI-STERIC mTOR INHIBITORS DRIVES THERAPEUTIC RESPONSE IN GLIOBLASTOMA
- P1761 SIDE EFFECTS OF MTOR INHIBITORS DEPEND ON THE BASELINE METABOLIC STATUS OF KIDNEY TRANSPLANT RECIPIENTS
- α7-Nicotinic acetylcholine receptor antagonist QND7 suppresses non-small cell lung cancer cell proliferation and migration via inhibition of Akt/mTOR signaling
- The effect of mTOR inhibitor rapamycin on a dietary Drosophila melanogaster model of calcium oxalate nephrolithiasis
- Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute
- Manganese-enhanced MRI depicts a reduction in brain response to nociception by mTOR inhibition in chronic pain rats
- P1752 THE ROLE OF MTOR INHIBITORS ON CARDIOVASCULAR AGING IN RENAL TRANSPLANT PATIENTS WITH CHRONIC GRAFT DYSFUNCTION
- … effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis
- Artesunate protects against surgery-induced knee arthrofibrosis by activating Beclin-1-mediated autophagy via inhibition of mTOR signaling
- Response of mTOR inhibitor associated with mutation of FBXW7 gene identified by comprehensive genomic profiling in cervical squamous cell carcinoma supports …
- MTOR INHIBITION ENHANCES HUMAN REGULATORY T CELL FUNCTION THROUGH INDUCTION OF A METABOLICALLY-CONTROLLED SOLUBLE FACTOR
- … membrane permeabilization and disruption of the molecular target of rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung cancer cell …
- Timosaponin A‑III induces autophagy of T‑cell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway
- Fibroblast growth factor 21 stimulates pancreatic islet autophagy via inhibition of AMPK-mTOR signaling
- Carrier-free small-molecule drug nanoassembly elicits chemoimmunotherapy via co-inhibition of PD-L1/mTOR
- … inhibition enhances Matrine derivative MASM induced apoptosis in cancer cells via a mechanism involving reactive oxygen species-mediated PI3K/Akt/mTOR …
- The VEGFR and mTOR inhibitors for treatment of advanced renal cell carcinoma: an economic analysis.
- Feasibility of mTOR inhibitor for the treatment of Fuchs endothelial corneal dystrophy
- … Electroacupuncture Ameliorates D-Galactose-Induced Alzheimer’s Disease-Like Pathology and Memory Deficits Probably via Inhibition of GSK3β/mTOR …
- mTOR inhibitor and VEGFR inhibitor combination therapy regress a doxorubicin resistant osteosarcoma in a patient-derived orthotopic xenograft model and in vivo …
- Outcomes after Early Initiation of mTOR-Inhibitors in Adult Cardiac Transplant Recipients
- mTOR Inhibitor in Combination with Cyclosporine as Primary Maintenance Immunosuppression in Combined Kidney/Pancreas Transplant Recipients
- Inhibition of p-mTOR represses transcription of PS1 and Notch 1-signaling
- Abstract A26: mTOR inhibition promotes differentiation of human regulatory T cells via privileged mRNA translation
- Novel Pineal Germinoma Model Demonstrates Sensitivity to MTOR Inhibition
- Combined mTOR inhibition and chemotherapy as an effective strategy to treat KRAS-mutant lung cancer
- Teaching an Old Dog New Tricks: Introducing a Hypothetical Mechanism of Synergy Between Metformin and New Generation mTOR Inhibitors in the Fight Against …
- Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines
- ErbB activation and heterodimerisation is responsible for resistance upon PI3K-mTOR inhibition in metastatic prostate cancer
- … chloride-induced memory loss and hippocampal apoptosis by increased intracellular glutathione stores and activation of PTEN/AMPK induced inhibition of Akt/mTOR …
- Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
- RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
- Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
- Down‐regulation of lncRNA OGFRP1 induces autophagy and growth inhibition by AKT/mTOR signaling pathway in HCAECs
- Mammalian Target of Rapamycin (mTOR) Inhibitor Induced Pulmonary Alveolar Proteinosis
- SP775 PERIPHERAL LYMPHOCYTE CHANGES IN RENAL ALLOGRAFT RECIPIENTS AFTER CONVERSION TO mTOR INHIBITORS
- GSK458, a novel oral dual PI3K/mTOR Inhibitor, is effective in preclinical model of T-cell lymphoma alone and in combination therapies
- Hydrogen-rich saline ameliorated LPS-induced acute lung injury via autophagy inhibition through the ROS/AMPK/mTOR pathway in mice
- mTOR Inhibition Delays Hepatoblastoma Growth in a Relevant Mouse Model
- Harnessing WYE-132 as an inhibitor of the mTOR signaling enriches the cytotoxicity effect of vinblastine in B16F10 melanoma cancer cells
- Analyses of PTEN gene aberrations and evaluation of the therapeutic potential of mTOR inhibitor in HPV negative cervical carcinoma
- Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway
- Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer
- A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery
- Impact of ER stress and PI3K-AKT-mTOR inhibitors on NIS glycosylation and subcellular localization in thyroid cell lines
- mTOR Inhibitor rapamycin can reverses the combination antiretroviral therapy induced central nervous system disorder
- … of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
- Feasibility of pre-operative mTOR inhibitor Sirolimus in children and young adults with desmoid tumor
- PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection
- SP779 DIFFERENT EFFECTS ON TRANSITIONAL B LYMPHOCYTES AFTER CONVERSION TO mTOR INHIBITORS OR STEROID WITHDRAWAL IN RENAL …
- Abstract B14: Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
- PP242, mTOR inhibitor, decreases phenylephrine‐induced vascular contractility in hypertensive and normotensive arteries
- Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-Induced Cardiotoxicity
- P1. 15-02 Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
- CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
- mTOR inhibition promotes LPS‐induced acute lung injury by inducing endothelial hyperpermeability
- Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival
- mTor inhibitor GDC-0349 improves ASO induced SAMMSON knock down resulting in enhanced anti-tumor efficacy in uveal melanoma
- … metabolism, encourages crosstalk between autophagy and apoptosis in lung carcinoma cells by use of an AMPK inhibition-independent blockade of the Akt/mTOR …
- … )-6-morpholino-1, 3, 5-triazin-2-yl) pyridin-2-amine (PQR530), a potent, orally bioavailable, and brain-penetrable dual inhibitor of class I PI3K and mTOR kinase
- Combined autophagy and mTOR inhibition reduces cells proliferation and induces apoptosis in a lung carcinoid in-vitro model
- Isoparvifuran isolated from Dalbergia odorifera attenuates H2O2-induced senescence of BJ cells through SIRT1 activation and AKT/mTOR pathway inhibition
- Novel Duel Mtor Inhibitors/AMPK Activators Improve Therapeutic Efficacy of Doxorubicin and Ameliorate Its Associated Cardiotoxicity in Mice
- Synthesis and syntehtic process optimization of mTOR protein inhibitor Torin2
- The Ca channel antagonist Verapamil exerts a protective effect against the negative actions of the mTOR inhibitor everolimus on ovarian follicle preservation
- Protosappanin‐A and oleanolic acid protect injured podocytes from apoptosis through inhibition of AKT‐mTOR signaling
- The PI3K/mTOR dual inhibitor PF-04691502 shows antitumor activity in Sezary cells and in a xenograft mouse model
- … TRANSPLANT PATIENTS HARBOR NEUTROPHILS SECRETING B-CELL ACTIVATING FACTOR (BAFF) WHICH CAN BE SUPPRESSED BY MTOR INHIBITORS
- PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED …
- First-in-human Phase I study to evaluate the brain-penetrant dual PI3K and mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade …
- P2. 48: Safety and efficacy of mTOR inhibitors following intestine and multivisceral transplantation
- Caffeine potentiates ethanol-induced neurotoxicity through mTOR/p70S6K/4E-BP1 inhibition in SH-SY5Y cells
- MP70-01 EARLY APPLICATION OF MTOR INHIBITORS REDUCE VASCULAR INFLAMMATORY RESPONSE AFTER ISCHEMIA-REPERFUSION INJURY
- Corrigendum to” The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)”[Cancer Lett. 392 (1)(2017) 9 …
- MicroRNA-6071 suppresses glioblastoma progression through the inhibition of PI3K/AKT/mTOR pathway by binding to ULBP2
- Manganese-enhanced magnetic resonance study on a reduction in brain responses to nociception by mTOR inhibition in chronic pain rats
- … pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR …
- PE-253: The Use of mTOR Inhibitors in Pediatric Liver Transplant Recipients: First Experience in a University Medical Center
- Correction: mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development
- Isoferulic acid inhibits human leukemia cell growth through induction of G2/M‑phase arrest and inhibition of Akt/mTOR signaling
- Phosphorylation of PRAS40 contributes to the activation of the PI3K/AKT/mTOR signaling pathway and the inhibition of autophagy following status epilepticus …
- A novel STAT3 inhibitor YHO-1701 inhibits ovarian and endometrial cancer cell growth, with augmented cytotoxicity in combination with an mTOR inhibitor
- Hypoxia-induced downregulation of SRC-3 suppresses trophoblastic invasion and migration through inhibition of the AKT/mTOR pathway: implications for the …
- Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway
- Abstract A27: The relationship between aspirin and cancer via its inhibition of mTOR pathway
- … acute liver injury by promoting liver‐resident macrophage NLRP 3 inflammasome activation via the inhibition of AMPK/mTOR‐mediated autophagy induction
- A SYSTEM TO IDENTIFY INHIBITORS OF MTOR SIGNALING USING HIGH-RESOLUTION GROWTH ANALYSIS IN S. CEREVISIAE
- Inhibition of mTOR signaling enhances trabectedin activity in soft tissue sarcoma
- Inhibition of mitochondrial autophagy protects donor lungs for lung transplantation against ischaemia‐reperfusion injury in rats via the mTOR pathway
- Epithelial cells expressed IL-33 to promote degranulation of mast cells through inhibition on ST2/PI3K/mTOR-mediated autophagy in allergic rhinitis
- An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro
- Inhibition of nasopharyngeal carcinoma by beta-lapachone occurs by targeting the mammalian target of rapamycin (mTOR)/PI3K/AKT pathway, reactive …
- THER-34. MEK BLOCKADE SYNERGISTICALLY INCREASES THE ANTI-TUMOR EFFECTS OF mTOR INHIBITION IN GLIOMAS
- Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor
- Transcriptome profiling of tolerogenic dendritic cells conditioned with dual mTOR kinase inhibitor, AZD8055
- Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer
- Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
- Interferon‐γ‐induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG‐CoA reductase
- Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway
- mTOR pathway components dictate cell response to Src inhibitors in prostate cancer cells
- HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways
- The regulation and mechanism of a dual PI3K/mTOR signaling inhibitor in hemangioma vascular endothelial cells in vitro
- … of THP-1 leukemia cells infected with cytomegalovirus to anti-tumor antibiotic doxorubicin and restoration of the sensitivity by inhibitors of the PI3K/AKT/mTOR …
- Systemic lupus erythematosus: PKCA is an inhibition pathway for mTOR by the active ingredient of green tea
- Glycogen synthase kinase 3-β inhibition induces lymphangiogenesis through β-catenin-dependent and mTOR-independent pathways
- … , synthesis and biological evaluation of thieno [3, 2-d] pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition
- The effect of combined PI3K/mTOR and ERK inhibition in monolayer, three-dimensional and in vivo ovarian cancer models.
- Activation of autophagy during farnesyl pyrophosphate synthase inhibition is mediated through PI3K/AKT/mTOR signaling
- Flavonoids from Apios americana Medikus Leaves Protect RAW264.7 Cells against Inflammation via Inhibition of MAPKs, Akt-mTOR Pathways, and Nfr2 …
- … Protein Kinase IV (CaMKIV) limits ER stress and improves insulin sensitivity through inhibition of autophagy via the mTOR/CREB signaling pathway
- Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets
- … of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2-metastatic breast cancer treated with everolimus (mTOR inhibitor).
- Knockdown of inhibitor of differentiation 1 suppresses proliferation and induces apoptosis by inactivating PI3K/Akt/mTOR signaling in hemangioma-derived …
- … A375 human malignant melanoma cells through apoptosis induction, DNA damage, cell invasion inhibition and downregulation of the mTOR/PI3K/Akt signalling …
- … vesicles derived from M2 bone marrow-derived macrophages attenuate apoptosis and promote motor function recovery via inhibition of mTOR in spinal cord …
- Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.
- … , a Pan-Pim kinase inhibitor, has anti-growth effect on 93T449 human liposarcoma cells via control of the expression and phosphorylation of Pim-3, mTOR, 4EBP-1, S6 …
- … cardioprotection against hypoxia/reoxygenation‐induced apoptosis in human cardiomyocytes via inhibition of PTEN and BCL2L11 and modulation of AKT/mTOR …
- Abstract B19: Susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition via PDK1
- Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
- 2-(2-(2, 4-dioxopentan-3-ylidene) hydrazineyl) benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma
- Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation
- A study of zederone for the inhibition on ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway
- Murrayanine exerts antiproliferative effects on human oral cancer cells through inhibition of AKT/mTOR and Raf/MEK/ERK signalling pathways In vitro and …
- Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans
- Inhibition of peiminine on invasion and migration of human lung cancer A549 cells by decreasing epithelial-mesenchymal transition process via PI3K/Akt/mTOR …
- Inhibition of mammalian target of rapamycin (mTOR) improves neurobehavioral deficit and modulates inflammatory response after traumatic brain injury
- Abstract P6-18-13: Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer
- mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells
- Inhibition of p-mTOR represses PS1 transcription by reducing p-JNK
- RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation …
- Abstract B11: mTOR pathway inhibition induces GPNMB expression and sensitizes breast cancer cells to an antibody-drug conjugate targeting GPNMB
- … is mediated via inhibition of cell migration and invasion, and suppression of phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR …
- Overexpression of ribonuclease inhibitor induces autophagy in human colorectal cancer cells via the Akt/mTOR/ULK1 pathway
- Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway
- PDK1 inhibitor GSK-470 exhibits potent anticancer activity in a pheochromocytoma PC12 cell tumor model via Akt/mTOR pathway
- Inhibition of nasopharyngeal cells mediated via G2/M cell cycle arrest, blocking PI3K/AKT/mTOR signalling pathway and suppression of cell migration and …
- Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer.
- In Silico Approach for Identification of PI3K/mTOR Dual Inhibitors for Multiple Myeloma Treatment
- Inhibition of MEK5 suppresses TDP-43 toxicity via the mTOR-independent activation of the autophagy-lysosome pathway
- PDK1 drives susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition
- Impact of Neuroinflammatory and mTOR Signaling Inhibition following Flurothyl Seizures on the Acute Development of Autistic-like Behavior in C57BL/6 Mice
- Synergistic Cytotoxic Effect of a Novel mTOR/PI3K Dual Inhibitor PF-04691502 and Radiation Therapy on Neuroendocrine Tumor Cells
- Pharmacological inhibition of mTOR attenuates replicative cell senescence and improves cellular function via regulating the STAT3-PIM1 axis in human cardiac …
- … penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
- Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
- A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
- CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A …
- Discovery of Hesperidin Based Novel AMPK/mTOR Kinase Inhibitor against Colorectal Cancer Cells.
- Microcytic anemia associated with mTOR or calcineurin inhibition: An unusual situation after allogeneic hematopoietic stem cell transplantation
- Altered Glutamine Metabolism Exposes EMT Derived Mesenchymal Cells to PI3K/Akt/mTOR Pathway Inhibition
- Combination of mTOR kinase inhibitors with Src inhibitors in PTEN-mt prostate cancer cells
- Identification of predictive biomarkers of response for mTOR pathway inhibitors in renal cell carcinoma
- … via mitochondrial-mediated apoptosis, inhibition of cell migration, invasion suppression, and mammalian target of rapamycin (mTOR)-TOR/PI3K/AKT …
- … , a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) …
- Progress of targeting PI3K-AKT-mTOR signaling pathway inhibitors in treatment of triple-negative breast cancer
- E2F2 inhibition induces autophagy to impair metastasis via the PI3K/Akt/mTOR pathway in gastric cancer
- Effect of novel mTOR-PI3K dual inhibitors on neuroendocrine tumor cell proliferation and apoptosis
- Maf1 suppresses hepatocarcinogenesis in mice through inhibition of Akt-mTOR signaling
- Corrigendum to” ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway”[Cancer Lett. 454 …
- SNX-2112, an Hsp90 inhibitor, suppresses cervical cancer cells proliferation, migration, and invasion by inhibiting the Akt/mTOR signaling pathway
- The Inhibition of EV71 Virus-Induced Apoptosis by ZVAD Through ROS and mTOR Pathway
- P11. 45 Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma …
- CK2 inhibitor CX4945 shows strong in vivo synergistic anti-leukemia activity with rapamycin in B-ALL due to enhanced ikaros mediated repression of mtor …
- Eriodictyol modulates glioma cell autophagy and apoptosis by inhibition of PI3K/Akt/mTOR signaling pathway
- Inhibition of mTOR during a postnatal critical sensitive window rescues deficits in GABAergic PV cell connectivity and social behavior caused by loss of TSC1
- Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
- Resistance to Cisplatin in NSCLC is Related to Autophagy Induced by PI3K/AKT/mTOR Signaling Pathway Inhibition
- Cardiac glycoside Cerberin exerts anticancer activity by PI3K/AKT/mTOR signal transduction inhibition.
- 30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung …
- Inhibition of hepatitis B virus replication by FAM176A via activation of PI3K-AKT-mTOR signaling pathway
- Abstract B02: Combined inhibition of mTOR and Src family kinases enhances treatment effects in prostate cancer cells
- APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and could suppress EMT process through PI3K/Akt/mTOR signaling …
- Effect of lithium chloride on AKT-mTOR signal pathway in osteoblasts after estrogen receptor inhibition
- … TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES
- Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition
- Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
- BRMS1 performs an anti-tumor effect on renal cell carcinoma via inhibition of PI3K/AKT/mTOR signaling pathway.
- … inhibition of Atypical Protein Kinase-C and mTOR impedes bladder canSimultaneous inhibition of atypical protein kinase-C and mTOR impedes bladder cancer cell …
- Abstract B33: Targeting PI3K/mTOR signaling with potent, selective and orally-available small-molecule inhibitors of eIF4E
- CXCR4 Blockade Enhances The Sensitivity Of Osteosarcoma To Doxorubicin By Inducing Autophagic Cell Death Via PI3K-Akt-Mtor Pathway Inhibition
- PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection (preprint)
- Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer
- Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells
- … TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES
- Combination of hemiasterlin derivative (R)(S)(S)-BF65 and PI3K/mTOR dual inhibitor NVP-BEZ235 as a new strategy to inhibit ovarian cancer growth and metastasis
- Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors
- Combined Pharmacologic Inhibition of MEK-ERK and PI3K/mTOR Signaling in Glioblastoma Models Enhances Therapeutic Antitumor Activity (P2. 6-023)
- … LIVER-RESIDENT MACROPHAGE NLRP3 INFLAMMASOME ACTIVATION VIA THE INHIBITION OF AMPK/MTOR-MEDIATED AUTOPHAGY INDUCTION
- … receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR …
- Inhibition of the mTOR and MAPK pathways suppresses growth, induces apoptosis, and decreases vascularity in pediatric low grade glioma
- Abstract P3-14-02: Upper extremity edema in the at-risk arm among patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer
- Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer …
- CC-115, a dual mTOR/DNA-PK inhibitor in clinical trial, is a substrate of ABCG2, a risk factor for CC-115 resistance
- Inhibition of mTOR-Akt-ULK1 signaling pathway and activation of autophagy by TNFAIP8 in metastasis of gastric cancer
- Correction to Discovery of 3-Oxabicyclo [4.1. 0] heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR …
- Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in …
- Abstract P6-21-08: Synergistic anti-cancer activity of cyclin-dependent kinase 4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing …
- FXR activation impairs liver progenitor cell‐driven liver regeneration by enhancing PTEN‐dependent inhibition of AKT‐mTOR axis
- Calcium/calmodulin-dependent Protein Kinase IV Limits ER stress and Insulin Resistance through Inhibition of Autophagy in Adipocytes by mTOR/CREB Signaling
- MP51-06 SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHAGY IN BLADDER CANCER VIA MTOR PATHWAY
- … potentiates paclitaxel and gemcitabine mediated antitumor effects against pancreatic cancer via inhibition of prosurvival PI3k/AKT/mTOR and ERK pathways
- … of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor
- Triptolide Suppresses Glomerular Mesangial Cell Proliferation in Diabetic Nephropathy Is Associated with Inhibition of PDK1/Akt/mTOR Pathway: Erratum
- 1015-INHIBITION OF ENDOTHELIAL MTOR DRIVES HEMATOPOIETIC STEM CELL AGING
- Inhibition of Long Non-Coding RNA LOC100996425 Suppresses the Proliferation, Migration and Promotes Apoptosis of Prostate Cancer Cells Through the AMPK …
- Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
- Induction of apoptosis in SGC-7901 cells by ruthenium (II) complexes through ROS-mediated lysosome–mitochondria dysfunction and inhibition of PI3K/AKT/mTOR …
- 3182–PHARMACOLOGICAL INHIBITION OF NEMO-LIKE KINASE RESCUES MTOR-MEDIATED TRANSLATION AND ERYTHROPOIESIS IN PRE-CLINICAL …
- ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC).
- Overview of research into mTOR inhibitors
- Recent advances and limitations of mTOR inhibitors in the treatment of cancer
- Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment
- The role of mTOR inhibitors in hematologic disease: from bench to bedside
- mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses
- Recent advances in dual PI3K/mTOR inhibitors for tumour treatment
- Perfect match: mTOR inhibitors and tuberous sclerosis complex
- Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
- Brain-restricted mTOR inhibition with binary pharmacology
- Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021)
- mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression
- mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
- A patent review of mTOR inhibitors for cancer therapy (2011–2020)
- p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance
- A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19
- Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer …
- The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages
- mTOR inhibitor INK128 promotes wound healing by regulating MDSCs
- mTOR inhibitors improve both humoral and cellular response to SARS‐CoV‐2 messenger RNA BNT16b2 vaccine in kidney transplant recipients
- Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction
- Targeting the biology of aging with mTOR inhibitors
- Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition
- mTOR inhibition: a double-edged sword in patients with COVID-19?
- Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
- Can we use mTOR inhibitors for COVID-19 therapy?
- Mechanistic target of rapamycin (mTOR) inhibitors
- Preclinical evaluation and phase Ib study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor
- Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell …
- mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
- Treatment of cardiac rhabdomyomas with mtor inhibitors in children with tuberous sclerosis complex—a systematic review
- Unbiased evaluation of rapamycin’s specificity as an mTOR inhibitor
- RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
- Pharmacologic activation of autophagy without direct mTOR inhibition as a therapeutic strategy for treating dry macular degeneration
- Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy
- A theoretical insight in interactions of some chemical compounds as mTOR inhibitors
- Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: Phase 2b and phase 3 randomised trials
- mTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy
- Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin
- Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
- Novel dual PI3K/mTOR inhibitor, apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma cells
- Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication
- mTOR inhibition impairs extinction memory reconsolidation
- Deficiency in the treatment description of mTOR inhibitor resistance in medulloblastoma, a systematic review
- mTOR inhibitor use is associated with a favorable outcome of COVID-19 in patients of kidney transplant: Results of a retrospective study
- An amino acid-defined diet impairs tumour growth in mice by promoting endoplasmic reticulum stress and mTOR inhibition
- Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience
- mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells
- Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
- mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus
- Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update
- The putative role of mTOR inhibitors in non-tuberous sclerosis complex-related epilepsy
- mTOR inhibitors prevent CMV infection through the restoration of functional αβ and γδ T cells in kidney transplantation
- Evaluating targeted therapies in ovarian cancer metabolism: novel role for PCSK9 and second generation mTOR inhibitors
- mTOR inhibition ablates cisplatin-resistant salivary gland cancer stem cells
- The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
- mTOR inhibition and T-DM1 in HER2-positive breast cancer
- Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations
- mTOR inhibition with Sirolimus in multiple system atrophy: a randomized, double‐blind, placebo‐controlled futility trial and 1‐year biomarker longitudinal analysis
- A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
- Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells
- mTOR inhibitors potentially reduce TGF-β2-induced fibrogenic changes in trabecular meshwork cells
- Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex
- mTOR inhibitor improves testosterone-induced myocardial hypertrophy in hypertensive rats
- TFEB Overexpression, Not mTOR Inhibition, Ameliorates RagCS75Y Cardiomyopathy
- Mtor inhibitors associated with higher cardiovascular adverse events—A large population database analysis
- … the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma?–ie Strategies to Revert Resistance to mTOR Inhibitors
- The 40S-LARP1 complex reprograms the cellular translatome upon mTOR inhibition to preserve the protein synthetic capacity
- Inhibitors of the PI3K/Akt/mTOR pathway in prostate cancer chemoprevention and intervention
- The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
- mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
- Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
- mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS‐CoV‐2 mRNA vaccines in solid organ transplant …
- mTOR inhibition prevents angiotensin II–induced aortic rupture and pseudoaneurysm but promotes dissection in Apoe-deficient mice
- Real life experience with mTOR-inhibitors after lung transplantation
- Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an …
- Targeting the tumor microenvironment through mTOR inhibition and chemotherapy as induction therapy for locally advanced head and neck squamous cell …
- Biodegradable stent with mTOR inhibitor-eluting reduces progression of ureteral stricture
- Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons
- Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors
- VEGFR inhibitors for uterine metastatic perivascular epithelioid tumors (PEComa) resistant to mTOR inhibitors. a case report and review of literature
- Arctigenin triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in PC-3M cells
- … mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition
- Discovery of the First Raptor (Regulatory-Associated Protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent
- The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation
- Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor− Positive Recurrent or Metastatic Endometrial …
- mTOR-inhibition and COVID-19 in kidney transplant recipients: focus on pulmonary fibrosis
- The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis
- Evaluation of a dual PI3K/mTOR inhibitor PF-04691502 against bladder cancer cells
- Low temperature and mTOR inhibition favor stem cell maintenance in human keratinocyte cultures
- The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review
- Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain
- PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition
- Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and-Positive HNSCC Cell …
- Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro
- … docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and …
- Medical Aspects of mTOR Inhibition in Kidney Transplantation
- Improvement of PD-1 blockade efficacy and elimination of immune-related gastrointestinal adverse effect by mTOR inhibitor
- Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition
- mTOR inhibition promotes pneumonitis through inducing endothelial contraction and hyperpermeability
- New insights into mTOR inhibition: understanding the mechanisms and their importance
- Mtor inhibition via rapamycin treatment partially reverts the deficit in energy metabolism caused by fh loss in rpe cells
- mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death
- Bioactive PI3-kinase/Akt/mTOR inhibitors in targeted lung cancer therapy
- mTOR inhibition attenuates cTfh cell dysregulation and chronic T-cell activation in multilineage immune cytopenias
- Sarcoidosis incidence after mTOR inhibitor treatment
- Connectivity map analysis indicates PI3K/Akt/mTOR inhibitors as potential anti-hypoxia drugs in neuroblastoma
- Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling
- mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction
- mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and …
- The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
- Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
- mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models
- The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry
- Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex
- Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA …
- Targeting ganglioneuromas with mTOR inhibitors
- Real-life experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant
- MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor
- Evidence that C/EBP-β LAP Increases Fat Metabolism and Protects Against Diet-Induced Obesity in Response to mTOR Inhibition
- Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
- mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation
- Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
- mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion
- Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition
- Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
- In silico development of new PET radiopharmaceuticals from mTOR inhibitors
- Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
- The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
- Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex
- Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients
- The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients …
- NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
- Compound library screening for synergistic drug combinations: mTOR inhibitor and proteasome inhibitor effective against osteosarcoma cells
- Phosphoproteome profiling revealed the importance of mTOR inhibition on CDK1 activation to further regulate cell cycle progression
- Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy
- AI-Predicted mTOR Inhibitor Reduces Cancer Cell Proliferation and Extends the Lifespan of C. elegans
- DHW-221, a dual PI3K/mTOR inhibitor, overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and akt-mediated FOXO3a Nuclear …
- Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors
- The PI3K/mTOR inhibitor ompalisib suppresses nonhomologous end joining and sensitizes cancer cells to radio-and chemotherapy
- CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated …
- CAVEAT mTOR: You’ve heard about the benefits of using mTOR inhibitors, here are some of the risks
- TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review
- Fibroblast-Induced Paradoxical PI3K pathway activation in PTEN-competent colorectal cancer: implications for therapeutic PI3K/mTOR Inhibition
- A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant
- Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α …
- The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats
- mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 upregulation
- Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative …
- m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition
- JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
- Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin
- mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis
- EMT-derived alterations in glutamine metabolism sensitize mesenchymal breast cells to mTOR inhibition
- Dual targeting of melanoma translation by MNK/eIF4E and PI3K/mTOR inhibitors
- Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients
- Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility
- Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
- DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
- Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
- Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
- mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma
- SPR965, a dual PI3K/mTOR inhibitor, as a targeted therapy in ovarian cancer
- The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid …
- Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells
- Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
- Combination of CDK4/6 and mTOR inhibitors suppressed doxorubicin-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model: a translatable …
- The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
- Biomimetic polyphenol-coated nanoparticles by Co-assembly of mTOR inhibitor and photosensitizer for synergistic chemo-photothermal therapy
- Role of natural mTOR inhibitors in treatment of diabetes mellitus
- Lactotransferrin downregulation serves as a potential predictor for the therapeutic effectiveness of mtor inhibitors in the metastatic clear cell renal cell …
- Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A …
- In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein–Barr virus–associated post …
- mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models
- mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms
- Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study
- The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment …
- Tetrahydroquinoline: an efficient scaffold as mTOR inhibitor for the treatment of lung cancer
- Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermolysis Bullosa Simplex
- A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and …
- Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
- Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
- PI3Kinase/AKT/mTOR Pathway in Breast Cancer; Pathogenesis and Prevention with mTOR Inhibitors
- … after lung transplantation–a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
- Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability
- The combination of Trametinib, a MEK inhibitor, and temsirolimus, an mTOR inhibitor, radiosensitizes lung cancer cells
- mTOR inhibition improves the formation of functional T cell memory following COVID-19 vaccination of kidney transplant recipients
- The incidence of cytomegalovirus and BK polyomavirus infections in kidney transplant patients receiving mTOR inhibitors: A systematic review and meta‐analysis
- HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models
- HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53
- Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells
- The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation
- mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4+CD57+ T Cells In Vivo and In Vitro
- … and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant …
- Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
- Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells
- Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
- mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by …
- Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
- Oxadiazol-based mTOR inhibitors with potent antiproliferative activities: synthetic and computational modeling
- As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression
- mTOR inhibition increases transcription factor E3 (TFE3) activity and modulates programmed death-ligand 1 (PD-L1) expression in translocation renal cell …
- Jabło nska, E.; Cechowska-Pasko, M. Novel dual PI3K/mTOR inhibitor, Apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma …
- Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation
- Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors
- Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients
- Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
- Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational …
- Mtor inhibition by INK128 extends functions of the ovary reconstituted from germline stem cells in aging and premature aging mice
- STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma
- Association of HLA mismatch and MTOR inhibitor regimens with malignancy and mortality after kidney transplantation
- Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and …
- BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate …
- PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors
- Inhibition of the PI3K/mTOR pathway in breast cancer to enhance response to immune checkpoint inhibitors in breast cancer
- Validated HPLC‐UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice
- … anti‑HLA class I antibodies on the immunological properties of human glomerular endothelial cells and their modification by mTOR inhibition or GCN2 kinase …
- Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
- Preventive Effect of Combined Zingiber officinale and Terminalia chebula against DMBA-Induced Breast Cancer Rats via mTOR Inhibition
- PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia
- Structural Aspects of mTOR Inhibitors: Search for Potential Compounds
- Design, synthesis and pharmacological evaluation of 2-arylurea-1, 3, 5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy
- Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
- The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury
- PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
- Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
- Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC‐AML patients with treatment of mTOR inhibitors
- Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor …
- The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in …
- Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
- Minimal mitochondrial respiration is required to prevent cell death by inhibition of mTOR signaling in CoQ-deficient cells
- Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe …
- Clinical validation of a liquid chromatography-tandem mass spectrometry method for the quantification of calcineurin and mTOR inhibitors in dried matrix on …
- Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive …
- Marine-derived natural products as ATP-competitive mTOR kinase inhibitors for cancer therapeutics
- Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review
- Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation
- XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the …
- Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation
- Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer
- Inhibition of mTOR in bovine monocyte derived macrophages and dendritic cells provides a potential mechanism for postpartum immune dysfunction in dairy …
- Geniposide protection against Aβ1-42 toxicity correlates with mTOR inhibition and enhancement of autophagy
- Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
- Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual …
- A Mechanistic Target of Rapamycin (mTOR) Inhibitor, Everolimus Safely Ameliorated Lupus Nephritis in a Patient Complicated with Tuberous Sclerosis.
- Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
- Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model
- nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access …
- mTOR inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease.
- Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction.
- The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells
- The impact of mTOR inhibitors in the regression of left ventricular hypertrophy in elderly kidney transplant recipients
- PI3K/Akt/mTOR pathways inhibitors with potential prospects in non-small-cell lung cancer
- In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines
- Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells
- … comparison of clinical outcomes for subependymal giant cell astrocytomas treated with laser interstitial thermal therapy, open surgical resection, and mTOR inhibitors
- Effective disease control after combinatorial treatment with a PD-1 antibody and an mTOR inhibitor for recurrent ovarian clear cell carcinomas: a case report and …
- Clinical trials of mTOR inhibitors to boost immunity to viral infection in older adults
- The effects of Pi3k/Akt/Mtor signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line
- … activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
- Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy
- Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
- Inhibition of MTOR signaling impairs rat embryo organogenesis by affecting folate availability
- Pseudomonas aeruginosa survives in epithelia by ExoS‐mediated inhibition of autophagy and mTOR
- How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
- mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis E Screening in …
- The anti-non-small cell lung cancer cell activity by a mTOR kinase inhibitor PQR620
- Cutaneous Adnexal Carcinoma with Apocrine Differentiation: A Challenging Diagnosis and Personalized Treatment with mTOR Inhibitor in a Very Rare …
- Mammalian target of rapamycin (mTOR) inhibitors in dermatology
- Repurposing HDAC and mTOR inhibitors for pancreatic cancer.
- 17P Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma
- Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
- An insight on PI3K/AKT/MTOR inhibitors in cancer: Opportunity and translational perspectives
- PI3K/AKT/mTOR and TLR4/MyD88/NF-κB signaling inhibitors attenuate pathological mechanisms of allergic asthma
- Uterine perivascular epithelioid tumors (PEComas) with lung metastasis showed good responses to mTOR and VEGFR inhibitors: A case report
- Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients
- How do mTOR inhibitors fit in the relapsed acute lymphoblastic leukemia treatment landscape?
- Bcl-2, JAK and mTOR Inhibitors
- Growth of Angiomyolipomas in Patients with Tuberous Sclerosis Complex Treated with mTOR Inhibitor Differs by Indication for Treatment (P8-13.003)
- The mTOR-inhibitor everolimus reduces hypervolemia in patients with primary aldosteronism.
- mTOR Inhibition Suppresses Salinomycin-Induced Ferroptosis in Breast Cancer Stem Cells by Ironing Out Mitochondrial Dysfunctions
- Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction
- Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid …
- Oral mTOR Inhibition Limits And Reduces Actinic Keratosis And Cutaneous Squamous Cell Carcinoma In A UVB-Induced Mouse Model
- mTOR inhibitor induces non-apoptotic, autophagy dependent cell death (ADCD) in TP53 mutant HNSCC
- Immunomodulatory properties of PI3K/AKT/mTOR and MAPK/MEK/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative …
- mTOR inhibitor treatment in patients with tuberous sclerosis Complex is associated with specific changes in microRNA Serum profile
- Searching for new mTOR kinase inhibitors: Analysis of binding sites and validation of docking protocols
- Comprehensive Evaluation of the Specificity of Rapamycin as an mTOR Inhibitor
- Enhancing plant-derived smart nano inhibitor in targeting mammalian target of rapamycin (mTOR) in breast cancer using Curcuma longa-derived compound …
- Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism
- Design, synthesis and biological evaluation of novel 9-methyl-9H-purine and thieno [3, 2-d] pyrimidine derivatives as potent mTOR inhibitors
- KRAS G12C mutated NSCLC and bladder cancer xenografts treated with sotorasib and adagrasib in combination with mTOR inhibitors show improved antitumor …
- An mTOR feedback loop mediates the ‘flare'(‘rebound’) response to MET tyrosine kinase inhibition
- P422: Omipalisib, a dual PI3K/MTOR inhibitor, targets mitochondria and impairs oxidative phosphorylation in acute myeloid leukemia
- Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
- PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling
- Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer
- Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
- Inhibition of mTOR decreases insoluble proteins burden by reducing translation in C. elegans
- Molecularly targeted radiation therapy using mTOR inhibition for the management of malignant perivascular epithelioid cell tumor (PEComa): a case report …
- Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple …
- An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model
- mTOR Inhibition via Low-dose, Pulsed Rapamycin with Intraovarian Condensed Platelet Cytokines: An Individualized Protocol to Recover Diminished Reserve
- Expanding the horizons of mTOR inhibitors for treating subependymal giant cell astrocytomas with obstructive hydrocephalus
- Plant-based mTOR inhibitors for the treatment of Parkinson’s Disease.
- Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR Inhibitor
- Discovery of novel 1, 3, 5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR
- Exploiting the Regulation of Apoptosis to Improve Therapeutic Responses of Tumors to mTOR Inhibitors
- Transcriptomic-Based in silico Drug Screening Reveals Dual PI3K/mTOR Inhibitors Overcome Cabozantinib-Resistance of FLT3-ITD AML Cells
- # 4364 LEUCOPENIA AFTER KIDNEY TRANSPLANTATION: SWITCHING MYCOPHENOLATE TO MTOR INHIBITOR APPEARS SAFE AND FEASIBLE TO REDUCE …
- Combined inhibition of Akt and mTOR is effective against non-Hodgkin lymphomas
- MTOR Inhibition Alters miRNA Profile in Cultured Bone Marrow Mesenchymal Stem Cells
- 314.2: MTOR Inhibitors Promote Highly Functional T Cell Immunity in Kidney Transplant Recipients Vaccinated Against COVID-19
- Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice
- Author Correction: Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons
- mTOR inhibitor-independent Autophagy Activator Ameliorates Cellular Tauopathy and Prionopathy Neurodegeneration Phenotypes
- 420.3: The Use of mTOR Inhibitors Is Associated With Reduced Mortality Among Kidney Transplant Patients Developing COVID-19
- Synergy of MALT1 and mTOR inhibition in DLBCL
- Immunological results of long-term use of mammalian target of rapamycin (Mtor) inhibitors and its effects on renal graft functions
- mTOR inhibitors in a patient with lupus nephritis; why not?
- Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
- … -122-5p inhibitor abolishes angiotensin II–mediated loss of autophagy and promotion of apoptosis in rat cardiofibroblasts by modulation of the apelin-AMPK-mTOR …
- Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway
- BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma
- Current status of mTOR inhibition in cancer therapy
- Mediation of Anti-Keloid Effects of mTOR Inhibitors by Autophagy-Independent Machinery
- AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung …
- Systemic actions of sglt2 inhibition on chronic mtor activation as a shared pathogenic mechanism between alzheimer’s disease and diabetes
- Impact of mTOR Inhibitor Conversion Protocol on Renal Function in Cardiac Transplant Recipients
- Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer
- Pneumocystis jirovecii Pneumonia and Use of mTOR Inhibitors in Kidney Transplantation
- Using mTOR Inhibitor Nanoimmunotherapy to Induce Cardiac Allograft Tolerance in Non-Human Primates
- Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells
- mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
- mTOR Inhibitor-Induced Transient Acantholytic Dermatitis.
- Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive state
- E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer
- MAPK AND AKT/MTOR INHIBITION IMPROVES CHILDHOOD RASOPATHY-ASSOCIATED CARDIOMYOPATHY
- Fleeting Efficacy of mTOR Inhibitors in RCC Produces the Need for Unique Combinations
- Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures
- Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells
- Inhibition of the PI3K/AKT/mTOR signaling promotes an M1 macrophage switch by repressing the ATF3-CXCL8 axis in Ewing sarcoma
- Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells
- Stress granules affect the dual PI3K/mTOR inhibitor response by regulating the mitochondrial unfolded protein response
- MAPK and mTOR Inhibition Improves Childhood RASopathy-Associated Hypertrophic Cardiomyopathy
- VS-5584, a PI3K/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas in vitro and in vivo
- Corrigendum to “mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19”[Gene Rep. 20 (2020) 100765]
- 20P Tissue agnostic application of mTOR inhibitors for the management of therapy-refractory solid tumors
- Artemisinin inhibits the migration and invasion in uveal melanoma via inhibition of the PI3K/AKT/mTOR signaling pathway
- Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
- Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor
- Celastrol inhibits rheumatoid arthritis by inducing autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway
- Inhibition of mTOR by temsirolimus overcomes radio‐resistance in nasopharyngeal carcinoma
- Synergistic inhibition of drug-resistant colon cancer growth with PI3K/mTOR dual inhibitor BEZ235 and nano-emulsioned paclitaxel via reducing multidrug resistance …
- Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors
- Abstract P138: nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and …
- Paxalisib. PI3K/mTOR inhibitor, Treatment of gliomas
- A preclinical investigation of GBM-N019 as a potential inhibitor of glioblastoma via exosomal mTOR/CDK6/STAT3 signaling
- Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy
- HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD
- Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors
- Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
- Familial uterine leiomyoma-associated germline oncogenic mutant VEGFR1 is sensitive to mTOR inhibitor
- Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells
- Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/β‑catenin/N‑cadherin axis
- Predictive value of EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers for head and neck squamous cell carcinoma: a systematic review
- Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway
- mTOR inhibition and T-DM1 in HER2-positive breast cancer
- PS-B02-10: MTOR INHIBITOR IMPROVES TESTOSTERONE-INDUCED MYOCARDIAL HYPERTROPHY IN HYPERTENSIVE RATS
- Discovery of Novel Mammalian target of rapamycin (mTOR) Inhibitors by Support Vector Machine
- … glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK–mTOR signaling pathway–mediated …
- ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
- Ponatinib, lestaurtinib, and mTOR/PI3K inhibitors are promising repurposing candidates against Entamoeba histolytica
- mTOR inhibition alleviates CD8+ T-cell senescence in activated phosphoinositide 3-kinase δ syndrome 2 patients
- RNF43 G659fs is an oncogenic mutation in colorectal cancer and sensitizes tumor cells to PI3K/mTOR inhibition
- Inhibition of mTOR signaling by genetic removal of p70 S6 kinase 1 increases anxiety-like behavior in mice
- Four-octyl itaconate improves osteoarthritis by enhancing autophagy in chondrocytes via PI3K/AKT/mTOR signalling pathway inhibition
- AUTOPHAGY ACTIVATION IN BREAST CANCER CELLS IN VITRO AFTER THE TREATMENT WITH PI3K/AKT/MTOR INHIBITORS
- Exploring the Link Between Mtor Inhibitors and Interstitial Lung Diseases: A Disproportionality Analysis Using Fda Adverse Event Reporting System Database
- Deubiquitinase USP9X loss Sensitizes Cancer Cells to mTOR Inhibitors through p62 Dysregulation
- 207P Comparison of CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors in the second-line treatment of hormone receptor-positive, HER2-negative …
- Molecular docking of potential inhibitors with the mTOR protein
- Inhibition of NLRP3 inflammasome activation and pyroptosis in macrophages by taraxasterol is associated with its regulation on mTOR signaling
- Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer …
- Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA-and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
- New amino acid Schiff bases as anticancer agents via potential mitochondrial complex I-associated hexokinase inhibition and targeting AMP-protein kinases/mTOR …
- Structure-Based Virtual Screening Towards The Discovery of Usnic Acid Derivatives as Novel mTOR Inhibitor to Treat Breast Cancer
- Correction to: Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
- Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer
- Mechanism of mTOR inhibitors mediated DDP resistance in pancreatic cancer through the mTOR pathway
- Inhibition of PI3K/AKT/mTOR signalling pathway activates autophagy and suppresses peritoneal fibrosis in the process of peritoneal dialysis
- Newer generation mTOR inhibition represents effective therapeutic strategy for BRAF-mutant melanoma
- Erianthridin suppresses non-small-cell lung cancer cell metastasis through inhibition of Akt/mTOR/p70S6K signaling pathway
- RAMS11 promotes CRC through mTOR-dependent inhibition of autophagy, suppression of apoptosis, and promotion of epithelial-mesenchymal transition
- Very-low-protein diets lead to reduced food intake and weight loss, linked to inhibition of hypothalamic mTOR signaling, in mice
- Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
- mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors
- Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
- Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer
- Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma
- YQFM alleviated cardiac hypertrophy by apoptosis inhibition and autophagy regulation via PI3K/AKT/mTOR pathway
- Characteristics, predictors and outcomes of early mTOR inhibitor use after heart transplantation: insights from the UNOS database
- The anti-proliferative effect of PI3K/mTOR and ERK inhibition in monolayer and three-dimensional ovarian cancer cell models
- TEOA promotes autophagic cell death via ros-mediated inhibition of mtor/p70s6k signaling pathway in pancreatic cancer cells
- Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC
- The effects of mTOR inhibition in ischemic stroke
- Cell Signaling Analysis of Metastatic Triple Negative Breast Cancer Following Dual PI3K/mTOR Inhibitor (PIKTOR)
- Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia
- Sulfamethizole attenuates poloxamer 407‐induced atherosclerotic neointima formation via inhibition of mTOR in C57BL/6 mice
- Myricetin induces apoptosis and autophagy in human gastric cancer cells through inhibition of the PI3K/Akt/mTOR pathway
- INVESTIGATING THE IMPACT OF mTOR INHIBITOR TREATMENT ON TRANSGENERATIONAL OFFSPRING HEALTH AND FERTILITY
- Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition
- Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive …
- mTOR inhibition attenuates chemosensitivity through induction of a persister state
- p53 inhibition protects against neuronal ischemia/reperfusion injury by the p53/PRAS40/mTOR pathway
- Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling
- Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
- Bipartite binding and partial inhibition links DEPTOR and mTOR in a mutually antagonistic embrace
- Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy
- … -down induced tau hyperphosphorylation at Thr181, Ser199, Thr231, Ser262, Ser396 epitopes and inhibition of autophagy by overactivation of GSK3β/mTOR …
- HDAC inhibitor cowanin extracted from G. fusca induces apoptosis and autophagy via inhibition of the PI3K/Akt/mTOR pathways in Jurkat cells
- PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia
- REVIEW ON APPLICABILITY OF mTOR INHIBITOR DOCKING SCORE ANALYSIS METHODS IN DRUG DEVELOPMENT OF LUNG CANCER
- Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway
- The glucosylceramide synthase inhibitor PDMP causes lysosomal lipid accumulation and mTOR inactivation
- Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy
- Cardiac-specific Trim44 knockout in rat attenuates isoproterenol-induced cardiac remodeling via inhibition of AKT/mTOR pathway
- Combined xCT and mTOR Inhibition as a New Therapeutic Option for Pancreatic Adenocarcinoma
- Malignancies and Pediatric Liver Transplantation: Promising Management with the mTOR-inhibitor Everolimus
- Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for the treatment of peripheral T cell lymphoma.
- Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity
- SMER28 attenuates PI3K/mTOR signaling by direct inhibition of PI3K p110 delta
- Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS …
- Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors
- Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway
- … ischemia/reperfusion injury‑induced damage to the blood‑brain barrier in hyperglycemia through PI3K/AKT/mTOR pathway‑mediated autophagy inhibition
- Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways
- eIF4A1 inhibitor suppresses hyperactive mTOR-associated tumors by inducing necroptosis and G2/M arrest
- Abstract PR009: RNF43 G659fs is an oncogenic and immune-modulating colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
- RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway
- ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR
- P-256 Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition
- Selenite Induces Cell Cycle Arrest and Apoptosis via Reactive Oxygen Species-Dependent Inhibition of the AKT/mTOR Pathway in Thyroid Cancer
- BNIP3 contributes to silibinin-induced DNA double strand breaks in glioma cells via inhibition of mTOR
- Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
- Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
- Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway
- Apoptotic effect of compound K in hepatocellular carcinoma cells via inhibition of glycolysis and Akt/mTOR/c‐Myc signaling
- TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
- Pharmacological inhibition of the PI3K/PTEN/Akt and mTOR signalling pathways limits follicle activation induced by ovarian cryopreservation and in vitro …
- Effect of MTOR Inhibitor Combined with Photodynamic Therapy on the Regulation of Cancer Stem Cells through Reactive Oxygen Species
- Putative dual inhibitors of mTOR and RET kinase from natural products: Pharmacophore-based hierarchical virtual screening
- Mammalian Target of Rapamycin (mTOR) Inhibitor Improves Local Immune Microenvironment and Reduces Seizures via Increasing miR-211 Level in Rat Brain
- Early Use of mTOR Inhibitors in Tuberous Sclerosis: Current State and Plan for a Prospective Clinical Trial of Early Prophylactic mTOR Inhibitor Treatment (PROTECT)
- Global mapping of protein and lipid network driven by mtor inhibition in oa cartilage
- Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β …
- Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways
- Uranium induces kidney cells apoptosis via reactive oxygen species generation, endoplasmic reticulum stress and inhibition of PI3K/AKT/mTOR signaling in culture
- Exosomes derived from M2 macrophages exert a therapeutic effect via inhibition of the PI3K/AKT/mTOR pathway in rats with knee osteoarthritic
- … attenuated oxygen and glucose deprivation/reperfusion-induced PC12ácell injury through inhibition of apoptosis and autophagy by activating the PI3K/AKT/mTOR …
- Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer
- Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway
- An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth
- SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances
- Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma
- Efficacy of Dual PI3K/mTOR Inhibitor Combined With Autophagy Suppression Against Laryngeal Squamous Cell Carcinoma
- Co-administration of mTor Inhibitors and Carbamazepine May Lead to Ineffectiveness of Therapy: A Case Report of a 24-year-old Man
- DHODH inhibition exerts synergistic therapeutic effect with cisplatin to induce ferroptosis in cervical cancer through regulating mTOR pathway
- Acquired sensitivity to ONC201/TIC10 in ER+ breast cancer progressing on the mTOR inhibitor everolimus
- Binding site hotspot map of PI3Kα and mTOR in the presence of selective and dual ATP-competitive inhibitors
- Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice
- Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism
- RapaBlock, a Novel Drug that Prevents the On-Target–Off-Tissue Effects of mTOR Inhibition
- Neuroprotective effect of chrysophanol as a PI3K/AKT/mTOR signaling inhibitor in an experimental model of autologous blood-induced intracerebral hemorrhage
- Discovery of Novel Hybrids of mTOR Inhibitor and NO Donor as Potential Anti-Tumor Therapeutics
- Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG
- Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational …
- Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma
- Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin
- Activation of AMPK/mTOR-driven autophagy and inhibition of NLRP3 inflammasome by saxagliptin ameliorate ethanol-induced gastric mucosal damage
- mTOR signaling inhibition decreases lysosome migration and impairs the success of Trypanosoma cruzi infection and replication in cardiomyocytes
- Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
- AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
- … a novel GLUT1 inhibitor and cisplatin synergistically inhibits breast cancer cell growth by enhancing the DNA damaging effect and modulating the Akt/mTOR …
- mTOR inhibition decreases angiotensin II-induced steroidogenesis in HAC15 human adrenocortical carcinoma cells.
- … regimen of carbamazepine and imipramine exhibits synergism against grandmal epilepsy in rats: Inhibition of pro-inflammatory cytokines and PI3K/Akt/mTOR …
- Inhibition of ANGPT2 activates autophagy during hypertrophic scar formation via PI3K/AKT/mTOR pathway
- Utilizing Catalytic mTOR Inhibition in Preclinical Models of Huntington Disease
- … photobiomodulation against hydrogen peroxide-induced oxidative damage by promoting autophagy through inhibition of PI3K/AKT/mTOR pathway in MC3T3 …
- Hepatitis E viral infection regulates estrogen signaling pathways: Inhibition of the cAMPK–PKA–CREB and PI3K–AKT–mTOR signaling pathways
- Compression stress induces nucleus pulposus cell autophagy by inhibition of the PI3K/AKT/mTOR pathway and activation of the JNK pathway
- PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and …
- Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in …
- Inhibition of PI3K/Akt/mTOR pathway by ammonium chloride induced apoptosis and autophagy in MAC-T cell
- Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR‐mediated inhibition of autophagy under …
- Design, synthesis, characterization and pharmacological evaluation of mTOR inhibitors for anticancer activity
- … profiling and protein analysis reveal suppression of the C-Myc oncogene and inhibition JAK/STAT and PI3K/AKT/mTOR signaling by thymoquinone in acute …
- Orf virus induces complete autophagy to promote viral replication via inhibition of AKT/mTOR and activation of the ERK1/2/mTOR signalling pathway in OFTu …
- IL-38 prevents induction of trained immunity by inhibition of mTOR signaling
- Natural prenylated xanthones as potential inhibitors of PI3k/Akt/mTOR pathway in triple negative breast cancer cells
- Effectiveness and durability of benefit of mTOR inhibitors (mTORi) in a real-world cohort of metastatic prostate cancer (mPCA) patients with PI3K pathway alterations.
- PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
- CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition
- mTOR inhibition enhances delivery and activity of antisense oligonucleotides in uveal melanoma cells
- Atractylenolide III alleviates the apoptosis through inhibition of autophagy by the mTOR-dependent pathway in alveolar macrophages of human silicosis
- Impact of PI3K/mTOR inhibitors on the development of taxane resistance
- Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties
- MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer
- Change Specifically Responses To Mtor Inhibition Based On Brain Of N. Guentheri
- Synthesis and antitumor evaluation of menthone-derived pyrimidine-urea compounds as potential PI3K/Akt/mTOR signaling pathway inhibitor
- Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells
- POS-791 Metabolic complications of mTOR inhibitors in kidney transplantation: a tunisian multicenter study
- … to combat doxorubicin-induced toxicity via inactivation of PI3K/AKT/mTOR signaling mediated ROS-dependent apoptosis and autophagic flux inhibition in MCF-7 …
- Alpinia katsumadai Hayata induces growth inhibition and autophagy‑related apoptosis by regulating the AMPK and Akt/mTOR/p70S6K signaling pathways in …
- Pulmonary toxicity of mTOR inhibitors in kidney transplantation: A single-center experience
- The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy …
- Targeting inhibition of accumulation and function of myeloid-derived suppressor cells by artemisinin via PI3K/AKT, mTOR, and MAPK pathways enhances anti …
- … -08-21: Development of novel inhibitors of the serum/glucocorticoid induced kinase (SGK) family to address limitations of AKT/PI3K/mTOR inhibitors in breast cancer
- Abstract A016: Selective delivery of fibroblast activation protein conjugated dual phosphoinositide 3-kinase–AKT Kinase-mTOR inhibitor associated with decreased …
- … eradication of colon cancer cells harboring PI3K and/or MAPK pathway mutations in 3D culture by combined PI3K/AKT/mTOR pathway and MEK inhibition
- Zingerone suppresses cell proliferation via inducing cellular apoptosis and inhibition of the PI3K/AKT/mTOR signaling pathway in human prostate cancer PC‐3 cells
- Tortured by mTOR Inhibitors? A Case of Pneumocystis Pneumonia Originally Diagnosed as mTOR Pneumonitis
- POS-792 Evolution of proteinuria after introduction of mTOR inhibitors in kidney transplant patients: a Tunisian multicenter study
- The eIF4A inhibitor silvestrol blocks the growth of human glioblastoma cells by inhibiting AKT/mTOR and ERK1/2 signaling pathway
- Real-world experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant
- Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach
- FOXD1-mTOR signaling pathway on oral squamous cell carcinoma and its inhibition by rosemary extract (invitro-study)
- Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition
- SGLT2 inhibition mitigates perturbations in nephron segment-specific metabolic transcripts and mTOR pathway activity in kidneys of young persons with type 2 …
- Depletion of glioma stem cells by synergistic inhibition of mTOR and c-Myc with a biological camouflaged cascade brain-targeting nanosystem
- … and vernonioside e from Vernonia amygdalina delile. Leaves as inhibitor of epidermal growth factor receptor (egfr) and mammalian target of rapamycin (mTOR)
- … to” Design, synthesis and pharmacological evaluation of 2-arylurea-1, 3, 5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy” …
- Spatial transcriptomics analysis of co-targeted PIM and PI3 K/mTOR in multikinase inhibitor and single kinase inhibitor combination-treated patient-derived prostate …
- … responses induced by polychlorinated bisphenol intoxication in rats via activation of the mTOR signaling pathway mediating inhibition of apoptosis, inflammation, and …
- Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer
- Combination Therapy With Pde5-mtor Inhibitors Attenuates Cardiotoxicity While Enhancing Cancer Cell Death Following Treatment With Doxorubicin and Human …
- P86. 14 Next-Generation Sequencing Guided the Gene Mutations Associated with mTOR-Inhibitors in Chinese Lung Cancer Patients
- Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK …
- Inhibition of ATF4-mediated elevation of both autophagy and AKT/mTOR was involved in antitumorigenic activity of curcumin
- PI3K/AKT/mTOR signalling inhibitor chrysophanol ameliorates neurobehavioural and neurochemical defects in propionic acid-induced experimental model of autism …
- Dual Ampk Activator/mtor Inhibitor Improves Metabolic Parameters in T2d Mice and Protects Cardiomyocytes Against Ischemic Injury
- Effect of mTOR inhibition in a 3D in vitro model of alveolar epithelium and epithelial regeneration
- … kinase inhibitor (Fasudil) suppresses TGF-β mediated autophagy in urethra fibroblasts to attenuate traumatic urethral stricture (TUS) through re-activating Akt/mTOR …
- Ticagrelor ameliorates bleomycin-induced pulmonary fibrosis in rats by the inhibition of TGF-Β1/Smad3 and PI3K/AKT/MTOR pathways
- Sophoridine Derivatives Induce Apoptosis and Autophagy to Suppress the Growth of Triple‐Negative Breast Cancer through Inhibition of mTOR Signaling
- mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition
- REGRESSION OF INTIMAL HYPERPLASIA USING MTOR INHIBITORS AFTER HEART TRANSPLANTATION
- mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsu ciency but not following developmental status epilepticus
- mTOR Inhibition Abrogates Human Mammary Stem Cells and Early Breast Cancer Progression Markers
- mTOR Inhibitor Therapy for Epilepsy Secondary to Tuberous Sclerosis
- Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC‐1A cells by the inhibition of the PI3K/Akt/mTOR pathway
- The acute transcriptional responses to dietary methionine restriction are triggered by inhibition of ternary complex formation and linked to Erk1/2, mTOR, and …
- Apelin-13 increases functional connexin-43 through autophagy inhibition via AKT/mTOR Pathway in the non-myocytic cell population of the heart
- Synergistic effect of CXCR5+ CD8+ TAb-supp cell therapy and mTOR inhibition (but not calcineurin inhibition) in suppressing alloantibody following kidney transplant …
- Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer
- AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis
- Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF …
- Development of TAT-fused mTOR Inhibitor Binding Proteins for the Treatment of Breast Cancer
- COX-2/sEH dual inhibitor alleviates hepatocyte senescence in NAFLD mice by restoring autophagy through Sirt1/PI3K/AKT/mTOR
- … and Validation of a Robust Genomic Classifier for High-Risk Sporadic Type 2 Papillary Renal Cell Carcinoma: Support More Accurate Utilization of mTOR inhibitors
- Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson’s Disease: A …
- AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo
- Liquiritigenin exerts the anti-cancer role in oral cancer via inducing autophagy-related apoptosis through PI3K/AKT/mTOR pathway inhibition in vitro and in vivo
- Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and …
- Inhibition of PI3K/Akt/mTOR signaling by NDRG2 contributes to neuronal apoptosis and autophagy in ischemic stroke
- The effect of mTOR activation and PTEN inhibition on human primordial follicle activation in ovarian tissue culture
- PD43-03 MCT INHIBITION SYNERGIZES WITH TYROSINE KINASE AND MTOR INHIBITOR TREATMENT IN RENAL CELL CARCINOMA
- Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death
- Mtor Inhibition Decreases Ligand-induced Mineralocorticoid Receptor Activation
- SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway
- mTOR inhibition represses transcription of cholesterol biosynthesis genes and alters cholesterol levels in primary neurons and in the developing brain
- … to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor.
- Colistin-induced pulmonary toxicity involves the activation of NOX4/TGF-β/mtROS pathway and the inhibition of Akt/mTOR pathway
- Abstract P036: Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant …
- mTOR pathway inhibition stimulates pharmacologically induced nonsense suppression
- Nimbolide-encapsulated PLGA nanoparticles induces mesenchymal-to-epithelial transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells
- Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer …
- Extended-Release Tacrolimus and mTOR Inhibitor-Based Immunosuppressive Regimen in Living Donor Kidney Transplantation: A Single-Center Retrospective …
- Impact of Age, Menopause and mTOR Inhibitor Use on Spontaneous Pneumothoraces in Lymphangioleiomyomatosis
- Low-dose mTOR inhibitor alleviates RPE cellular senescence and pro-inflammation induced by accumulation of cytosolic nuclear DNA fragments
- The positive feedback exerted by mtor inhibitor everolimus in pituitary neuroendocrine tumoral cells is reverted by cabergoline co-treatment
- Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
- Astragaloside IV protects from PM2. 5-induced lung injury by regulating autophagy via inhibition of PI3K/Akt/mTOR signaling in vivo and in vitro
- Mtor Inhibition Prolongs Survival and Improves Contractile Function after Onset of Lamin A/C Mutation Cardiomyopathy
- Anticancer effects of morusin in prostate cancer via inhibition of Akt/mTOR signaling pathway
- Anticancer effects of the HDAC inhibitor, 3β, 6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways
- Growth inhibition and suppression of the mTOR and Wnt/β‐catenin pathways in T‐acute lymphoblastic leukemia by rapamycin and MYCN depletion
- Amifostine attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the PI3K/Akt/mTOR signaling pathway
- P15. 06: Distinct FOXP3 Gene Expression in the Peripheral Blood And Inside Renal Allografts Is Associated With Use of MTOR Inhibitors and Extended Criteria Kidney …
- PD24-08 SEQUENTIAL USAGE OF MTOR INHIBITOR FOLLOWED BY IMMUNOTHERAPIES FOR CABOZANTINIB-RESISTANT METASTATIC CLEAR CELL RENAL …
- Gomisin N attenuated cerebral ischemia-reperfusion injury through inhibition of autophagy by activating the PI3K/AKT/mTOR pathway
- Xanthohumol alleviates oxidative stress and impaired autophagy in experimental severe acute pancreatitis through inhibition of AKT/mTOR
- CD5-mediated mTOR inhibition on T cells through binding of soluble CEACAM1
- … differential expression status of endogenous PTEN helps in KSHV oncogenesis and acts as the key determinant for the sensitivity of mTOR inhibitors which induce a …
- … ‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum …
- Anisomycin sensitizes non‐small‐cell lung cancer cells to chemotherapeutic agents and epidermal growth factor receptor inhibitor via suppressing PI3K/Akt/mTOR
- … antitumor evaluation of (aryl) methyl-amine derivatives of dehydroabietic acid-based B ring-fused-thiazole as potential PI3K/AKT/mTOR signaling pathway inhibitors
- Dieckol exerts anticancer activity in human osteosarcoma (MG-63) cells through the inhibition of PI3K/AKT/mTOR signaling pathway
- Dual inhibition of autophagy and PI3K/mTOR pathway as a potential therapeutic strategy against laryngeal squamous cell carcinoma
- PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR
- Bifidobacterium infantis Promotes Foxp3 Expression in Colon Cells via PD-L1-Mediated Inhibition of the PI3K-Akt-mTOR Signaling Pathway
- Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitors suitable for the treatment of CNS disorders
- Insulin‑like growth factor 1 promotes neurological functional recovery after spinal cord injury through inhibition of autophagy via the PI3K/Akt/mTOR signaling …
- Tomentosin inhibits cell proliferation and induces apoptosis in MOLT‐4 leukemia cancer cells through the inhibition of mTOR/PI3K/Akt signaling pathway
- Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR‐138‐5p and activation of AKT/mTOR signaling pathway
- PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
- Synthesis and evaluation of [18F] mIpoPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on an imidazo [4, 5-b] pyrazin-2-one backbone.
- Inhibition of SRSF3 alleviates proliferation and migration of gastric cancer cells by regulating the PI3K/AKT/mTOR signalling pathway
- Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo …
- Lycopene prevents oxygen-glucose deprivation-induced autophagic death in SH-SY5Y cells via inhibition of the oxidative stress-activated AMPK/mTOR …
- Inhibition of Connexin 43 reverses ox-LDL-mediated inhibition of autophagy in VSMC by inhibiting the PI3K/Akt/mTOR signaling pathway
- CHARACTERISTICS, PREDICTORS AND OUTCOMES OF EARLY MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR USE AFTER HEART …
- Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling
- Potential new therapy of Rapalink-1, a new generation mTOR inhibitor, against sunitinib-resistant renal cell carcinoma.
- Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways
- Abstract P5-08-15: Overcoming mTOR inhibitor resistance by targeting the lysosomal deregulation
- First, second, and third generation mTOR pathways inhibitors for treatment of glioblastoma
- … Attenuates Myocardial Hypertrophy and Fibrosis in Pressure Overload-Induced Mice Involving mTOR and TGF-β1/Smad Signaling Pathway Inhibition
- ATL1 inhibits the proliferation and invasion of trophoblast cells via inhibition of the mTOR signaling pathway
- … -5-(3-(pyridin-4-yl)-1H-pyrazolo [3, 4-b] pyridin-5-yl) pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of …
- Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
- Alkali exposure induces autophagy through activation of the MAPKpathway by ROS and inhibition of mTOR in Eriocheir sinensis
- Targeting CDK4/6 inhibitor resistance in relapsed RB-proficient osteosarcoma patient-derived xenografts via PI3 Kinase/mTOR inhibition
- … cell death induced by the quinoline derivative 2‐(6‐methoxynaphthalen‐2‐yl) quinolin‐4‐amine in pancreatic cancer cells is via ER stress and inhibition of Akt/mTOR …
- Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K‐Akt–mTOR pathway
- LncRNA RHPN1‐AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR‐7‐5p/EGFR/PI3K/AKT/mTOR signaling pathway
- Endogenous Aβ induces osteoporosis through an mTOR-dependent inhibition of autophagy in bone marrow mesenchymal stem cells (BMSCs)
- Inhibition of PI3K/mTOR/KATP channel blunts sodium thiosulphate preconditioning mediated cardioprotection against ischemia–reperfusion injury
- … , a novel phosphatidylinositol 3-kinase inhibitor, inhibits colorectal carcinoma cell proliferation and suppresses angiogenesis by attenuating PI3K/AKT/mTOR …
- Nicorandil mitigates amiodarone‐induced pulmonary toxicity and fibrosis in association with the inhibition of lung TGF‐β1/PI3K/Akt1‐p/mTOR axis in rats
- Down regulation of fatty acid synthase via inhibition of PI3K/AKT/mTOR in ovarian cancer cell line by novel organoselenium pseudopeptide
- Abstract PO-094: Gα13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition
- LSC-2021-Effect of mTOR inhibition in a 3D in vitro model of alveolar epithelium and epithelial regeneration
- Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells
- Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis
- The Potent Anti-Tumor Effects of Rhodiola Drinking Are Associated with the Inhibition of the mTOR Pathway and Modification of Tumor Metabolism in the UPII …
- Inhibition of NF-κB might enhance the protective role of roflupram on SH-SY5Y cells under amyloid β stimulation via PI3K/AKT/mTOR signaling pathway
- … -01: Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
- Effect of 2-deoxyglucose-mediated inhibition of glycolysis on the regulation of mTOR signaling and protein synthesis before and after high-intensity muscle contraction
- Abstract P1-10-06: Effect of aging and mTOR inhibition on human mammary stem cells and early breast cancer progression markers
- Rehmanniae Radix-Induced apoptosis via inhibition of PI3K/AKT/mTOR signaling pathways in human hepatocellular carcinoma cell lines SMMC-7721
- … like activity in mice by a mechanism involving receptor potentiation but not neurotransmitter reuptake inhibition. Correlation with mTOR intracellular pathway activation
- Investigation of mTOR, JAK/STAT, and Hedgehog pathways inhibitor effect on the proliferation of haematological cancer cell lines
- MicroRNA‑223‑induced inhibition of the FBXW7 gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways
- Abstract P102: Inhibition Of Mtor Decreases Angiotensin Ii-induced Steroidogenesis In Hac15 Cells
- Inhibition of autophagy by CRMP2-derived peptide ST2-104 (R9-CBD3) via a CaMKKβ/AMPK/mTOR pathway contributes to ischemic postconditioning …
- The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway
- PI3K/mTOR Dual Inhibitor Pictilisib Stably Binds to Site I of Human Serum Albumin as Observed by Computer Simulation, Multispectroscopic, and Microscopic Studies
- Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells
- JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR …
- … enhancing potential of piracetam with diethylstilbestrol in prevention of grand-mal seizures in rats: inhibition of PI3K/Akt/mTOR signaling pathway and IL-1ß, IL …
- Facile synthesis of rapamycin-peptide conjugates as mTOR and Akt inhibitors
- Overexpression of Notch2 enhances radiosensitivity via inhibition of the AKT/mTOR signaling pathway in nasopharyngeal carcinoma
- Efficient protocol for the differentiation of kidney podocytes from induced pluripotent stem cells, involving the inhibition of mTOR
- Itaconate attenuates autoimmune hepatitis via PI3K/AKT/mTOR pathway-mediated inhibition of dendritic cell maturation and autophagy
- Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in …
- Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice
- Neuroblastoma cell death induced by eEF1A2 knockdown is possibly mediated by the inhibition of Akt and mTOR phosphorylation
- … agent, 4′-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibition of Akt/mTOR …
- Sinigrin Impedes the Breast Cancer Cell Growth through the Inhibition of PI3K/AKT/MTOR Phosphorylation-Mediated Cell Cycle Arrest
- Abstract P4-01-18: Acquired sensitivity strategies in ER+ breast cancer progressing on CDK4/6 and mTOR inhibitors
- The effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on Immune Evasion Mechanisms of Acute Myeloid Leukemia Cell Line
- … butyrate/polyethylene glycol nanocomposite‐induced apoptosis and cell death in nasopharyngeal cancer (C666‐1) cells through the inhibition of the PI3K/AKT/mTOR …
- … nanoparticles exhibit antibacterial activity and induce reactive oxygen species mediated apoptosis in MCF‐7 breast cancer cells through inhibition of PI3K/Akt/mTOR …
- Inhibition of STX17–SNAP29–VAMP8 complex formation by costunolide sensitizes ovarian cancer cells to cisplatin via the AMPK/mTOR signaling pathway
- Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK …
- … acid promotes the formation of autophagosomes in MCF-7 breast cancer cells through oxidative stress-induced growth inhibitor 1 mediated activation of AMPK/mTOR …
- Influence of Notch Inhibition on mTOR and Wnt Signaling in Repairing Muscle
- Inhibition of TRIM32 by ibr‐7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway
- Ubiquitously specific protease 4 inhibitor‐Vialinin A attenuates inflammation and fibrosis in S100‐induced hepatitis mice through Rheb/mTOR signalling
- … Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and …
- The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis
- Study on the interaction of two quinazoline derivatives as novel PI3K/mTOR dual inhibitors and anticancer agents to human serum albumin utilizing spectroscopy and …
- … /6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR
- The Exploration of PI3K/Akt/mTOR, JAK/STAT, and Hedgehog pathways inhibitor effect on CALR Del52 cells proliferation
- In vitro Anti-Hantavirus Activity of Protein Kinase Inhibitor 8G1 Targeting AKT/mTOR/eIF4E Signaling Pathway
- Function-oriented synthesis of Imidazo [1, 2-a] pyrazine and Imidazo [1, 2-b] pyridazine derivatives as potent PI3K/mTOR dual inhibitors
- … umbilical-cord-derived mesenchymal stem cells in combination with rapamycin reduce cartilage degradation via inhibition of the AKT/mTOR signaling pathway
- Inhibition of VDAC1 prevents oxidative stress and apoptosis induced by bisphenol A in spermatogonia via AMPK/mTOR signaling pathway
- … /neodymium nanocomposites from Avaram senna flower extract induces apoptosis in gastric cancer ags cell line through inhibition of the PI3K/AKT/mTOR …
- Single cell proteomics of tumor compartments identifies differential kinase activities defining sensitivity to mTOR-PI3-kinase inhibition
- Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T …
- The SGLT2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR-signaling, endoplasmic reticulum stress and …
- … Imidazo[1,2-a]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1α and MAPK Signaling Inhibition, Promoting Antiproliferative Effect …
- … of tumor necrosis factor-alpha promote human periodontal ligament stem cells osteogenic differentiation by activation of autophagy via inhibition of AKT/mTOR …
- Atractylodin induces oxidative stress‐mediated apoptosis and autophagy in human breast cancer MCF‐7 cells through inhibition of the P13K/Akt/mTOR pathway
- Inhibition of the AKT1/mTOR pathway through SIRT6 over expression downregulated the expression of programmed death-ligand 1 and prolonged overall …
- 1288P Mutations in MTOR pathway and response of immune checkpoint inhibitors
- … [4,5]thieno[2,3‐d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR …
- … cells by inducing mitochondrial mediated apoptosis, G2/M phase cell cycle arrest, inhibition of cell migration and invasion and modulating mTOR/PI3K/AKT signalling …
- The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma
- Role of the mTOR Pathway and Autophagy in Mediating PARP Inhibitor Sensitivity in Small Cell Lung Cancer
- Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial Biogenesis
- … of a novel glucocorticoid-resistant human B-cell acute lymphoblastic leukemia cell line, with AMPK, mTOR and fatty acid synthesis pathway inhibition
- Inhibition of mTOR protects against skeletal muscle and kidney injury following hindlimb ischemia-reperfusion in rats by regulating MEK1/ERK1/2 activity
- P09. 01 The use of FDA approved JAK, mTOR and Src inhibitors to regulate T cell-bispecific antibody-induced cytokine release while not preventing T cell …
- Inhibition of Oxidative Phosphorylation and Glycolysis Reduces Viability in Multiple Myeloma By Affecting mTOR-Mediated Protein Synthesis
- The Effects of PKI-402 On Breast Tumor Models’ Radiosensitivity via Dual Inhibition of PI3K/mTOR
- … -2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR …
- … signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors
- Triptolide exhibits anti-inflammatory effects on adipocytes and macrophages by inhibition of AMPK/mTOR pathway
- … Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression
- Inhibition of APLN suppresses cell proliferation and migration and promotes cell apoptosis in esophageal cancer cells in vitro, through activating PI3K/mTOR …
- Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate …
- … Mouse Model Ptch1+/−/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611
- … -steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS (ON) inhibitors in RAS-addicted …
- Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced …
- Network analysis and basic experiments on the inhibition of renal cancer proliferation and migration by alpinetin through PI3K/AKT/mTOR pathway
- 42P Apigenin: An immunomodulatory nutraceutical overriding PD-L1 inhibitors by halting AKT/mTOR pathway in triple-negative breast cancer (TNBC)
- MicroRNA-137-mediated inhibition of lysine-specific demethylase-1 prevents against rheumatoid arthritis in an association with the REST/mTOR axis
- MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer
- Anticancer activity of caffeic acid n-butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling …
- Dietary restriction and mTOR and IIS inhibition: the potential to antiaging drug approach
- … hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors
- Inhibition effect of active fraction from clove on PI3K/Akt/mTOR signaling pathway to induce apoptosis of human colon cancer HCT116 cells
- A Brain-Penetrant mTOR Kinase Inhibitor for the Treatment of Neurological Disorders
- … hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors
- Retraction notice to “Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits …
- DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis
- Design and development of novel 1, 2, 3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signaling pathway
- mSWI/SNF interacts with the ribosome and its inhibition/mutations alter translation and sensitize to mTOR/PI3K inhibitors
- AKT/mTOR and MAPK Inhibition Improves Childhood RASopathic Cardiomyopathy
- Rapamycin, mTOR, TNF Inhibition, RA, Longevity and Canadian Content
- miR-183 enhances autophagy of GC cells by targeted inhibition of mTOR
- The UCHL1 Inhibitor LDN-57444 Promotes the Transdifferentiation of Supporting Cells into Hair Cells by Regulating the mTOR Pathway
- Tipifarnib potentiates the antitumor effects of PI3Kα blockade in HNSCC via convergent inhibition of mTOR activity
- RETROPERITONEAL PERIVASCULAR EPITHELIOID CELL NEOPLASM (PECOMA) RESPONSE TO MTOR KINASE INHIBITION. A CASE REPORT WITH …
- Inhibition of mTOR enhances sorafenib-induced activated HSC ferroptosis.
- Runner Up: Incidence of Cutaneous Adverse Events with PI3K-Akt-mTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis
- Novel specific PKM2 inhibitor, compound 3h, induces apoptotic and autophagic cell death through Akt/mTOR signaling pathway in prostate cancer cells
- mTOR kinase inhibitor AZD8055 reverses acquired rapamycin resistance in prostate cancer cells
- mTOR signaling pathway-mediated autophagy involved in inhibition of osteoblast differentiation induced by cadmium in human bone marrow mesenchymal stem cells
- … and Enriched Environment Ameliorated Low Protein-Induced Intrauterine Growth Retardation by IGF-1 And mtor Signaling Pathway and Autophagy Inhibition in Rats
- A commentary on” PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern …
- Synergistic Renoprotective Effect of Melatonin and Zileuton by Inhibition of Ferroptosis via the AKT/mTOR/NRF2 Signaling in Kidney Injury and Fibrosis.
- Therapeutic Resistance to FLT3 Inhibition in Acute Myeloid Leukemia Cells Is Driven by a Novel ATM/mTOR Pathway Regulating Oxidative Phosphorylation
- MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer
- Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice
- Icariin Suppresses Activated Macrophages-Mediated Inflammatory Response Inhibition of mTOR/S6K1 and NF-κB Signaling
- Inhibition of Neuropilin-1 improves non-alcoholic fatty liver disease via PI3K/AKT/mTOR signaling in high-fat-diet induced obese mouse
- Autophagy Inhibition Amplifies Anti-Tumor Immunity Effect of Dinutuximab Beta On Neuroblastoma via the VEGFR/AKT/mTOR and ROS/NF-κB Pathways
- Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity through autophagy inhibition by activating PI3K/Akt/mTOR pathway in glioblastoma
- WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.
- Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis
- Lung cancer growth inhibition and autophagy activation by tetrazole via ERK1/2 up-regulation and mTOR/p70S6K signaling down-regulation
- Erratum to “The Inhibition of Insulin-stimulated Proliferation of Vascular Smooth Muscle Cells by Rosiglitazone Is Mediated by the Akt-mTOR-P70S6K Pathway” by …
- Proton Pump Inhibitors Could Ameliorate Cachexia of Gastric Cancer by Down-regulating Vacuolar H+-ATPases and Disrupting PI3K/AKT/mTOR/HIF-1α/PKM2 …
- O012/# 761 INHIBITION OF PAIN-RELATED MTOR PROTEINS USING DIFFERENTIAL TARGET MULTIPLEXED SCS IN AN ANIMAL NEUROPATHIC PAIN MODEL …
- Cell growth of sunitinib-resistant renal cell carcinoma was inhibited by Shikonin through necroptosis induction and Akt/mTOR signaling inhibition
- Retracted: Inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway …
- … P2-07-05: Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2 …
- … therapy for temozolomide-resistant GBM: identification of temozolomide/small molecule inhibitor combinations that target the MDM2/p53 and PI3K-AKT/mTOR …
- PI3K/AKT/mTOR pathway and CDK4/6 inhibitors efficiently inhibit cell growth of HPV-positive and HPV-negative head and neck squamous cell carcinoma in vitro
- SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1-splicing and mTOR/sz-catenin pathways imbalances
- Inhibition of the mToR pathway with everolimus can modulate heat shock genes and ERCC1 gene expression and improves outcomes on serous ovarian cancer in …
- Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair …
- Down-regulation of PHLPP1 expression ameliorates high glucose-induced autophagy inhibition and apoptosis promotion of podocytes by activating PI3K/AKT/mTOR …
- … Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT …
- EGFR inhibition in combination with PI3K/AKT/mTOR and/or Bcl-2 inhibition is a promising novel therapeutic approach for inverted sinonasal papillomas and …
- … : Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR …
- Combined inhibition of mTOR and HSP90 potentiates cisplatin antitumor effect and reverts cisplatin resistance in vitro and in vivo models of epithelial ovarian cancer …
- Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in …
- … post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors
- … Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) …
- Abstract PS16-18: Inhibition of mTOR signaling by rapamycin abrogates mammary stem/progenitor cell activity in aged mice
- P-444 Presence of pharmacological inhibitors of the PI3K/PTEN/Akt and mTOR signalling pathways during cryopreservation and organotypic cultures of murine …
- Effect of microRNA-221 targeting tissue inhibitor of metalloproteinase-2 to mediate Akt/mTOR signaling pathway on non-small cell lung cancer transplanted tumor …
- Modulation of immune checkpoints on linage HL-60 of acute myeloid leukemia treated with BRD4 inhibitor and mTOR pathway inhibitor
- FTI-277 and GGTI-289 induce apoptosis via inhibition of the Ras/ERK and Ras/mTOR pathway in head and neck carcinoma HEp-2 and HSC-3 cells
- EP16. 03-028 Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
- … derived from naive and pretreated metastatic patients with high-risk CDK4/6 hyperactivation signatures are sensitive to dual inhibition of CDK4/6 and PI3K/mTOR
- Anti-proliferation effect of polo-like kinase-4 inhibitor in ovarian cancer via AKT/mTOR/p70S6K pathway
- … ) phenyl)-1H-pyrazolo [4, 3-c] pyridin-4 (5H)-one (FMPPP) exhibits anti-proliferative effect on prostate cancer via autophagy induction and mTOR/p70S6K inhibition
